The role of the AdeRS two component system and the AdeABC RND Efflux pump in antibiotic resistance, biofilm formation and virulence in Acinetobacter baumannii by Richmond, Grace Emma
 The Role of the AdeRS Two Component System and the 
AdeABC RND Efflux Pump in Antibiotic Resistance, Biofilm 
Formation and Virulence in Acinetobacter baumannii 
by 
Grace Emma Richmond 
 
A thesis submitted to the University of Birmingham for the degree of 
DOCTOR OF PHILOSOPHY 
 
 
 
Antimicrobials Research Group 
Institute of Microbiology and Infection 
College of Medical and Dental Sciences 
University of Birmingham 
July 2016 
 
 
 
 
 
 
 
 
 
University of Birmingham Research Archive 
 
e-theses repository 
 
 
This unpublished thesis/dissertation is copyright of the author and/or third 
parties. The intellectual property rights of the author or third parties in respect 
of this work are as defined by The Copyright Designs and Patents Act 1988 or 
as modified by any successor legislation.   
 
Any use made of information contained in this thesis/dissertation must be in 
accordance with that legislation and must be properly acknowledged.  Further 
distribution or reproduction in any format is prohibited without the permission 
of the copyright holder.  
 
 
 
Abstract 
Acinetobacter baumannii is a nosocomial pathogen and causes infections in 
hospitals worldwide. This organism is often multi-drug resistant (MDR), can persist in 
the environment and forms a biofilm on environmental surfaces and wounds. 
This thesis describes research that investigates the role of the two component 
system AdeRS, which regulates production of the AdeABC MDR efflux pump. Its role 
in MDR, biofilm formation and virulence of A. baumannii was determined in mutants 
constructed for this study. Deletion of AdeRS or AdeABC resulted in increased 
susceptibility to antibiotics, decreased biofilm formation on biotic and abiotic surfaces 
and decreased virulence in a strain dependent manner. RNA-Seq revealed that loss 
of AdeRS or AdeB significantly altered the transcriptome, resulting in changed 
expression of many genes, notably those associated with antimicrobial resistance 
and virulence interactions. 
This study demonstrated the scope of AdeRS mediated regulation and suggests that 
inhibition of AdeABC could prevent biofilm formation or colonisation in patients by A. 
baumannii and so provides a good target for drug discovery. This study also 
highlighted the differences between A. baumannii strains and shows that conclusions 
for the species should not be drawn from the study of single strains. 
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1. Introduction 
1.1. Acinetobacter species 
Acinetobacter are Gram-negative coccobacilli responsible for an increasing number 
of nosocomial infections in the UK and worldwide. Acinetobacter are currently 
defined as aerobic, non-fermenting, non-fastidious, non-motile, catalase-positive and 
oxidase-negative bacteria, with a DNA G+C content of ~40% (Rossau, Van 
Landschoot et al. 1991). They are opportunistic pathogens and are a serious problem 
in immunocompromised patients within the hospital setting (Antunes, Visca et al. 
2014). The clinical success of this organism is due to a number of factors including 
its propensity to acquire antibiotic resistance determinants and to over-express 
existing intrinsic resistance genes, allowing it to avoid eradication by antibiotics and 
biocides. Its ability to survive desiccation means it is also able to persist in the 
hospital environment for extended periods of time (Wendt, Dietze et al. 1997, Jawad, 
Seifert et al. 1998, Jawad, Snelling et al. 1998).  
The taxonomy of Acinetobacter has a long and complicated background and there 
are still difficulties with species identification. The bacterium was first identified in 
1911 by the Dutch microbiologist, Beijerinck, who isolated a bacterium he named 
Micrococcus calcoaceticus from soil samples (Beijerink 1911). Since then, bacteria 
now known as Acinetobacter have been isolated many times and assigned to various 
genera. In 1971, the genus Acinetobacter was officially acknowledged by the 
Subcommittee on Nomenclature of Moraxella and Allied Bacteria (Lessel 1971). In 
1986, the genera was divided into 12 DNA groups with formal species names 
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(Bouvet and Grimont 1987) and has since been further categorised to give at least 38 
genomic groups with formal species names (Table 1.1.1) (Towner 2009, Visca, 
Seifert et al. 2011) (http://www.bacterio.net/acinetobacter.html). 
1.1.1. Natural habitat 
Not all Acinetobacter species pose a threat to human health. Many species are non-
pathogenic and can be isolated from the soil; they also often form part of the normal 
human skin flora (Baumann 1968, Seifert, Dijkshoorn et al. 1997). This has led to the 
common misconception that all Acinetobacter species are ubiquitous and that 
pathogenic species such as A. baumannii can be isolated from environmental 
sources. However, it is now generally accepted that this is not the case. Although 
Acinetobacter can be isolated from human skin, highly pathogenic species such as A. 
baumannii are rarely found colonising the skin of healthy humans (Berlau, Aucken et 
al. 1999). Clinically relevant strains of Acinetobacter are often found colonising 
hospital surfaces, hospital staff and medical instrumentation (Lewis, Loman et al. 
2010, Kirkgoz and Zer 2014, Duszynska, Rosenthal et al. 2015, Ye, Shan et al. 
2015), although the natural habitat of these strains remains unknown. 
1.1.2. Epidemiology 
Acinetobacter is well-recognised for its ability to cause nosocomial outbreaks, and 
particular strains are able to cause epidemics in multiple hospitals within a city, in 
various regions in a country and can even spread worldwide (van Dessel, Dijkshoorn 
et al. 2004, Coelho, Woodford et al. 2006, Coelho, Turton et al. 2006). A. baumannii 
European (EU) clones I and II were first identified as outbreak strains in North-
western Europe in 1996 (Dijkshoorn, Aucken et al. 1996). A third clone was later  
3 
 
Table 1.1.1 Acinetobacter spp. with formal species names 
Species name 
Representative 
strain 
Reference 
A. apis HYN 18 (Kim, Shin et al. 2014) 
A. baumannii ATCC 19606 (Bouvet and Grimont 1986) 
A. baylyi DSM 14961 (Carr, Kämpfer et al. 2003) 
A. beijerinckii NIPH 838 (Nemec, Musílek et al. 2009) 
A. bereziniae ATCC 17924 (Nemec, Musílek et al. 2010) 
A. bohemicus ANC 3994 (Krizova, McGinnis et al. 2015) 
A. boissieri SAP 284.1 (Álvarez-Pérez, Lievens et al. 2013) 
A. bouvetii DSM 14964 (Carr, Kämpfer et al. 2003) 
A. brissouii 5YN5-8 (Anandham, Weon et al. 2010) 
A. calcoaceticus ATCC 23055 (Baumann 1968) 
A. gandensis UG 60467T (Smet, Cools et al. 2014) 
A. gerneri DSM 14967 (Carr, Kämpfer et al. 2003) 
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Species name 
Representative 
strain 
Reference 
A. grimontii DSM 14968 (Carr, Kämpfer et al. 2003) 
A. guangdongensis 1NM-4 (Feng, Yang et al. 2014) 
A. guillouiae ATCC 11171 (Nemec, Musílek et al. 2010) 
A. gyllenbergii NIPH 2150 (Nemec, Musílek et al. 2009) 
A. haemolyticus ATCC 17906 (Bouvet and Grimont 1986) 
A. harbinensis HLTLi-7 (Li, Zhang et al. 2014) 
A. indicus A648 (Malhotra, Anand et al. 2012) 
A. johnsonii ATCC 17909 (Bouvet and Grimont 1986) 
A. junii ATCC 17908 (Bouvet and Grimont 1986) 
A. kookii 11-0202 (Choi, Ko et al. 2013) 
A. lwoffii ATCC 15309 (Brisou and Prevot 1954) 
A. nectaris SAP 763.2 (Álvarez-Pérez, Lievens et al. 2013) 
A. nosocomialis RUH 2376 (Nemec, Krizova et al. 2011) 
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Species name 
Representative 
strain 
Reference 
A. parvus NIPH384 (Nemec, Dijkshoorn et al. 2003) 
A. pittii RUH 2206 (Nemec, Krizova et al. 2011) 
A. puyangenesis BQ4-1 (Li, Piao et al. 2013) 
A. quingfengenesis 2BJ1 (Li, He et al. 2014) 
A. radioresistens IAM 13186 (Nishimura, Kanzaki et al. 1988) 
A. rudis G30 (Vaz-Moreira, Novo et al. 2011) 
A. schindleri NIPH1034 (Nemec, De Baere et al. 2001) 
A. soli KCTC 22184 (Kim, Baik et al. 2008) 
A. tandoii DSM 14970 (Carr, Kämpfer et al. 2003) 
A. tjernbergiae DSM 14971 (Carr, Kämpfer et al. 2003) 
A. towneri DSM 14962 (Carr, Kämpfer et al. 2003) 
A. ursingii NIPH137 (Nemec, De Baere et al. 2001) 
A. venetianus ATCC 31012 (Vaneechoutte, Nemec et al. 2009) 
Adapted from http://www.bacterio.net/acinetobacter.html 
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identified as a European outbreak strain and named EU clone III (van Dessel, 
Dijkshoorn et al. 2004). These clones are widespread throughout Europe and 
contribute significantly to the spread of carbapenem-resistant Acinetobacter (Towner, 
Levi et al. 2008). Other individual lineages are more prevalent in certain areas of 
Europe, such as the AYE-VEB-1 clone found in France and Belgium (Naas, Bogaerts 
et al. 2006) and the OXA-40 (OXA-24) carbapenem-resistant clone found in Spain 
and Portugal (Da Silva, Quinteira et al. 2004). The EU clones are in fact international 
lineages and not limited to Europe. Outbreaks have been identified in the USA and 
South Africa (van Dessel, Dijkshoorn et al. 2004, Petersen, Cannegieter et al. 2011). 
In Asia, carbapenem resistant European clones have been described in hospitals in 
China (Fu, Zhou et al. 2010) and Korea (Park, Lee et al. 2010). In Singapore, 
carbapenem resistance is also observed in clinical isolates, with outbreak isolates 
related to EU clones I and II identified in the hospital setting, and the majority of 
carbapenem resistance due to OXA-23 carrying clones (Park, Lee et al. 2010). In a 
study of UK hospitals between 2003 and 2006, sub-lineages of EU clone II 
dominated, with the South-east (SE) and OXA-23 clones being the most prevalent 
(Coelho, Turton et al. 2006). 
1.2. Acinetobacter baumannii complex 
Four of the identified Acinetobacter species are often grouped into the Acinetobacter 
calcoaceticus – baumannii (Acb) complex. This group comprises of A. baumannii, A. 
calcoaceticus, A. pittii and A. nosocomialis (Gerner-Smidt 1992, Nemec, Krizova et 
al. 2011). A. baumannii, A. pittii and A. nosocomialis are clinically relevant species, 
often implicated in infection, whereas A. calcoaceticus is largely non-pathogenic and 
is rarely identified in the hospital setting (Peleg, Seifert et al. 2008, Koh, Tan et al. 
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2012). Therefore, from a clinical perspective, identification of different species of 
Acinetobacter, especially those within the Acb complex, is extremely important. 
Species also has implications for treatment and infection control as many of the non-
A. baumannii complex species are drug susceptible and strict infection control is not 
necessary (Chuang, Sheng et al. 2011). However, discrimination between species is 
difficult, particularly between members of the A. baumannii complex, which cannot be 
differentiated phenotypically and are often misidentified (Gerner-Smidt, Tjernberg et 
al. 1991, Gerner-Smidt 1992). Semi-automated systems such as the API 20NE 
system are often unreliable and also cannot distinguish between closely related 
species (Bernards, van der Toorn et al. 1996). There are a number of methods 
currently used for the routine identification of Acinetobacter species in clinical 
laboratories; DNA-DNA hybridisation was first used to describe a total of 12 genomic 
species of Acinetobacter (Bouvet and Grimont 1986). However this process is 
lengthy and is impractical for a routine diagnostic laboratory. For this reason various 
methods have been adopted and verified for species identification. These include 
16S rRNA gene restriction (ARDRA) (Vaneechoutte, Dijkshoorn et al. 1995), high 
resolution fingerprint analysis by amplified fragment length polymorphism (AFLP) 
(Janssen, Maquelin et al. 1997), ribotyping (Gerner-Smidt 1992), tRNA spacer 
analysis (Ehrenstein, Bernards et al. 1996), restriction analysis of 16S-23S rRNA 
intergenic spacer regions (Dolzani, Tonin et al. 1995, Chang, Wei et al. 2005) and 
sequence analysis of the rpoB gene (La Scola, Gundi et al. 2006). Nonetheless, 
apart from a small number of Acinetobacter reference laboratories, species 
identification is not always possible in most clinical laboratories. 
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1.3. Acinetobacter baumannii infection 
1.3.1. Hospital acquired infections 
A. baumannii most commonly causes nosocomial infections, including ventilator-
associated pneumonia, skin and soft-tissue infections, wound infections, surgical site 
infections, catheter-related and urinary tract infections, secondary meningitis and 
bloodstream infections (Forster and Daschner 1998). Studies have found that up to 
18% of patients infected with A. baumannii develop bacteraemia, most often acquired 
in the intensive care unit (ICU) (Cisneros, Reyes et al. 1996). The assessment of the 
outcome of Acinetobacter infection is difficult and reported mortality rates range from 
5% in general wards to 54% in the ICU (Poutanen, Louie et al. 1997, Siau, Yuen et 
al. 1999). Seifert et al. showed the crude mortality rate of A. baumannii bacteraemia 
to be as high as 44%. However, it is difficult to determine morbidity and mortality 
directly attributable to A. baumannii as opposed to co-morbidity, which is very 
common in these patients. Death attributable to A. baumannii bacteraemia, at 19%, 
was assessed to be much lower than the crude mortality rate (Seifert, Strate et al. 
1995). Several predisposing factors to infections with A, baumannii have been 
identified. These include immunosuppression, unscheduled hospital admission, 
respiratory failure at admission, previous antimicrobial therapy, previous sepsis in the 
ICU and invasive procedures; all of which have been recognised as risk factors for A. 
baumannii infection (Garcia-Garmendia, Ortiz-Leyba et al. 2001). A. baumannii can 
be cultured from different environmental sites within hospitals and it is thought that 
cross contamination between sites is a major mode of transmission in hospital 
outbreaks (van den Broek, Arends et al. 2006). Carriage of A. baumannii on the 
hands of hospital staff and on medical instrumentation can contribute to the spread of 
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the organism (Ye, Shan et al. 2015, Al-Mousa, Omar et al. 2016). The ability of A. 
baumannii to survive on dry surfaces for extended periods of time may also increase 
transmissibility. It has been suggested that desiccation tolerance, along with multi-
drug resistance (MDR) demonstrated by some strains, may explain why A. baumannii 
is able to establish itself in the hospital environment and cause recurring nosocomial 
outbreaks (Jawad, Heritage et al. 1996, Jawad, Seifert et al. 1998, Jawad, Snelling et 
al. 1998). 
Hospital outbreaks often occur within the intensive care unit, where 
immunocompromised patients provide a niche for opportunistic pathogens such as A. 
baumannii (Dijkshoorn, Nemec et al. 2007). Whole genome sequencing to 
investigate genome dynamics of clinical isolates of A. baumannii within the hospital 
have indicated that an endemic and interacting population can exist in the hospital 
environment or in colonised patients. Movement of patients and staff may contribute 
to transmission and diversification of this population (Halachev, Chan et al. 2014, 
Wright, Haft et al. 2014). A. baumannii wound infections in military casualties are also 
a concern and can spread to civilian patients in the hospital (Davis, Moran et al. 
2005, Hujer, Hujer et al. 2006, Sebeny, Riddle et al. 2008, O'Shea 2012). Military 
casualties repatriated to Selly Oak Hospital, Birmingham or the Queen Elizabeth 
Hospital (QEH), Birmingham were often treated alongside civilian patients. 
Investigation of a MDR A. baumannii outbreak in the Selly Oak Hospital showed two 
civilian and four military patients to be colonised with isolates identical by variable 
number tandem repeats (VNTR) and pulsed field gel electrophoresis (PFGE) 
analyses. Subsequent whole genome sequencing (WGS) provided insight into 
transmission events and supported transmission from the wound of a military patient 
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to the respiratory tract of a civilian patient (Lewis, Loman et al. 2010). Similarly, WGS 
of 114 isolates from a second protracted hospital outbreak of A. baumannii at the 
QEH, Birmingham, between July 2011 and February 2013 linked military patient 
derived isolates directly to civilian patient and environmental isolates (Halachev, 
Chan et al. 2014). 
1.3.2. Community acquired infections 
Although most common in the hospital environment, community acquired 
Acinetobacter infection has been observed. In Portugal, necrotising community 
acquired pneumonia due to Acinetobacter lwoffii contamination of a nebuliser in a 
previously healthy child was identified (Moreira Silva, Morais et al. 2011). This type of 
infection is usually associated with underlying conditions such as alcoholism, 
smoking, chronic obstructive pulmonary disease and diabetes mellitus and is a 
particular problem in tropical climates such as Southeast Asia and Australia, where 
skin carriage is more common due to environmental conditions (Anstey, Currie et al. 
1992, Chu, Leung et al. 1999). In these areas A. baumannii can be a cause of severe 
community-acquired pneumonia, especially in young alcoholic patients (Chen, Hsueh 
et al. 2001) and mortality rates as high as 64% have been reported (Dexter, Murray 
et al. 2015). 
1.3.3. Infection in military and disaster zone casualties 
Acinetobacter species are also commonly isolated from deep wound and burn 
infections, and osteomyelitis in military and disaster zones. Reports from the 
Marmara earthquake in Turkey in 1999 described a high incidence of Acinetobacter 
strains as responsible for healthcare associated infection in trauma patients (Oncul, 
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Keskin et al. 2002). Acinetobacter wound infections have been reported in military 
casualties returning from Iraq and Afghanistan, many of them exhibiting MDR 
(Murray, Roop et al. 2006, Johnson, Burns et al. 2007, Petersen, Riddle et al. 2007, 
Scott, Deye et al. 2007). Due to the misconception that A. baumannii is ubiquitous 
and can be isolated from environmental sources it was initially considered that the 
organism was being introduced at the site of injury, or was due to skin colonisation at 
the time of injury. However, there is now evidence of the role of environmental 
contamination and transmission of organisms within health care facilities and it is 
likely that patients with a prolonged stay in US field hospitals provide a reservoir for 
this organism (Davis, Moran et al. 2005, Scott, Deye et al. 2007). 
1.4. Persistence in the hospital environment 
A. baumannii is found almost exclusively in the hospital environment and 
environmental contamination is often responsible for the high incidence of infections 
in military and civilian patients (Catalano, Quelle et al. 1999, Scott, Deye et al. 2007, 
Chaladchalam, Diraphat et al. 2008, O'Shea 2012). A. baumannii has a high level of 
desiccation tolerance and in addition can form biofilms (Tomaras, Dorsey et al. 2003, 
Gaddy and Actis 2009, Gaddy, Tomaras et al. 2009, de Breij, Haisma et al. 2012, 
Greene, Vadlamudi et al. 2016), in which cells are enclosed in an extracellular matrix 
composed of polysaccharides, extracellular DNA and protein (Hobley, Harkins et al. 
2015). Biofilms are significantly more resistant to biocide and antimicrobial treatment, 
host immune responses, desiccation and UV light, which enables them to persist in 
harsh environments, including the hospital setting (Hall-Stoodley, Costerton et al. 
2004, Rajamohan, Srinivasan et al. 2009). In a biofilm, a gradient of nutrients and 
oxygen from the top to the bottom is associated with decreased bacterial metabolic 
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activity and increased doubling times of bacterial cells, which is in part responsible 
for tolerance to antibiotics. Furthermore, biofilm growth can be associated with an 
increased level of mutations, leading to antibiotic resistance (Høiby, Bjarnsholt et al. 
2010). Growth on medical devices and tissue surfaces can lead to biofilm formation 
and increase the risk of bloodstream and respiratory infections (Dijkshoorn, Nemec et 
al. 2007). In vitro studies have shown that biofilms can survive antibiotic 
concentrations of up to 1000 x the minimum inhibitory concentration (MIC) of a 
planktonic culture and in vivo bacteria that survive antibiotic exposure in a biofilm 
state can cause recurrence of infection once antibiotic treatment is stopped (Mah and 
O'Toole 2001, Stewart and William Costerton 2001) 
1.5. Treatment of Acinetobacter infections 
1.5.1. Antibiotics 
Due to the wide spectrum of intrinsic and acquired antibiotic resistance mechanisms 
present in A. baumannii, treatment of infections poses a major challenge. Clinical 
isolates displaying resistance to several classes of antibiotics are commonly 
observed and treatment of MDR isolates is now limited to very few antibiotics. 
1.5.1.1. Sulbactam  
Sulbactam is a β-lactamase inhibitor that binds penicillin binding protein (PBP) 2 in A. 
baumannii (Urban, Go et al. 1995). Whilst its primary purpose is to limit the 
degradation of active β-lactams by β-lactamases, it also demonstrates some intrinsic 
activity against Acinetobacter species when used alone (Levin 2002, Higgins, 
Wisplinghoff et al. 2004). Sulbactam is most commonly used in combination with 
other antibiotics and an ampicillin-sulbactam combination provides an effective 
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therapeutic option for the treatment of MDR Acinetobacter infections (Levin, Levy et 
al. 2003). Oliveira et al. showed that ampicillin-sulbactam may be more efficacious in 
treating carbapenem-resistant Acinetobacter spp. than polymyxins (Oliveira, Prado et 
al. 2008). However, one clinical study has shown that the in vitro activity of an 
ampicillin-sulbactam combination was a result of the antimicrobial activity of 
sulbactam alone and no synergy was observed between ampicillin and sulbactam 
(Corbella, Ariza et al. 1998). It has been suggested that sulbactam should be the 
preferred treatment for infections with this pathogen (Levin 2002, Peleg 2007). 
Unfortunately, increasing clinical use has led to a rise in sulbactam resistance and 
minimum inhibitory concentrations (MICs) of >32 μg/ml have been observed in 
clinical isolates (Henwood, Gatward et al. 2002, Higgins, Wisplinghoff et al. 2004). 
However, spontaneous resistance is rare, with high-level resistance due to mutations 
in pbp3 resulting in a fitness cost in A. baumannii (Penwell, Shapiro et al. 2015). 
Low-level resistance is associated with mutations in genes involved in cell wall 
biosynthesis, such as galE and mraY or stress responses such as rpoC (Penwell, 
Shapiro et al. 2015). Resistance to an ampicillin-sulbactam combination has also 
been seen; in a study conducted in Taiwan, 70% of clinical isolates were ampicillin-
sulbactam resistant (Yang, Chang et al. 2010).  
1.5.1.2. Polymyxins 
Polymyxins are polycationic lipopeptide antimicrobials that show bactericidal activity 
against Acinetobacter spp. They include polymyxin B, polymyxin E and colistin. The 
polymyxins were discovered as chemotherapeutic agents in 1947 (Stansly, Shepherd 
et al. 1947), but use has been minimal due to concerns over neurotoxicity and 
nephrotoxicity (Falagas, Fragoulis et al. 2005, Falagas, Rafailidis et al. 2006). 
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However, with MDR bacteria becoming more prevalent, the use of polymyxins has 
increased and in some cases is recommended for the treatment of carbapenem-
resistant Acinetobacter (Kim, Peleg et al. 2009). Polymyxins show high success rates 
in the clinical setting. Kallel et al. showed successful treatment of 76% of patients 
with MDR A. baumannii or Pseudomonas aeruginosa treated with colistin in the ICU 
(Kallel, Bahloul et al. 2006) and others have also shown success with polymyxin 
treatment against MDR Acinetobacter (Holloway, Rouphael et al. 2006, Falagas, 
Rafailidis et al. 2010). Resistance to these drugs has been rare, however increasing 
use means that the isolation of resistant strains is on the rise (Matthaiou, 
Michalopoulos et al. 2008) with reported polymyxin resistance levels of up to 18% in 
A. baumannii isolates in South Korea (Ko, Suh et al. 2007). Colistin and other 
polymyxins target the lipid A component of lipopolysaccharide (LPS) of Gram 
negative bacteria during initial binding of the outer membrane. Mutations in the lipid A 
biosynthesis genes lpxA, lpxC, and lpxD can result in loss of ability to produce lipid A 
and therefore LPS. This prevents the interaction of colistin with LPS in colistin 
resistant A. baumannii isolates (Moffatt, Harper et al. 2010). An alternative 
mechanism of resistance was identified by Beceiro et al. who observed mutations in 
pmrB and upregulation of pmrAB leading to modification of lipid A and consequently 
colistin resistance (Beceiro, Llobet et al. 2011). Modifications in pmrAB resulting in 
upregulation of the phosphethanolamine gene pmrC, and lipid A modification have 
been also identified in clinical isolates displaying resistance to colistin (Arroyo, 
Herrera et al. 2011, Lesho, Yoon et al. 2013). Resistance to colistin has been shown 
to have a virulence and fitness cost in A. baumannii (López-Rojas, Jiménez-Mejías et 
al. 2011, Hraiech, Roch et al. 2013, Pournaras, Poulou et al. 2014). However, studies 
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have identified pmrB mutants with resistance to colistin and retention of virulence 
(Durante-Mangoni, Del Franco et al. , Wand, Bock et al. 2015). Recent studies have 
shown the emergence of the first plasmid-mediated polymyxin resistance 
mechanism, MCR-1, in Enterobacteriaceae, posing the threat of dissemination 
of mcr-1 among other Gram-negative bacteria such as A. baumannii (Liu, Wang et al. 
2016). 
1.5.1.3. Carbapenems 
Carbapenems are one of the most valuable treatment options against MDR A. 
baumannii. This class of β-lactams shows good bactericidal activity against β-
lactamase producing MDR Acinetobacter isolates (Fishbain and Peleg 2010). 
However, increasing resistance to imipenem and meropenem has been observed in 
the last decade (Karageorgopoulos and Falagas 2008). Resistance to carbapenems 
is most commonly due to production of class D β-lactamases e.g. OXA-51-like, and 
OXA-23-like enzymes (Turton, Ward et al. 2006, Corvec, Poirel et al. 2007), 
increased production of multi-drug efflux pumps, such as AdeABC (Magnet, 
Courvalin et al. 2001, Huang, Sun et al. 2008), and decreased permeability due to 
reduced expression of porins such as CarO (Ravasi, Limansky et al. 2011). 
Carbapenem resistant isolates are often resistant to other classes of antibiotics, 
leaving polymyxins and tigecycline as the only remaining treatment options. A 2007 
study of antimicrobial susceptibility in isolates collected from around the world 
identified susceptibility to imipenem ranging from 60.6% in Latin America to 88.6% in 
North America. Susceptibility was also high in Europe (85.9%), whereas susceptibility 
rates in Asia were moderate to low (69.2%) (Reinert, Low et al. 2007). Since then, 
various studies have highlighted the emergence of carbapenem-resistant isolates in 
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the clinical setting (Scott, Deye et al. 2007, Enoch, Summers et al. 2008, Lee, Fung 
et al. 2011, Kempf and Rolain 2012). However, susceptibility data based on a 
particular carbapenem antibiotic cannot be generalised to all drugs in this class. 
Differing imipenem and meropenem resistance levels have been observed in clinical 
isolates (Ikonomidis, Pournaras et al. 2006). Misinterpreted susceptibility results can 
also give rise to dire consequences; based on susceptibility to imipenem, a case of 
A. baumannii pneumonia by a meropenem resistant isolate was treated with 
meropenem, leading to patient death (Lesho, Wortmann et al. 2005).  
1.5.1.4. Tigecycline 
Tigecycline is a glycycline antibiotic and is a semi-synthetic modified minocycline 
(Neonakis, Spandidos et al. 2011). In vitro activity has been demonstrated against 
595 clinical isolates of Acinetobacter spp. isolated throughout the UK (Henwood, 
Gatward et al. 2002) and global studies have shown MIC90 values of 1-2 μg/ml 
(Reinert, Low et al. 2007, Garrison, Mutters et al. 2009), although breakpoint 
concentrations to define resistance have not yet been established by The Clinical 
and Laboratory Standards Institute (CLSI), The European Committee on 
Antimicrobial Susceptibility Testing (EUCAST) or The British Society for Antimicrobial 
Chemotherapy (BSAC) for this antibiotic class. A good clinical and microbiological 
response to tigecycline treatment of MDR A. baumannii has been observed in some 
cases (Poulakou, Kontopidou et al. 2009). Vasilev et al. identified a cure rate of 
82.4% for resistant A. baumannii infections in a multicentre study (Vasilev, Reshedko 
et al. 2008). However, Gordon et al. observed microbiological clearance of the 
infection in only 68% of cases in a retrospective study of tigecycline treated A. 
baumannii infections in a UK hospital and of 30 patients with pneumonia caused by 
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MDR A. baumannii treated with tigecycline in Korea, only 47% showed clinical 
success (Kim, Moon et al. 2016). This result suggests that tigecycline monotherapy 
may not always be appropriate (Gordon and Wareham 2009). Treatment failure has 
also been observed with tigecycline therapy. In one case of a MDR A. baumannii 
infection of the urinary tract, tigecycline resistance developed during therapy, after 
only three weeks exposure to the drug (Reid, Grim et al. 2007). Evaluation of 
tigecycline treatment in unrelated studies of patients with MDR A. baumannii 
infections has also identified single isolates that developed resistance during 
treatment (Schafer, Goff et al. 2007, Anthony, Fishman et al. 2008). In a study of 70 
A. baumannii isolates from patients in ICU and surgical wards in Poland, 90% 
exhibited tigecycline MICs of > 2 µg/ml (Talaga, Krzysciak et al. 2016). Tigecycline 
diffuses rapidly into tissues resulting in low mean peak serum concentrations at 
recommended doses. As a consequence, therapeutic failure is possible, even with 
susceptible isolates, and so tigecycline is not recommended for bloodstream 
infections (Fishbain and Peleg 2010).  
1.5.1.5. Synergistic combinations 
Due to the increase in the occurrence of MDR Acinetobacter infections and the 
increasingly limited choice of antibiotics available for treatment, there have been 
numerous attempts to identify synergistic combinations of antibiotics to use to treat 
patients. However, many of these studies have been conducted in vitro or in animal 
models and there are few clinical studies to confirm their findings. Most work focuses 
on combinations that increase the efficacy of last line drugs such as carbapenems, 
tigecycline and colistin. Sheng et al. used time kill studies to identify synergism 
between imipenem and colistin, tigecycline, amikacin and ampicillin-sulbactam 
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against carbapenem-resistant Acinetobacter species (Sheng, Wang et al. 2011). 
Synergy was also observed with a combination of colistin and the glycopeptide 
antibiotics vancomycin and teicoplanin, which are usually associated with the 
treatment of Gram-positive infections (Gordon, Png et al. 2010, Wareham, Gordon et 
al. 2011). Clinical data comes from a limited number of studies and these do not 
always support the findings of in vitro studies. In a cohort study, Falagas et al. found 
that cure of infection was not improved with colistin-meropenem combination therapy 
compared with colistin monotherapy (Falagas, Rafailidis et al. 2006). Nonetheless, 
there are some clinical studies that identify a synergistic effect with antibiotic 
combinations; a carbapenem and ampicillin-sulbactam combination was shown to 
give a lower mortality rate than carbapenem monotherapy in a retrospective study of 
55 MDR A. baumannii bacteraemia infections in Taiwan (Kuo, Lai et al. 2007). A 
combination of rifampicin with both colistin and imipenem has shown activity against 
carbapenem resistant A. baumannii infections in critically ill patients (Motaouakkil, 
Charra et al. 2006, Saballs, Pujol et al. 2006). The use of minocycline in combination 
with other antimicrobials has also been suggested as a valid, alternative therapy for 
MDR A. baumannii (Neonakis, Spandidos et al. 2014). 
1.5.2. Novel therapeutics 
With the rapid emergence of MDR, extremely-drug resistant (XDR) and even pan-
drug resistant (PDR) isolates of A. baumannii, it is becoming necessary to develop 
alternative therapies for the treatment of this pathogen. Anti-virulence drugs, anti-
biofilm drugs and phage therapy are thought promising in the treatment of resistant 
infections. For example, Lood et al. identified a highly active therapeutic lysin capable 
of killing A. baumannii clinical isolates, representing a potential novel treatment for A. 
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baumannii infection (Lood, Winer et al. 2015). The development of an effective 
vaccine for A. baumannii could also provide a solution for reducing morbidity and 
mortality in certain patient populations. OmpA (Luo, Lin et al. 2012), Bap (Fattahian, 
Rasooli et al. 2011), Ata (Bentancor, Routray et al. 2012) and Poly-β-1-6-N-
acetylglucosamine (PNAG) (Bentancor, O'Malley et al. 2012) have all been shown to 
be good candidates and multicomponent vaccines have also shown potential as 
therapeutics (Garcia-Quintanilla, Pulido et al. 2014).  
1.6. Mechanisms of antibiotic resistance 
Acinetobacter spp. possess a wide range of antibiotic resistance mechanisms, both 
intrinsic and acquired, chromosomal and plasmid borne, allowing this bacterium to 
survive challenge by many classes of antibiotics (Peleg, Seifert et al. 2008, Roca, 
Espinal et al. 2012). The plasticity of the Acinetobacter genome also allows it to 
adapt to antibiotic pressure by capturing antibiotic resistance genes. An 86 kb 
genomic resistance island (AbaR1) was identified in clinical isolates of MDR A. 
baumannii, harbouring 45 genes conferring resistance to various classes of 
antibiotics including β-lactams, aminoglycosides, tetracycline and chloramphenicol 
(Fournier, Vallenet et al. 2006). This highlights the remarkable ability of this organism 
to acquire large mobile genetic elements, allowing it to rapidly adapt to its 
surroundings. Recent studies have also shown that A. baumannii can act as a source 
of emerging antibiotic resistance genes. Bonnin et al. suggested that the genetic 
structure responsible for the dissemination of the bla NDM-1 gene most probably 
originates from Acinetobacter and that the bla NDM-1 gene itself may be constructed 
through a recombination event in Acinetobacter (Bonnin, Poirel et al. 2014). The 
most widespread mechanisms of resistance in A. baumannii are modification of the 
20 
 
target, degradation or inactivation of the antibiotic and reduced permeability and 
active efflux of the agent. These mechanisms often work in combination to produce 
high levels of antibiotic resistance. For example, production of β-lactamases, 
overexpression of outer membrane proteins such as CarO and PBP modifications 
may all contribute towards carbapenem resistance in A. baumannii (Poirel and 
Nordmann 2006). A summary of the mechanisms of resistance to commonly used 
classes of antibiotics is shown in Table 1.6.1. 
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Table 1.6.1 Resistance mechanisms in Acinetobacter spp. 
 
Antimicrobial Resistance mechanism Protein 
β-Lactams 1. Target site modification 
Modified penicillin-binding 
proteins 
PBP 
2. Drug Inactivation 
Chromosomal 
cephalosporinase 
AmpC 
Carbapenem-hydrolysing class 
D β-lactamases 
OXA-51-like, OXA-23-like, OXA-
24/40-like, OXA-58-like, OXA-143-
like 
Metallo-β-lactamases IMP, VIM, SIM-1, NDM 
Other β-lactamases TEM, SHV, SCO-1, CARB, PER, 
VEB, CTX-M, GES, KPC, OXA-2, 
10, 20, 37 
3. Reduced drug accumulation 
Decreased permeability CarO, 47 kDa OMP, 44 kDa OMP, 
37 kDa OMP, 33–36 kDa OMP, 22–
33 kDa OMP, 
HMP-AB, 43 kDa OMP 
Efflux pump AdeABC, AdeIJK, AdeFGH, AdeDE, 
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Antimicrobial Resistance mechanism Protein 
AdeXYZ 
Aminoglycosides 1. Target site modification 16S rRNA methylases 
2. Drug Inactivation 
Aminoglycoside-modifying 
enzymes 
Acetyltransferases, 
Nucleotidyltransferases, 
Phosphotransferases 
3. Reduced drug accumulation 
Efflux pump AdeABC, AbeM, AdeDE 
Quinolones 1.Target site modification GyrA/ParC 
3. Reduced drug accumulation 
Efflux pump AdeABC, AdeIJK, AdeFGH, AdeDE, 
AbeM, AbeS 
Chloramphenicol 3. Reduced drug accumulation 
Efflux pump AdeABC, AdeIJK, AdeFGH, AdeDE, 
AdeXYZ, CmlA, CraA, AbeM, AbeS 
Tetracyclines 1. Target site modification 
Ribosomal protection TetM 
3. Reduced drug accumulation 
Efflux pump TetA, TetB, AdeDE, AdeXYZ 
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Antimicrobial Resistance mechanism Protein 
Tigecycline 3. Reduced drug accumulation 
Efflux pump AdeABC, AdeIJK 
Polymyxins 1. Target site modification 
Lipid A modification PmrCAB 
Loss of lipopolysaccharide LpxABC 
3. Reduced drug accumulation 
Decreased permeability CarO, OmpA38, OmpA32, OmpW 
Adapted from (Roca, Espinal et al. 2012). 
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1.6.1. Target site modification 
Target modification occurs in various systems in A. baumannii. Mutations in gyrA and 
parC are common, resulting in modified DNA gyrase or topoisomerase and 
preventing fluoroquinolones from interacting with the DNA-gyrase complex 
(Hamouda and Amyes 2004). Changes in PBPs and ribosomal protection by the 
TetM protein have also been observed (Lambert 2005). Phosphoethanolamine 
modification of lipid A was shown to lead to resistance to colistin in Acinetobacter by 
reducing the affinity of LPS for the antibiotic (Beceiro, Llobet et al. 2011). Modification 
of LPS may occur via two pathways; complete loss of LPS due to mutations in the 
lipid biosynthesis genes lpxA, lpxC and lpxD (Moffatt, Harper et al. 2010), or 
mutations in the two component system (TCS) genes pmrAB that lead to 
upregulation of pmrC, which encodes a phosphethanolamine responsible for 
modification of LPS (Durante-Mangoni, Del Franco et al. , Arroyo, Herrera et al. 2011, 
Lesho, Yoon et al. 2013, Wand, Bock et al. 2015). 
1.6.2. Drug inactivation 
β-lactamases confer resistance to various β-lactam antibiotics in Acinetobacter spp. 
by inactivation of the drug. Chromosomally encoded AmpC cephalosporinases can 
be found in all strains of A. baumannii and increased expression due to an upstream 
insertion sequence (IS) element, ISAba1, provides resistance to cephalosporins (Bou 
and Martinez-Beltran 2000, Hujer, Hujer et al. 2006, Ruiz, Marti et al. 2007). 
Extended spectrum β-lactamases (ESBLs) including VEB (Carbonne, Naas et al. 
2005), PER (Naas, Bogaerts et al. 2006), TEM (Endimiani, Luzzaro et al. 2007), SHV 
(Huang, Mao et al. 2004) and CTX-M (Nagano, Nagano et al. 2004) have all been 
described in A. baumannii, and can be found both plasmid and chromosomally 
25 
 
encoded. Carbapenem hydrolysing enzymes are the most clinically relevant β-
lactamases in Acinetobacter and both metallo-β-lactamases (MBLs) and serine 
oxacillinases (OXA) have been identified in Acinetobacter (Poirel and Nordmann 
2006). The most widespread of these are the OXA-type enzymes, which can be 
encoded chromosomally or on a plasmid. blaOXA-51-like enzymes are naturally 
occurring in A. baumannii and encoded chromosomally. In the presence of an 
upstream promoter found associated with ISAbaI, blaOXA-51-like genes provide 
intrinsic resistance to carbapenems (Turton, Ward et al. 2006, Turton, Woodford et 
al. 2006). blaOXA-51-like genes have a high prevalence worldwide and have been 
described in several studies (Héritier, Poirel et al. 2005, Coelho, Woodford et al. 
2006, Hujer, Hujer et al. 2006, Turton, Woodford et al. 2006, Evans, Brown et al. 
2007). blaOXA-23-like, blaOXA-24-like and blaOXA-58 like gene clusters have also 
been described as conferring carbapenem resistance in Acinetobacter (Donald, 
Scaife et al. 2000, Afzal-Shah, Woodford et al. 2001, Da Silva, Quinteira et al. 2004, 
Boo, Walsh et al. 2006, Coelho, Woodford et al. 2006, Corvec, Poirel et al. 2007). 
Aminoglycoside-modifying enzymes (AMEs) are the primary mechanism of 
resistance to aminoglycosides in A. baumannii. AME genes are typically found on 
transposable elements and isolates of A. baumannii may carry a number of different 
ones (Gallego and Towner 2001, Zhu, Wang et al. 2009). AME genes ant(3")-Ia, 
aac(6')-Ib, aph(3')-1a, aac(3)-Ia, aph(3')-VI, ant(3")-Ia, aac(6')-Ib and 16S ribosomal 
RNA (rRNA) methylase armA have all been previously identified in A. baumannii 
(Cho, Moon et al. 2009). 
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1.6.3. Reduced drug accumulation 
1.6.3.1. OMP expression 
Loss of outer membrane proteins (OMPs) has also been implicated in A. baumannii 
resistance to antibiotics. A. baumannii possess few outer membrane porins, and 
intrinsic low level resistance can be partly attributed to low permeability of the outer 
membrane (Sato and Nakae 1991). Altered expression of OMPs in response to 
antibiotic challenge can further reduce permeability to antimicrobials and lead to 
MDR. Expression of OmpA38, OmpA32, CarO and OmpW is reduced in the 
presence of sub-MIC levels of tetracycline, suggesting a role for OMPs in tetracycline 
resistance (Yun, Choi et al. 2008) and disruption of the OmpA gene in A. baumannii 
leads to decreased MICs of chloramphenicol, aztreonam and nalidixic acid (Smani, 
Dominguez-Herrera et al. 2013). Furthermore, loss of OMPs has been implicated in 
carbapenem resistance and is seen in clinical isolates worldwide (Bou, Cerveró et al. 
2000, Tomás, Beceiro et al. 2005, Hwa, Subramaniam et al. 2010). 
1.6.3.2. Efflux  
Intrinsic expression of efflux pumps in A. baumannii allows a broad range of 
substrates to be removed from the cell, conferring resistance to various antibiotic 
classes. Increased expression of chromosomal efflux pumps and acquisition of 
additional efflux systems can then lead to MDR (Coyne, Courvalin et al. 2011). 
1.6.3.2.1. RND efflux pumps 
The resistance nodulation division (RND) family are the most common efflux systems 
causing MDR in Acinetobacter and six pumps of this type have been identified and 
characterised in species belonging to the Acb complex. RND pumps in Gram 
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negative bacteria comprise of three components, forming a tripartite pump. The efflux 
protein is located in the inner membrane, the OMP channel spans the outer 
membrane and a membrane fusion protein (MFP) links the two (Figure 1.6.1) 
(Piddock 2006). There is often a high level of homology between proteins in this 
family and RND pump proteins identified in A. baumannii show similarity to the 
MexXY-OprM and MexD previously characterised in P. aeruginosa and MtrC from 
Neisseria gonorrhoeae (Magnet, Courvalin et al. 2001, Coyne, Courvalin et al. 2011). 
Much of the work to characterise the Acinetobacter RND family efflux pumps comes 
from the Courvalin team and is based on analysis of a single strain of A. baumannii, 
BM4454. This may not necessarily represent all strains or species and further work is 
required to confirm these findings in other strains. 
AdeABC is the most well characterised tripartite RND MDR efflux system in 
Acinetobacter. AdeA is a MFP, AdeB is a RND protein and AdeC is an OMP 
(Magnet, Courvalin et al. 2001). Found in both A. baumannii and other clinically 
relevant species (Magnet, Courvalin et al. 2001, Roca, Espinal et al. 2011), AdeABC 
is chromosomally encoded but has only been identified in clinical isolates, is tightly 
regulated and only confers MDR when overexpressed (Magnet, Courvalin et al. 
2001, Yoon, Courvalin et al. 2013, Yoon, Nait Chabane et al. 2015). MIC studies with 
mutants that lack or overexpress specific efflux pump genes revealed that substrates 
for this pump include aminoglycosides, β-lactams, fluoroquinolones, tetracyclines, 
tigecycline, macrolides, chloramphenicol and trimethoprim (Magnet, Courvalin et al. 
2001, Marchand, Damier-Piolle et al. 2004, Yoon, Nait Chabane et al. 2015). A role 
for AdeABC in efflux of carbapenems has also been shown. Studies of clinical MDR 
isolates showed a correlation between carbapenem resistance and overexpression 
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Figure 1.6.1 Schematic diagram of the AdeABC tripartite RND system 
The RND pump (e.g. AdeB) is situated in the inner membrane in complex with the 
outer membrane channel (e.g. AdeC) and a periplasmic adaptor protein (e.g. AdeA) 
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of AdeABC (Héritier, Poirel et al. 2005, Huang, Sun et al. 2008, Hou, Chen et al. 
2012) and AdeABC has been shown to work synergistically with enzymatic 
mechanisms to contribute towards carbapenem resistance. However, addition of 
efflux inhibitors carbonyl cyanide-m-chlorphenyl hydrazone (CCCP) did not affect 
carbapenem MICs in imipenem-resistant clinical isolates from Greece (Pournaras, 
Markogiannakis et al. 2006). Inactivation of adeB causes loss of intrinsic resistance 
to multiple antibiotics (Magnet, Courvalin et al. 2001), whereas inactivation of adeC 
does not have the same effect. This suggests that AdeC is not essential for MDR and 
that other OMPs may be recruited by AdeAB (Marchand, Damier-Piolle et al. 2004). 
AdeABC is encoded as an operon, adeABC, and is regulated by the two-component 
system AdeRS (Marchand, Damier-Piolle et al. 2004). However, MDR due to 
AdeABC overexpression has been seen in the absence of AdeRS mutations, 
suggesting another mechanism causing increased pump activity is also possible 
(Peleg, Adams et al. 2007, Sun, Chan et al. 2010). It has been proposed that the two 
component system BaeSR may also influence transcription of adeAB by functioning 
as a global regulator (Lin, Lin et al. 2014). 
AdeIJK is found only in A. baumannii and has not been observed in any of the other 
members of the Acb complex. AdeJ shows 57% identity with AcrB from Escherichia 
coli and 97% identity with the AdeY RND protein from Acinetobacter pittii (Chu, Chau 
et al. 2006) and confers intrinsic MDR (Damier-Piolle, Magnet et al. 2008, Lin, Ling et 
al. 2009). AdeIJK is constitutively expressed and is responsible for intrinsic 
resistance to multiple classes of antibiotics in A. baumannii (Yoon, Nait Chabane et 
al. 2015). Evidence from MIC studies with mutants that lack specific efflux pump 
genes suggest that AdeIJK exports β-lactams, fluoroquinolones, tetracyclines, 
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tigecycline, lincosamides, rifampicin, chloramphenicol, co-trimoxazole, novobiocin 
and fusidic acid, but not aminoglycosides (Damier-Piolle, Magnet et al. 2008, Coyne, 
Guigon et al. 2010, Amin, Richmond et al. 2013). AdeIJK is only expressed at low 
levels in A. baumannii BM4454 and once expression reaches threshold levels in E. 
coli AG100A the pump becomes toxic to the host (Damier-Piolle, Magnet et al. 2008, 
Coyne, Guigon et al. 2010). AdeIJK is encoded by the adeIJK operon and regulated 
by the TetR transcriptional regulator adeN (Rosenfeld, Bouchier et al. 2012).  
AdeFGH is encoded by the adeFGH operon but is not expressed constitutively and 
so does not appear to contribute to intrinsic resistance (Coyne, Rosenfeld et al. 2010, 
Yoon, Nait Chabane et al. 2015). MIC data for mutants overexpressing adeFGH 
indicate that the substrates of this pump include fluoroquinolones, chloramphenicol, 
trimethoprim, clindamycin, tetracyclines, tigecycline and sulfamethoxazole (Coyne, 
Rosenfeld et al. 2010, Yoon, Nait Chabane et al. 2015). Spontaneous MDR mutants 
selected from BM4652 (BM4454ΔadeABCΔadeIJK) on norfloxacin and 
chloramphenicol contain mutations in a putative LysR-type transcriptional regulator 
gene, adeL, located upstream of adeFGH. It is proposed that these mutations cause 
a constitutive phenotype, leading to increased expression of the AdeFGH efflux 
system (Coyne, Rosenfeld et al. 2010).  
AdeDE was identified as a novel RND efflux system in A. pittii by Chau et al. (Chau, 
Chu et al. 2004) but no OMP gene was found encoded alongside adeDE. It is 
suggested that AdeDE recruits an OMP encoded elsewhere on the chromosome. 
Inactivation of adeE in a clinical isolate reduced susceptibility to aminoglycosides, 
carbapenems, ceftazidime, fluoroquinolones, erythromycin, tetracycline, rifampicin 
and chloramphenicol (Chau, Chu et al. 2004). Although initially described in A. pittii, 
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AdeDE has also been observed in A. nosocomialis and Acinetobacter gsp 17. 
However, prevalence is highest in A. pittii, with 70% of 83 clinical isolates studied 
containing the adeDE operon (Chu, Chau et al. 2006). AdeE was also found to 
coexist with AdeB in six out of 50 A. baumannii isolates studied (Hou, Chen et al. 
2012). 
AdeXYZ is a RND pump found in Acinetobacter spp. other than A. baumannii. It was 
identified in 90% of 83 A. pittii isolates tested in a study of blood culture isolates in 
China and was also been observed in A. nosocomialis and A. gsp. 17 (Chu, Chau et 
al. 2006). Although AdeXYZ has not been well characterised, the pump proteins 
show high homology with AdeIJK, suggesting a similar function and possibly 
substrate range (Chu, Chau et al. 2006, Damier-Piolle, Magnet et al. 2008, Coyne, 
Courvalin et al. 2011). 
1.6.3.2.2. Non-RND efflux pumps  
Acinetobacter spp. also possess other chromosomally encoded non-RND efflux 
systems: CraA contributes to intrinsic resistance to chloramphenicol (Roca, Marti et 
al. 2009), AmvA is a major facilitator superfamily (MFS) pump that exports 
erythromycin (Rajamohan, Srinivasan et al. 2010), AbeM is a member of the multi-
drug and toxic compound extrusion (MATE) family and has a suggested role in 
resistance to a range of antibiotics and dyes (Su, Chen et al. 2005), and AbeS is a 
small multi-drug resistance (SMR) efflux pump involved in chloramphenicol, 
fluoroquinolone, erythromycin, novobiocin and dye and detergent resistance 
(Srinivasan, Rajamohan et al. 2009). AceI is a member of the new family of 
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antibacterial efflux pumps discovered in A. baumannii that confers resistance to 
biocides (Hassan, Jackson et al. 2013, Hassan, Liu et al. 2015). 
Various acquired efflux systems have also been identified in Acinetobacter spp., 
carried either on plasmids, transposons or resistance islands (Vila, Martí et al. 2007). 
Most common are pumps of the MFS type that give resistance to tetracycline. The 
TetA pump, has been observed in 13.6% of 59 tetracycline resistant strains of A. 
baumannii and the TetB pump, conferring tetracycline and minocycline resistance, in 
66% of the 59 isolates (Marti, Fernandez-Cuenca et al. 2006)(Marti, Fernandez-
Cuenca et al. 2006). In a study of 32 clinical isolates of A. baumannii conducted by 
Mak et al., 28 contained the tetB gene whilst tetA was not present in any isolate 
(Mak, Kim et al. 2009)(Mak, Kim et al. 2009). The tetG and tetR MFS pump genes 
have also been observed in Acinetobacter spp., as part of the acquired ISAbaR1 
resistance island (Fournier, Vallenet et al. 2006). The MFS pumps CmlA and FloR, 
and the SMR pump QacE are also acquired on the ISAbaR1 resistance island 
identified in A. baumannii AYE (Fournier, Vallenet et al. 2006). 
1.7. Regulation of antibiotic resistance 
Very little is known about the regulatory networks of A. baumannii. A number of two 
component systems (TCSs) are encoded in the genome of this pathogen and of 
these, AdeRS and PmrAB have been most well characterised with regards to 
antimicrobial resistance. TCSs allow bacteria to regulate their internal environment in 
response to extracellular signals. A signal recognition domain on a sensor kinase 
recognises an external cue and activates an autokinase domain, resulting in ATP 
hydrolysis and phosphorylation of a histidine located on the phosphotransferase sub-
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domain of the autokinase. The phosphoryl group is then transferred to the receiver 
domain of a response regulator (Figure 1.7.1). This relieves inhibition of the output 
domain of the response regulator and results in changes in DNA binding and 
transcription, enzymatic activity, binding of RNA or protein–protein interactions (Hoch 
2000, Mitrophanov and Groisman 2008).  
1.7.1.1. AdeRS 
AdeRS is a two component system responsible for the regulation of the RND efflux 
pump AdeABC (Marchand, Damier-Piolle et al. 2004). The system is encoded by 
adeRS, which is upstream and in the opposite direction to adeABC (Marchand, 
Damier-Piolle et al. 2004). AdeS is a sensor kinase and AdeR is its associated 
response regulator. Whole genome analysis of longitudinal clinical isolates has 
revealed that genes involved in antibiotic resistance and host interaction, such as 
adeRS, are significantly enriched for novel genetic variants (Wright, Iovleva et al. 
2016). In an analysis of 40 patients, 16 independent mutations and insertion events 
were observed in 12 patients. Sequence variation in adeRS has been previously 
associated with tigecycline resistance, however only three patients were confirmed to 
have received tigecycline therapy, suggesting that the regulation of adeABC is under 
selection for more than just tigecycline efflux. The amino acid sequence of AdeRS is 
widely variable in clinical isolates and mutations in the adeRS regulatory system 
genes are associated with constitutive expression of AdeABC and MDR (Marchand, 
Damier-Piolle et al. 2004, Peleg, Adams et al. 2007, Hornsey, Loman et al. 2011, 
Yoon, Courvalin et al. 2013). The Gly186Val amino acid substitution in AdeS is 
crucial for reducing tigecycline susceptibility and results in increased expression  
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Figure 1.7.1 A schematic of a two component signal transduction system  
 
(Jensen, Wang et al. 2002) 
AdeR AdeS 
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adeA and adeB (Sun, Jeng et al. 2016). The Asp20Asn amino acid substitution in 
AdeR is associated with reduced susceptibility to meropenem, amikacin, 
fluoroquinolones, erythromycin and tetracycline due to increased expression of adeB 
and enhanced efflux activity (Nowak, Schneiders et al. 2016). Overexpression of 
AdeABC has also been seen in a clinical isolate due to the insertion of ISAba1 into 
adeS (Ruzin, Keeney et al. 2007). A truncated AdeS generated by the Pout promoter 
within the ISAbaI insertion of the adeS gene that is able to activate AdeR and 
increase expression of adeABC has been proposed by Sun et al. (Sun, Perng et al. 
2012). Furthermore, it has been suggested that genetic variability in AdeRS may 
account for differing levels of tigecycline resistance in clinical isolates of A. baumannii 
(Montaña, Vilacoba et al. 2015). 
1.7.1.2. PmrAB 
PmrAB is a TCS that has been linked to colistin resistance in several species 
including Klebsiella pneumoniae and P. aeruginosa (Moskowitz, Ernst et al. 2004, 
Cheng, Chen et al. 2010) as well as A. baumannii (Adams, Nickel et al. 2009). The 
system is encoded by pmrAB where pmrA encodes the response regulator and pmrB 
encodes the sensor kinase (Adams 2009). In Salmonella enterica, PmrAB controls 
the modification of lipid A with aminoarabinose and phosphethanolamine (Zhou, 
Ribeiro et al. 2001). Phosphorylation of PmrA by PmrB activates the pmrC gene, 
which is an inner membrane protein that is required for the incorporation of 
phosphoethanolamine into lipid A. This modification of lipid A reduces the binding 
affinity for polymyxins and results in resistance (Lee, Hsu et al. 2004). Mutations in, 
or increased expression of, pmrA or pmrB in A. baumannii has been associated with 
resistance to colistin (Adams, Nickel et al. 2009, Beceiro, Llobet et al. 2011, Park, 
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Choi et al. 2011, Kim, Bae et al. 2014, Wand, Bock et al. 2015). Arroyo et al. showed 
that deletion of the pmrB gene led to a decrease in susceptibility to polymyxins in A. 
baumannii clinical isolates and demonstrated a correlation between increased 
expression of pmrC and polymyxin resistance. Addition of phosphethanolamine to 
lipid A also correlated with resistance, in line with results previously seen in S. 
enterica (Zhou, Ribeiro et al. 2001, Arroyo, Herrera et al. 2011). 
1.8. Pathogenesis and virulence of Acinetobacter 
As well as the concern of rising antibiotic resistance, investigation into the 
pathogenicity of Acinetobacter is also an important area of research. Relatively little 
is known about pathogenicity and virulence factors in Acinetobacter as most studies 
have focused on epidemiology and risk factors for infection. Key to the success of 
pathogenic species of Acinetobacter is their metabolic adaptability. Their ability to 
persist on abiotic surfaces allows them to survive in the hospital environment and 
cause nosocomial outbreaks (Wendt, Dietze et al. 1997, Jawad, Seifert et al. 1998). 
Outbreak strains of A. baumannii have been isolated from bed rails up to nine days 
after the infected patient was discharged, allowing transmission of the organism 
throughout the hospital (Catalano, Quelle et al. 1999). Pathogenic species, such as 
A. baumannii, are able to adhere to, colonise and invade human epithelial cells 
(Choi, Lee et al. 2008) and are often able to survive antibiotic treatment due to 
upregulation of existing antibiotic resistance genes and acquisition of foreign genetic 
material (Peleg, Seifert et al. 2008).  
Various approaches have been taken to identify genes that are associated with 
pathogenicity in this organism. Figure 1.8.1 shows the genes known to be involved in  
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Figure 1.8.1 Summary of the genes shown to be directly or indirectly involved in antibiotic resistance, virulence, 
biofilm formation, motility and adherence in A. baumannii 
 
Shaded circles indicate regulatory genes. Red arrows indicate a direct association between regulator and phenotype. 
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antibiotic resistance, virulence, biofilm, motility and adherence in Acinetobacter. Sahl 
et al. conducted a global comparison of genomic features between species of 
Acinetobacter in order to identify genes that had been acquired and lost in different 
species in the genus (Sahl, Gillece et al. 2013). Pathogenic species, such as A. 
baumannii, and other species included in the Acb complex, had acquired various 
genes when compared to the Acinetobacter root species, A. radioresistens. They 
proposed that these acquired genes may be associated with the increased ability of 
these species to persist and cause infection in the hospital environment. Amongst 
those genes unique to the Acb complex were several genes that have been 
previously linked to Acinetobacter pathogenicity including iron acquisition systems 
and the csuE gene. 
The csuA/BABCDE operon encodes a chaperone-usher pilus assembly system and 
is involved in attachment to, and biofilm formation on, abiotic surfaces in A. 
baumannii (Tomaras, Dorsey et al. 2003, de Breij, Gaddy et al. 2009). Disruption of 
csuE in strain ATCC 19606 eliminated pilus formation and cells were no longer able 
to attach or form a biofilm (Tomaras, Dorsey et al. 2003). The csuE gene is highly 
conserved in A. baumannii and its absence from non-Acb complex species may 
explain why these species are not able to persist in the hospital environment (Sahl, 
Gillece et al. 2013). However, de Breij et al. have shown that deletion of csuE has no 
effect on adherence to bronchial epithelial cells and suggest that an alternative 
mechanism is responsible for attachment to host cells (de Breij, Gaddy et al. 2009). 
Unique to the Acb complex were also a number of regulatory genes with unknown 
function, which may contribute to persistence and virulence in pathogenic 
Acinetobacter. The importance of the two component system BfmRS in regulating 
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expression of the CsuA/BABCDE system has been shown in A. baumannii ATCC 
19606, suggesting a role for BfmRS in attachment to, and biofilm formation on, 
abiotic surfaces (Tomaras, Flagler et al. 2008). The role of BfmRS in the regulation of 
Csu dependent attachment could suggest that this regulatory system has no 
involvement in attachment to biotic surfaces. However, deletion of bfmS in A. 
baumannii strain ATCC 17978 resulted in a reduction in biofilm formation, loss of 
adherence to A549 human alveolar epithelial cells and greater sensitivity to serum 
killing, indicating that it may regulate virulence genes other than csu (Liou, Soo et al. 
2013). 
Siderophore mediated iron acquisition systems are also known virulence factors in 
Acinetobacter. The acinetobactin iron acquisition cluster is highly conserved in A. 
baumannii and is required for persistence and killing of A549 human alveolar 
epithelial cells in ATCC 19606 (Gaddy, Arivett et al. 2012, Sahl, Gillece et al. 2013). 
BasD and BauA, two proteins required for acinetobactin biosynthesis and transport, 
are not required for initial interaction with human alveolar epithelial cells. However, 
these proteins are necessary for persistence and cell death in epithelial cells and for 
effective killing of Galleria mellonella larvae (Gaddy, Arivett et al. 2012). 
The most well studied virulence factor in Acinetobacter is OmpA, previously called 
Omp38. This outer membrane protein (OMP) binds to human laryngeal epithelial 
HEp-2 cells, localises to the mitochondria and leads to apoptosis. A mutant of A. 
baumannii ATCC 19606 lacking OmpA showed a decrease in invasion and death of 
human laryngeal epithelial HEp-2 cells, and less lung and tissue destruction in a 
murine pneumonia model (Choi, Lee et al. 2005, Choi, Lee et al. 2008). OmpA is also 
involved in a number of other functions including biofilm formation (Gaddy, Tomaras 
40 
 
et al. 2009) and serum resistance (Kim, Choi et al. 2009). Another porin associated 
with virulence in A. baumannii is the Omp33-36 porin. Omp33-36 plays an important 
role in fitness and virulence in A. baumannii and is a virulence factor in a systemic 
mouse model of infection (Smani, Dominguez-Herrera et al. 2013, Rumbo, Tomás et 
al. 2014). 
Other virulence factors identified in Acinetobacter species include surface antigen 
protein 1 (SurA1) (Liu, Liu et al. 2016), the type VI secretion system (Repizo, Gagne 
et al. 2015), penicillin binding protein (PBP) 7/8 (Russo, MacDonald et al. 2009), 
capsule formation (Russo, Luke et al. 2010), and phospholipase C and D 
(Camarena, Bruno et al. 2010, Jacobs, Hood et al. 2010), However, little is known 
about how these factors affect pathogenicity and virulence. 
1.8.1. Biofilm formation 
Formation of a biofilm is commonly a feature of A. baumannii clinical isolates and the 
ability to form a biofilm has been linked to pathogenesis in this organism (Hall-
Stoodley, Costerton et al. 2004, Sanchez, Mende et al. 2013, Badave and Kulkarni 
2015, He, Lu et al. 2015). Biofilms are an important virulence factor in wound 
infection (Percival, Hill et al. 2012) and infection with A. baumannii is often 
associated with indwelling medical devices, which can provide a surface for biofilm 
development (Rodríguez-Baño, Martí et al. 2008, Jung, Park et al. 2010). Biofilm 
formation has also been correlated with MDR in clinical A. baumannii isolates 
(Badave and Kulkarni 2015). Furthermore, high biofilm phenotype is important for 
both clinical and environmental isolates to tolerate desiccation (Hu, Johani et al. 
2015, Greene, Vadlamudi et al. 2016). A homologue of the staphylococcal biofilm-
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associated protein (Bap) has been identified as a virulence factor in A. baumannii 
(Loehfelm, Luke et al. 2008). A transposon mutant lacking Bap was unable to sustain 
biofilm thickness and volume on a glass coverslip. Lack of Bap did not affect primary 
attachment, suggesting a role in maintaining the mature biofilm architecture. Bap is 
also important for adherence to normal human bronchial epithelial cells and normal 
human neonatal keratinocytes, although it has no involvement in invasion of these 
cells (Brossard and Campagnari 2012). Poly-β-1-6-N-acetylglucosamine (PNAG) is a 
key virulence factor in the formation of biofilms (Choi, Slamti et al. 2009). Deletion of 
pgaABCD, which encodes proteins that synthesise cell-associated PNAG resulted in 
the loss of a strong biofilm phenotype under dynamic conditions, simulated by 
vigorous shaking of cultures, but had no effect under static conditions (Choi, Slamti et 
al. 2009). The abaI autoinducer synthase gene is also important in biofilm formation 
in A. baumannii and encodes a distinct acyl-homoserine lactone (AHL) signal. The 
AbaI autoinducer synthase was required for the later stages of biofilm development, 
suggesting that quorum sensing influences expression of genes involved in 
maturation of the biofilm (Niu, Clemmer et al. 2008). Extracellular DNA (eDNA) is a 
component of microbial biofilms and is able to augment A. baumannii biofilms on an 
abiotic surface, suggesting a role in biofilm formation in this organism (Sahu, Iyer et 
al. 2012). Furthermore, pre-formed A. baumannii biofilms were destroyed by DNase I, 
supporting the role of eDNA in biofilms (Sahu, Iyer et al. 2012). 
1.9. Biofilm models for Acinetobacter 
Expression of virulence factors involved in bacterial biofilm formation can vary widely 
depending on the model system used (Anderson, Moreau-Marquis et al. 2008, Otto 
2008, Anderson, Lin et al. 2012). Previous studies have shown that genes involved in 
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biofilm formation on abiotic surfaces are not necessarily required for attachment to, 
and biofilm formation on, biological surfaces (Anderson, Moreau-Marquis et al. 2008, 
Otto 2008, Anderson, Lin et al. 2012). For example, production of the A. baumannii 
CsuA/BABCDE-mediated pilus is essential for biofilm formation on abiotic surfaces 
but is not required for attachment to bronchial epithelial cells in vitro (de Breij, Gaddy 
et al. 2009). This highlights the need to measure biofilm formation in multiple models 
to determine the specific roles of individual virulence factors.  
There are several models used to study biofilm formation on biotic and abiotic 
surfaces. Formation of biofilms on hospital surfaces and indwelling medical devices is 
a particular problem with A. baumannii and it is therefore necessary to investigate the 
mechanisms of biofilm formation on abiotic surfaces. The most common method of 
measuring biofilm formation on solid surfaces, such as plastics, is by staining with 
crystal violet, a dye that stains bacterial cells but not the surface they are bound to 
(Tomaras, Dorsey et al. 2003, Tomaras, Flagler et al. 2008, de Breij, Gaddy et al. 
2009, Gaddy, Tomaras et al. 2009). Liou et al. demonstrated the involvement of 
bfmS in formation of biofilms by A. baumannii by growing cultures in polyvinylchloride 
(PVC) microtitre dishes and staining the biofilm that formed in each well with crystal 
violet (Liou, Soo et al. 2013). This method has also been used by King et al. to study 
biofilm formation on polystyrene by serum resistant isolates of A. baumannii (King, 
Pangburn et al. 2013). The Calgary biofilm device (Ceri, Olson et al. 1999) uses a 
similar principle and measures formation of a biofilm on plastic pegs suspended in a 
bacterial culture, by crystal violet staining. This method has been successfully used 
to measure biofilm formation by clinical isolates of A. baumannii (Wand, Bock et al. 
2012). 
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Study of A. baumannii biofilm formation on biotic surfaces is also a key area of 
research. Infection of wounds by A. baumannii has been a significant problem in 
military casualties (Murray, Yun et al. 2006, Scott, Deye et al. 2007, Sebeny, Riddle 
et al. 2008, Johnson, Marconi et al. 2009) and it is possible that the ability of this 
organism to form a biofilm is a major virulence factor in this environment (Beachey 
1981, Costerton, Stewart et al. 1999). However, research in this area is limited. 
Although mouse models have been used to investigate A. baumannii infections in 
partial-thickness skin abrasions and full-thickness burns, biofilm formation was not 
studied (Dai, Murray et al. 2012). Most work in this area has focussed on attachment 
to and invasion of respiratory surfaces such as human bronchial epithelial H292 cell 
lines (de Breij, Gaddy et al. 2009), human epithelial HeLa cells (Lee, Oh et al. 2001) 
and human laryngeal Hep-2 cells (Choi, Lee et al. 2005). 
Anderson et al. have developed a novel ex vivo model of biofilm formation on a 
mucosal surface that allows the contribution of microbial virulence factors to biofilm 
formation to be studied (Anderson, Parks et al. 2013). This model measures growth 
of bacterial cells on porcine vaginal mucosal (PVM) tissue by measuring the number 
of planktonic and adherent cells on tissue explants over time. Previous work has 
shown uninfected PVM explants to remain viable for up to six days (Anderson, Parks 
et al. 2013). Confocal laser scanning microscopy can also be used to visualise 
biofilm formation. The model was developed using Staphylococcus aureus, as this is 
an important mucosal pathogen that colonises the human vaginal mucosa. Porcine 
vaginal mucosa is made up of stratified squamous epithelium, similar in structure to 
human vaginal and other mucosal surfaces (Squier, Mantz et al. 2008, Anderson, 
Parks et al. 2013) and so provides a surface to study S. aureus in an environment 
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that mimics a natural infection. Specimens are relatively large so many small biopsies 
can be produced from a single animal, allowing many variables to be tested without 
inter-animal variation. In addition, tissue is inexpensive, easy to procure from 
abattoirs and the model is semi-high throughput (Anderson, Parks et al. 2013). A. 
baumannii infections often initiate at wound or mucosal surfaces and the PVM model 
allows this organism to be studied in a more clinically relevant environment. 
1.10. The role of efflux pumps in biofilm formation and virulence 
Efflux pumps have several roles in the bacterial cell and are required for virulence in 
several species and their hosts (Piddock 2006). For instance, lack of efflux pumps in 
Gram-negative bacteria has previously been shown to affect the organism’s ability to 
infect the host (Buckley, Webber et al. 2006, Nishino, Latifi et al. 2006, Padilla, Llobet 
et al. 2010, Unemo and Shafer 2011, Perez, Poza et al. 2012) and Yoon et al. 
recently showed that overproduction of the AdeABC efflux pump in A. baumannii 
BM4587 resulted in increased virulence in a mouse model of pneumonia (Yoon, 
Balloy et al. 2016). Inactivation of efflux pumps in S. enterica, E. coli and P. 
aeruginosa reduces biofilm formation on abiotic surfaces (Kvist, Hancock et al. 2008, 
Matsumura, Furukawa et al. 2011, Baugh, Ekanayaka et al. 2012, Liao, Schurr et al. 
2013). The role of efflux pumps in biofilm formation of A. baumannii on plastic has 
implications for biofilm formation on hospital surfaces and on intravenous medical 
devices, such as catheters, which can result in UTIs and other device related 
infections (Dijkshoorn, Nemec et al. 2007). Yoon et al. showed a 39% decrease in 
biofilm formation in 24-well plates by an adeB deletion mutant of clinical strain 
BM4587 when measured using a crystal violet colorimetric assay (Yoon, Nait 
Chabane et al. 2015). A 63% and 82% decrease in biofilm formation was also 
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observed with overexpression of either of the RND efflux systems AdeABC or 
AdeFGH, respectively (Yoon, Nait Chabane et al. 2015). Upregulation of adeG was 
also correlated with biofilm formation in 48 clinical isolates and a potential role of 
AdeFGH in the synthesis and transport of autoinducer molecules, such as acylated 
homoserine lactones (AHLs), during biofilm formation has been suggested (He, Lu et 
al. 2015). 
1.11. Background to this research 
AdeRS is a two component system that regulates expression of the multi-drug efflux 
pump AdeABC. Mutations in adeRS can cause overexpression of AdeABC and lead 
to MDR (Marchand, Damier-Piolle et al. 2004, Peleg, Adams et al. 2007). Deletion of 
either adeR or adeS in clinical isolates overexpressing AdeABC results in 
susceptibility to substrates of this pump (Marchand, Damier-Piolle et al. 2004). Strain 
AYE is a well-characterised clinical isolate that is MDR (Fournier, Vallenet et al. 
2006, Hornsey, Loman et al. 2011) and represents a clinically successful clone. AYE 
contains an Ala94Val mutation in AdeS that has been previously associated with 
upregulation of the AdeABC efflux system and increased resistance to antibiotics 
(Hornsey, Loman et al. 2011). Increased expression of MDR efflux pump genes such 
as adeABC leads to MDR and is commonly seen in clinical isolates of A. baumannii 
(Marchand, Damier-Piolle et al. 2004, Yoon, Courvalin et al. 2013). Deletion of adeB 
in clinical isolate BM4587 resulted in decreased MICs of multiple classes of 
antibiotics and a reduction in biofilm formation (Yoon, Nait Chabane et al. 2015). 
Multi-drug efflux systems have previously been associated with biofilm formation and 
virulence in a number of organisms using various models (Buckley, Webber et al. 
2006, Nishino, Latifi et al. 2006, Kvist, Hancock et al. 2008, Padilla, Llobet et al. 
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2010, Matsumura, Furukawa et al. 2011, Baugh, Ekanayaka et al. 2012, Perez, Poza 
et al. 2012, Liao, Schurr et al. 2013, Baugh, Phillips et al. 2014, Yoon, Nait Chabane 
et al. 2015). 
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1.12. Hypotheses 
 Disruption of MDR efflux pumps in A. baumannii will alter the expression of 
many genes in related regulatory networks. 
 Deletion of adeRS, adeAB or adeB alone will affect the A. baumannii 
transcriptome and hence antibiotic resistance, biofilm formation and virulence. 
 Inactivation of adeR, adeS, adeA or adeB by transposon mutagenesis will 
affect antibiotic resistance, biofilm formation and motility in A. baumannii.. 
1.13. Aims 
 To determine the effect of deletion of the TCS AdeRS on antibiotic resistance, 
biofilm formation and virulence in A. baumannii strain AYE. 
 To use RNA-Seq to identify transcriptomic changes in A. baumannii strain 
AYE with the deletion of AdeRS. 
 To determine the effect of lack of AdeB on antibiotic resistance, biofilm 
formation and virulence in A. baumannii strain AYE and clinical isolate S1. 
 To identify transcriptomic changes in A. baumannii strain AYE and clinical 
isolate S1 with the deletion of the RND efflux pump gene adeB by RNA 
sequencing and compare these with changes in AYEΔadeRS. 
 To optimise the porcine vaginal model mucosal model to measure A. 
baumannii biofilm formation on a mucosal surface. 
 To determine the effect of inactivation of adeR, adeS, adeA or adeB by 
transposon mutagenesis on antibiotic resistance, biofilm formation and motility 
in A. baumannii strain AB5075. 
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2. Materials and Methods 
2.1. Bacterial strains, growth, storage and identification 
2.1.1. Bacterial strains 
Acinetobacter baumannii strain AYE (Table 2.1.1) was selected as a reference MDR 
strain for use in this study. A fully annotated genome sequence is available for AYE 
and shows this epidemic strain to contain 52 antibiotic resistance genes, including all 
of the previously described efflux pumps (Fournier, Vallenet et al. 2006, Evans 2012). 
Clinical isolate, S1 (Table 2.1.1), was cultured from a hospital infection in Singapore 
and was provided by collaborator Kim Lee Chua (National University of Singapore, 
Singapore). Deletion of adeRS in AYE and adeAB in S1 to give AYEΔadeRS and 
S1ΔadeAB was carried out by Laura Evans (University of Birmingham, UK), and Kim 
Lee Chua, respectively, using a markerless deletion method (Amin, Richmond et al. 
2013). Deletion of adeB in AYE was carried in this project in collaboration with 
Matthew Wand (Public Health England (PHE), UK) using a modification to the 
markerless deletion method (Amin, Richmond et al. 2013) (see Chapter 4.5). Due to 
the difficulties with making genetic modifications in A. baumannii, clinical isolate 
AB5075 and transposon mutants Tn-adeR1, Tn-adeR2, Tn-adeS1, Tn-adeS2, Tn-
adeA1, Tn-adeA2, Tn-adeB1 and Tn-adeB2 of this strain (Table 2.1.1) were 
purchased from The University of Washington Transposon Mutant Library (Gallagher, 
Ramage et al. 2015) (http://www.gs.washington.edu/labs/manoil/baumannii.htm). 
Strain ATCC 19606 (obtained from American Type Culture Collection, USA) was 
used as a reference strain as it has been previously characterised for biofilm 
formation (Gaddy, Tomaras et al. 2009).  
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Table 2.1.1 Bacterial strains used in this study 
Code Source Supplier 
AYE MDR bloodstream isolate, 
France 
Laurent Poirel (Poirel, 
Menuteau et al. 2003) 
AYE∆adeRS adeRS deletion mutant in 
AYE 
L. P. Evans & L. J. V. 
Piddock, unpublished 
AYEΔadeB adeB deletion mutant in 
AYE 
This study 
S1 Clinical isolate (Singapore) K. L. Chua, unpublished 
S1∆adeAB adeAB deletion mutant in 
S1 
K. L. Chua, unpublished 
ATCC 19606 Clinical isolate, type strain American Type Culture 
Collection 
AB5075 Osteomyelitis isolate, USA 
military 
University of Washington, 
USA 
AB5075 Tn-adeR1 Transposon inserted in 
nucleotide (nt) 671 in adeR 
University of Washington, 
USA 
AB5075 Tn-adeR2 Transposon inserted in 
nucleotide (nt) 121 in adeR 
University of Washington, 
USA 
AB5075 Tn-adeS1 Transposon inserted in 
nucleotide (nt) 593 in adeS 
University of Washington, 
USA 
AB5075 Tn-adeS2 Transposon inserted in 
nucleotide (nt) 133 in adeS 
University of Washington, 
USA 
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AB5075 Tn-adeA1 Transposon inserted in 
nucleotide (nt) 558 in adeA 
University of Washington, 
USA 
AB5075 Tn-adeA2 Transposon inserted in 
nucleotide (nt) 782 in adeA 
University of Washington, 
USA 
AB5075 Tn-adeB1 Transposon inserted in 
nucleotide (nt) 1030 in 
adeB 
University of Washington, 
USA 
AB5075 Tn-adeB2 Transposon inserted in 
nucleotide (nt) 2185 in 
adeB 
University of Washington, 
USA 
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2.1.2. Growth and storage 
All strains and isolates were routinely cultured on Luria-Bertani (LB) (Sigma-Aldrich 
Ltd., UK, cat. no. L2897) or tryptic soy agar (TSA) II (Sigma-Aldrich Ltd., UK, cat. no. 
22091) containing 5% sheep’s blood and in LB (Sigma-Aldrich Ltd., UK, cat. no. 
L3022) or Todd Hewitt (TH) broth (Sigma-Aldrich Ltd., UK, cat. no. T1438), overnight, 
statically at 37°C. Agar plates were stored at 4°C for two weeks. All strains were kept 
at -20°C on Protect™ beads (Technical Service Consultants Ltd., U.K., cat. no. 
Tn/80-GN) for long-term storage. 
2.1.3. Phenotypic and genotypic identification 
Colonies were confirmed as Gram-negative coccobacilli by Gram staining and 
microscopic observation. Isolates were confirmed as A. baumannii using a gyrB 
specific polymerase chain reaction (PCR) (Higgins, Wisplinghoff et al. 2007, Higgins, 
Lehmann et al. 2010). Details of the primers used can be found in Table 2.2.1. 
2.2. Primer design and PCR 
All primers were designed using Genious software (Biomatters, New Zealand) and 
made by ThermoFisher Scientific (UK). For use in PCRs, primers were diluted in 
sterile distilled water to a concentration of 25 µM. Primers were stored at -20°C. 
Unless otherwise specified, PCRs were carried out using ReddyMix™ PCR buffer 
(ThermoFisher Scientific, cat. no. AB0575DCLDA). Reaction volumes for a typical 
PCR are shown in Table 2.2.2. 
A negative water contamination control was used for each PCR experiment.
52 
 
Table 2.2.1 Primers 
Primer 5’ to 3’ sequence PCR 
Sp2F GTTCCTGATCCGAAATTCTCG gyrB species check 
Sp4F CACGCCGTAAGAGTGCATTA 
Sp4R AACGGAGCTTGTCAGGGTA 
D14 GACAACAGTTATAAGGTTTCAGGTG 
D19 CCGCTATCTGTATCCGCAGTA 
D16 GATAACAGCTATAAAGTTTCAGGTGGT 
D8 CAAAAACGTACAGTTGTACCACTGC 
AYE UP FW adeS GGGGCGGCCGCCCTCCGACTTGCGGACGGAT Check for deletion of 
adeRS in AYE 
AYE DOWN RV adeS GGGGCATGCAGGTGAGCAAGTCGGCCCTT 
AYE adeB UP F (NotI) GCGGCGGCCGCTGTAGCCCCGCCACAGGTGA Amplify adeB UP 
fragment 
AYE adeB UP R (BamHI) GCGGGATCCAACGGCGCGGTGTCGTAAGG 
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AYE adeB DOWN F (BamHI) GCGGGATCCTGAAGGGTTGCCACAAGGTGAC Amplify adeB DOWN 
fragment 
AYE adeB DOWN R (SphI) GCGGCATGCGCCACCAAAAACCCCTGTGCC 
pMO130 insert flanking F TTTACCACGACCGCATTCTC Check for UP or 
DOWN fragment 
integration in pMO130-
TelR 
pMO130 insert flanking R AAATAGGCGTATCACGAGGC 
AYE adeB external F TCGATGGGTTGGCTAGCGTGC Check for deletion of 
adeB in AYE 
AYE adeB external R TGCCGCACTGCATTTCCCGT 
gyrB RT F AGGGTGACTCTGCGGGTGGT Primers for 
quantification of RNA 
gyrB RT R TCAAAGCGCGCACGCTCAAC 
Tn26 check F TGAGCTTTTTAGCTCGACTAATCCAT Check for Tn26 
insertion 
in Tn-adeR1 and Tn-
adeS1 
adeS gene R GAATGCAGCTATCGCACATG 
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adeR RT-PCR upstream F AGGCATCATCTTTTACAGCTAGGGGA Check for Tn101 
insertion in Tn-adeR2 
adeR RT-PCR downstream R GTGGTAGAAGATGAC 
adeS gene F TGCGTGGCGTGGGATATAGACTA Check for Tn26 
insertion 
in Tn-adeS2 
adeS gene R GAATGCAGCTATCGCACATG 
Tn26 check F TGAGCTTTTTAGCTCGACTAATCCAT Check for Tn26 
insertion 
in Tn-adeA1, Tn-adeA2 
and Tn-adeB1 
adeAB DOWN R ATCTATTGGGCTGATATTAC 
AYE adeB F TGTAGCCCCGCCACAGGTGA Check for Tn26 
insertion 
in Tn-adeB2 
Tn26 check F TGAGCTTTTTAGCTCGACTAATCCAT 
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Table 2.2.2 Generic PCR reaction volumes 
Reagent Volume (µl) in a 25 µl PCR 
2x ReddyMix™ buffer 
(ThermoFisher Scientific) 
12.5 
10 µM Forward primer 1 
10 µM Reverse primer 1 
Sterile distilled water 9.5 
Cell lysate 1 
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PCR parameters varied upon size of expected amplimer and annealing temperature 
of the primers but a typical PCR cycle for an amplimer of around 1kilobase (kb) is 
shown in Table 2.3.1. Full details of all primers and PCRs are shown in Table 2.2.1. 
PCR amplimers were electrophoresed on a 1% agarose gel supplemented with 5 µl 
Midori green (Nippon Genetics, Germany, cat. no. MG04) per 100 ml agarose 
alongside Hyperladder 1kb (Bioline, UK, cat.no. BIO33053), at 100 V for one hour. 
Agarose gels were visualised using a G:Box (Syngene, UK) PCR products were 
purified using a QIAQuick PCR Purification Kit (Qiagen, UK, cat. no. 28106). 
2.3. Construction of gene deletion mutants 
Deletion of adeB in AYE was carried out in collaboration with Matthew Wand and 
Laura Bonney (PHE, UK) using a modified version of the markerless deletion method 
used previously to delete adeRS in AYE and adeAB in S1 (Amin, Richmond et al. 
2013) (Figure 2.3.1). Briefly, E. coli S17-1 containing a modified version of the 
pMo130-TelR suicide vector was created by Matthew Wand (PHE) and sent to the 
University of Birmingham, UK. Fragments upstream (UP) and downstream (DWN) of 
the region of adeB to be deleted were amplified and the UP fragment was ligated into 
the digested pMo130-TelR vector at the University of Birmingham by Grace 
Richmond. The DOWN fragment was ligated into the digested pMo130-TelR vector at 
PHE, UK by Grace Richmond and Laura Bonney. The vector was then conjugated 
into AYE and candidate colonies containing an adeB deletion were verified by 
Matthew Wand and Laura Bonney at PHE, UK. Candidates were sent to the 
University of Birmingham for verification by PCR and sequencing by Grace 
Richmond. 
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Figure 2.3.1 A schematic diagram of the markerless deletion method used to 
create gene deletions in A. baumannii  
A. Fragments upstream and downstream of the gene of interest were amplified 
by PCR and ligated into pMo130-TelR. 
 
B. Plasmid was transformed into A. baumannii AYE and double recombination 
events selected for. 
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Table 2.3.1 Generic PCR parameters 
Step Temperature °C Time No. of cycles 
Initial denaturation 95 2 min 1 
Denaturation 95 25 sec 30-40 
Annealing 53* 35 sec 30-40 
Extension 72 1 min* 30-40 
Final extension 72 5 min 1 
*Variable parameters – annealing temperature was dependent on GC content of 
primers and extension time was typically 1 min per kb. 
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2.3.1. Construction of pMo130-TelR-adeBUPDOWN 
Isolation of the pMo130-TelR plasmid created by Matthew Wand (PHE, UK) from E. 
coli S17-1 was carried out using the QIAprep® Spin Cell Mini Kit (Qiagen, UK, cat. 
no. 27106). To construct the plasmid used in this method, an 885 base pair (bp) and 
an 874 bp fragment upstream (UP) and downstream (DWN), respectively, of the 
region of adeB to be deleted were amplified by PCR using primers containing 
restriction enzyme sites (Table 2.2.1, Table 2.3.2). Amplification of the correct sized 
amplimers was confirmed by electrophoresis. Amplimers were purified using a 
QIAquick Purification Kit (Qiagen, UK, cat. no. 28104) and ligated sequentially into 
pMO130-TelR digested with NotI and BamHI for ligation of the UP fragment and 
BamHI and SphI for ligation of the DOWN fragment using Quick Stick Ligase (Bioline, 
UK, cat. no. BIO27027). All restriction enzymes were from New England Biolabs, UK, 
(cat. no. R0189S, R0136S, R0182S) and were used according to manufacturer’s 
instructions. The modified construct was then transformed into α-Select 
Electrocompetent Cells (Bioline, UK, cat. no. BIO-85028) by electroporation (4.5 kV, 
200 Ω, 25 µF) and transformants were selected on LB supplemented with 50 µg/ml 
kanamycin (Sigma-Aldrich Ltd., UK, cat. no. B5264). Presence of the UP or DWN 
fragments was confirmed by PCR (Table 2.2.1). 
2.3.2. Integration of pMo130-TelR-adeBUPDOWN into A. 
baumannii AYE chromosome 
The pMO130-TelR-adeBUPDWN construct was introduced into Escherichia coli 
electrocompetent S17-1 by electroporation. Cells were made competent by 
harvesting cells from a 100 ml mid-logarithmic S17-1 culture by centrifugation in a 
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Table 2.3.2 Restriction enzymes used in this study 
Restriction 
Enzyme 
Cut site Reaction conditions 
BamHI HF® 
 
37°C for 2 hr in CutSmart® 
buffer 
NotI HF® 
 
37°C for 2 hr in CutSmart® 
buffer 
SphI HF® 
 
37°C for 2 hr in CutSmart® 
buffer 
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Hereaus Megafuge 40R (ThermoFisher Scientific, UK) at 2200 x g for 15 min at 4°C. 
Cells were washed five times in ice-cold 15% glycerol and resuspended in 1 ml 
glycerol. For transformation, 50 μl of competent cells and 1 ng of plasmid DNA was 
added to a microcentrifuge tube and incubated on ice for 20 minutes. Suspensions 
were transferred to a 2 mm electrocuvette and electroporated immediately (4.5 kV, 
200 Ω, 25 µF). Cells were recovered by adding 950 μl of LB broth and incubated at 
37°C with shaking (200 rpm) for 1.5 hours. Transformants were selected on LB 
supplemented with 50 µg/ml kanamycin and confirmed by PCR (Table 2.2.1). The 
pMO130-TelR-adeBUPDWN construct was introduced into A. baumannii AYE by 
patch-mating at PHE, UK. Transformants with the plasmid integrated into the 
chromosome were selected for by growth on LB supplemented with 50 µg/ml 
ampicillin (Sigma-Aldrich Ltd., UK, cat. no. A9393) and 30 µg/ml tellurite (Sigma-
Aldrich Ltd., UK, cat. no. 60539). Yellow colonies with a green-yellow haze, indicating 
XylE gene expression due to presence of the plasmid were PCR screened to 
confirmed plasmid integration into the chromosome.  
2.3.3. Gene deletion 
Colonies that grew with a green-yellow haze on LB agar and were confirmed by PCR 
to have pMo-TelR-adeBUPDOWN integrated onto the chromosome were cultured on 
LB agar supplemented with 10% sucrose (Sigma-Aldrich Ltd., UK, cat. no. S0389) 
and incubated overnight at 37°C. Colonies were examined for loss of plasmid 
encoded XylE gene activity by loss of the yellow colour. White colonies were selected 
and streaked onto LB agar before PCR testing for gene deletion. 
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2.4. Bacterial growth kinetics 
Bacterial strains were grown with aeration in LB broth at 37°C overnight. Bacterial 
cultures were diluted 1:1000 in sterile LB broth and 100 µl of this suspension was 
added to each well of a clear, sterile 96 well microtitre tray. Optical density (OD) at an 
absorbance of 600 nm (OD600) was measured over 16 hours in a BMG FLUOstar 
Optima (BMG labtech, UK) at 37°C. The FLUOstar is sensitive to an OD600 of 
between 0.0 and 4.0 and reproducibility is ±0.010 for the OD range of 0.0-2.0 
(www.BMG-labtech.com). 
2.5. Susceptibility testing 
The MICs of antibiotics (Table 2.5.1) were determined by the agar doubling dilution 
method according to the British Society for Antimicrobial Chemotherapy (BSAC) 
standard methodology (Andrews 2001). Stock solutions of 10,000, 1000 and 100 
µg/ml of antibiotics were made up and appropriate amounts added to 20 ml of 
cooled, molten Iso sensitest agar (ThermoFisher Scientific, UK, cat. no. CM0471) in 
sterile universals. This was dispensed aseptically into petri dishes and allowed to set. 
Overnight cultures of each bacterial strain to be tested were diluted 1:100 to give a 
final inoculation in 1 µl of approximately 107 CFU/ml. Each agar plate was inoculated 
with 1 µl of diluted culture giving approximately 104 CFU per spot. Plates were 
incubated overnight at 37ºC and read according to BSAC guidelines (Andrews 2001). 
The MIC of each agent was determined as the lowest concentration of antibiotic that 
inhibited visible growth (Andrews 2001) The MICs of imipenem and meropenem were 
determined by E-test (Biomerieux, UK). Colonies grown overnight on LB agar were 
emulsified in sterile water to a concentration of approximately 108 CFU/ml. A sterile 
swab was soaked in the suspension and the surface of an Isosensitest agar 
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Table 2.5.1 Antibiotics and dyes used in this study 
Agent Solvent Supplier 
Ciprofloxacin Distilled water and acetic 
acid 
Sigma-Aldrich, UK, cat no. 17850 
Kanamycin Distilled water Sigma-Aldrich, UK, cat. no. B5264 
Gentamicin Distilled water Sigma-Aldrich, UK, cat. no. G3632 
Ceftazidime 0.1 M sodium hydroxide Sigma-Aldrich, UK, cat. no. A6987 
Imipenem n/a Biomerieux, UK, cat. no. IP0,002-32 
Meropenem n/a Biomerieux, UK, cat. no. 513858 
Ampicillin 1 M sodium bicarbonate Sigma-Aldrich, UK, cat. no. A1593 
Chloramphenicol 70% methanol Sigma-Aldrich, UK, cat. no. C0378 
Tigecycline Distilled water Pfizer, UK 
Tetracycline Distilled water Sigma-Aldrich, UK, cat. no. 87128 
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Colistin Distilled water Sigma-Aldrich, UK, cat. no. C4461 
Ethidium Bromide Distilled water Sigma-Aldrich, UK, cat. no. E7637 
Carbonyl cyanide m-chlorophenyl 
hydrazine 
Dimethyl sulphoxide Sigma-Aldrich, UK, cat. no. C2759 
Phenylalanine-arginine β-
naphthylamide 
Distilled water Sigma-Aldrich, UK, cat. no. P4157 
Hoechst 33342 Distilled water Sigma-Aldrich, UK, cat. no. B2261 
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 (ThermoFisher Scientific, UK, cat. no. CM0471) plate streaked in three directions. 
The plate was allowed to dry for approximately 15 minutes before E-test gradient 
strips were positioned on the surface. Plates were incubated overnight at 37ºC and 
read according to the manufacturer’s instructions. Resistance was determined using 
EUCAST recommended breakpoint concentrations for A. baumannii 
(http://www.eucast.org/clinical_breakpoints/). 
2.6. Measurement of efflux activity 
Two methods were used to determine the permeability and efflux activity of A. 
baumannii strains. A Hoechst 33342 (H33342) (Table 2.5.1) accumulation assay and 
an ethidium bromide (Table 2.5.1) efflux assay. The use of two different dyes allowed 
the efflux of different substrates of the AdeABC efflux pump to be measured. 
Furthermore, the ethidium bromide efflux assay directly measured the rate of efflux 
from the cell, whereas the H33342 accumulation assay measured the total 
accumulation of dye within the cell and may also be affected by the rate of influx. 
2.6.1. Accumulation of Hoechst 33342 
A H33342 accumulation assay developed by (Coldham, Webber et al. 2010) and 
modified for use with A. baumannii (Richmond, Chua et al. 2013) was used to 
measure differences in accumulation between strains. Higher concentrations of 
H33342 within the cell indicate reduced efflux or increased permeability when 
compared with an isogenic control. Bacterial strains were grown with aeration in LB 
broth at 37°C overnight. A 4% inoculum (120 µl in 3 ml) of bacterial culture was 
added to fresh LB broth. This suspension was incubated with aeration at 37°C until 
the cells reached mid-logarithmic phase (OD600 of 0.6-0.7). Cells were harvested by 
66 
 
centrifugation at 2200 x g in a Hereaus Megafuge 40R (ThermoFisher Scientific) for 
ten minutes at room temperature and resuspended in phosphate buffered saline 
(PBS) (Signma-Aldrich, UK, cat. no. D8537) at room temperature. The OD600 was 
adjusted to 0.3 and 180 µl of the cell suspension was dispensed into the wells of a 
black, 96 well microtitre tray (Corning, Amsterdam, cat. no. 3792). A 25 µM H33342 
stock solution was prepared to give a final concentration of 2.5 μM and loaded into 
the FLUOstar OPTIMA for injection after an initial fluorescence reading. 
Fluorescence was measured over 117 minutes at excitation and emission 
wavelengths of 350 nm and 461 nm, respectively, in a FLUOstar OPTIMA. The time 
and fluorescence values at which maximum fluorescence was reached and remained 
unchanged within the time period of the assay was taken to indicate the steady state 
of accumulation. As fluorescence is measured in arbitrary units which can vary 
between assays, fold change in fluorescence of mutants compared to the parental 
strain was calculated to enable comparison between experiments.  
2.6.2. Efflux of ethidium bromide 
To measure efflux of ethidium bromide, bacterial strains were grown with aeration in 
LB broth at 37°C overnight. A 4% inoculum (120 µl in 3 ml) of bacterial culture was 
added to fresh LB broth. This suspension was incubated with aeration at 37°C until 
the cells reached mid-logarithmic phase (OD600 of 0.6-0.7). Cells were harvested by 
centrifugation at 2200 x g in a Hereaus Megafuge 40R (ThermoFisher Scientific) for 
ten minutes at room temperature and resuspended to an OD600 of 0.2 in ice cold 50 
mM phosphate buffer. Cells were exposed to 20 µg/ml ethidium bromide for 20 min 
and, washed and resuspended in phosphate buffer. The wells of a black, 96 well 
microtitre tray were inoculated with 180 µl of the cell suspension and fluorescence 
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was measured over 1 hour at an excitation of 530 nm and an emission of 600 nm in a 
FLUOstar OPTIMA. The time and fluorescence at which minimum fluorescence was 
reached and remained unchanged within the time period of the assay was taken to 
indicate the steady state of efflux. As fluorescence is an arbitrary number and can 
vary between assays, fold change in fluorescence of mutants compared to the 
parental strain was calculated to enable comparison between individual experiments.  
2.7. Measurement of biofilm formation 
To measure the formation of a biofilm on different abiotic and abiotic surfaces, four 
different in vitro models and an ex vivo model was used. 
2.7.1. Biofilm formation on porcine vaginal mucosal tissue 
Biofilm formation on mucosal tissue was measured as described by Anderson et al. 
(Anderson, Parks et al. 2013). Specimens of normal porcine vaginal mucosa (PVM) 
were excised from animals at slaughter and washed in Roswell Park Memorial 
Institute 1640 medium (RPMI) (ThermoFisher Scientific, USA, cat. no. 21875-034) 
supplemented with 10% fetal bovine serum (ThermoFisher Scientific, USA, cat. no. 
26400044), penicillin (50 IU/ml, MP Biomedicals, USA, cat. no. 029194537), 
streptomycin (50 μg/ml, MP Biomedicals, cat. no. 02194797) and amphotericin B 
(2.5 μg/ml, Hyclone, USA, cat. no. SV30078-01) to remove any bacteria and fungi 
colonising the mucosa. Tissue explants of 5 mm were cut and excess muscle was 
trimmed away. Tissue explants were washed in serum- and antibiotic-free media 
three times. Explants were placed mucosal side up on a 0.4 μm cell culture insert 
(BD Bioscience, USA, cat. no. 353090) in 6-well plates (BD Bioscience, USA, cat. no. 
353502) containing fresh serum- and antibiotic-free RPMI 1640 (Figure 2.7.1). 1 ml  
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Figure 2.7.1 Experimental setup of the porcine vaginal mucosal model 
A. A cartoon depiction of explants resting on a transwell membrane inside a 
well of a cell culture plate (Anderson, Parks et al. 2013). 
 
B. A mucosal explant placed on the membrane of a transwell seated in a 6-well 
tissue culture plate (Anderson, Parks et al. 2013). 
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overnight culture of bacterial cells was pelleted by centrifugation, washed twice in 1 
ml RPMI 1640 medium and resuspended in 1 ml RPMI 1640 medium. 300 µl of this 
suspension was diluted in 5 ml RPMI 1640 medium to give 5 x 106 CFU/ml. Explants 
were inoculated with 2 µl of this suspension and incubated at 37ºC. Bacterial cell 
counts of adherent and planktonic cells were carried out at 24, 48, 72, 96, 120 and 
144 h. To enumerate planktonic cells, explants were washed in 3 ml sterile PBS at 
room temperature and the wash medium collected. The wash was sub-cultured onto 
TSA II agar plates containing 5% sheep’s blood using a Wasp II spiral plater 
(Microbiology International, USA) and incubated at 37°C overnight. Colonies were 
counted using a Protocol plate reader (Microbiology International, USA) and the 
CFU/ml was calculated. To enumerate cells adhering to the mucosa, washed 
explants were placed in a 1.5 ml tube containing 250 µl sterile PBS at room 
temperature and mixed by vortexing for 4 min. The wash was then sub-cultured onto 
TSA II agar plates containing 5% sheep’s blood using a Wasp II spiral plater 
(Microbiology International, USA) and incubated at 37°C overnight. Colonies were 
counted using a Protocol plate reader (Microbiology International) and CFU/ml was 
calculated. The difference in the number of adherent cells between parental strain 
and mutant or clinical isolates versus index isolate was calculated. For imaging, 
explants were stained using FilmTracer™ LIVE⁄DEAD® Biofilm Viability kit 
(ThermoFisher Scientific, cat. no. L10316). Three microliters of propridium iodide and 
3 µl of SYTO9 were added to 1 ml sterile water and 200 µl was distributed over three 
explants by pipetting. Explants were incubated at room temperature, without light, for 
20 minutes and excess liquid was removed by pipetting. Explants were then gently 
washed three times with 1 ml Hanks Balanced Salt Solution (HBSS) (ThermoFisher 
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Scientific, cat. no. 14170070) and the final wash solution was left in the well. Explants 
were placed mucosal side up on glass slides and covered with a 20 mm coverwell 
imaging chamber (VWR, USA, cat. no. 100490-802). After staining, specimens were 
gently washed 3 x with HBSS and transferred to glass slides. A coverslip with 1 mm 
spacer (Electron Microscopy Sciences) was then applied and specimens were 
imaged on an Olympus Fluoview 1000 BX2 (Olympus America Corporation, USA) 
using a 60 x oil immersion objective. Images were captured and processed using 
Fluoview software (Olympus America Corporation, USA, http://www.olympus-
lifescience.com/en/support/downloads). 
2.7.2. Biofilm formation in a microfluidic flow cell 
A Bioflux 200 (Fluxion, USA) was used to visualise biofilm formation under 
microfluidic flow conditions. To prime the flow cells with media, 200 μl of LB broth 
was added to the inner circle of the output wells of a 48 well Bioflux flow cell plate 
(Fluxion, USA, cat. no. 910-004) (Figure 2.7.2) and the Bioflux 200 manifold was 
attached. Medium was flowed through the wells at 5 dyne and any residual medium 
was removed. Flow channels were inoculated by transferring 50 μl of overnight 
culture diluted to an OD600 of 0.1 to the output wells. To ensure that there was no 
flow from output to the inlet well, 50 μl of fresh LB broth was added to the inlet well 
also. Bacteria were introduced into the flow channel at 3 dynes for approximately 3 
seconds. Even coverage of the bacterial cells in the flow channel was ensured by 
microscopic visualisation before the bacteria were left to attach at 30°C for 1 hour. 
Fresh LB broth was then added to the inlet well and flowed through the channel at 
0.3 dynes for 16 hours. Biofilm formation was imaged at various time points using a 
LTSi-1000 inverted microscope (Labtech, USA). 
71 
 
Figure 2.7.2 Cartoon representation of a Bioflux 200 microfluidic channel 
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2.7.3. Biofilm formation on polypropylene pegs 
Crystal violet staining was used to measure biofilm formation on plastic pegs (Ceri, 
Olson et al. 1999, Baugh, Ekanayaka et al. 2012). Bacterial strains were grown with 
aeration overnight at 37°C and cultures were diluted in LB broth to an OD at 600 nm 
of 0.1. The wells of a 96 well microtitre tray were inoculated with 100 µl of diluted 
culture and a sterile, 96 well PCR plate (Starlabs, UK, cat. no. E1403-0209) was 
placed into the microtitre tray. Plates were sealed and incubated with gentle agitation 
for 8 hrs at either 30°C or 37°C. After incubation, the liquid culture was removed and 
pegs were washed with sterile distilled water to remove planktonic cells. PCR plates 
were placed in fresh microtitre trays containing 100 µl 1% crystal violet, in order to 
stain the biofilm, and left at room temperature for 15 min. The crystal violet was 
removed and pegs were washed with sterile distilled water. PCR plates were placed 
in fresh microtitre trays containing 100 µl 70% ethanol, to solubilise the dye and left 
at room temperature for 2 hrs. OD at an absorbance of 600 nm was measured a 
BMG FLUOstar Optima. As final OD can vary between individual experiments, 
OD600 was converted to fold change compared to the parental strain in order to 
compare results between experiments.  
2.7.4. Pellicle formation 
In order to measure the ability of the strains to form a biofilm at the air-liquid 
interface, pellicle formation was measured as described previously (Nait Chabane, 
Marti et al. 2014). Bacterial strains were grown with aeration in LB broth at 37°C 
overnight. Cultures were diluted in LB broth to an OD at 600 nm of 0.1 and 2 ml was 
added to polystyrene test tubes (13 mm x 75 mm). Cultures were incubated statically 
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at 37°C for 72 hrs and pellicle formation was identified visually. Isolates were 
considered positive when the surface was covered with an opaque layer of biomass. 
2.7.5. Biofilm formation on glass cover slips 
In order to visualise biofilm formation on an abiotic surface, biofilms were grown on 
glass cover slips and imaged at the Centre for Electron Microscopy (CEM), University 
of Birmingham, by scanning electron microscopy. A 4% inoculum (200 µl in 5 ml) of 
bacterial culture grown overnight was added to fresh LB broth containing a 10 mm 
glass coverslip (ThermoFisher Scientific, UK, cat. no. 12658116) and incubated at 
37°C for 24 hrs. The cover slip was removed and placed in a primary fixative of 2.5% 
gluteraldehyde in phosphate buffer. Subsequent dehydration and mounting steps 
were carried out by Paul Stanley at the CEM. Scanning electron microscopy images 
were viewed at various magnifications on a Philips XL30 FEG ESEM (FEI, USA.) 
2.8. Measurement of twitching and swarming motility 
To investigate motility of strains the ability to migrate in the medium-plastic interface 
of solid media (twitching) and migration on semi-solid agar (swarming) was measured 
as described previously for A. baumannii (Eijkelkamp, Stroeher et al. 2011). To 
investigate twitching motility, 1 µl of a liquid culture grown overnight at 37°C was 
stabbed through Mueller-Hinton medium (Sigma-Aldrich, UK, cat. no. 70192) 
containing 1% agar (Sigma-Aldrich, UK, cat. no. A5306) to the bottom of the petri 
dish. To investigate swarming motility, 1 µl of a liquid culture grown overnight at 37°C 
was inoculated onto the surface of LB medium containing 0.3% agar. Plates were 
incubated for 24 hrs at 37°C after which the motility phenotype was assessed visually 
and using ImageJ software (Schneider, Rasband et al. 2012). 
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2.9. Measurement of virulence in Galleria mellonella 
Survival assays in G. mellonella were carried out by Matthew Wand (PHE), as 
previously described (Wand, Bock et al. 2012). Bacteria were injected into G. 
mellonella larvae at an inoculum of 106 CFU. Larvae were incubated statically at 
37°C inside petri dishes and the number of dead larvae scored at 24, 48, 72, 96 and 
120 hr. Data were sent to Birmingham for statistical analysis and interpretation. 
2.10. Statistical analysis 
All data was analysed using Prism version 6.00 for Windows (GraphPad Software, 
USA). Growth kinetics, H33342 accumulation, ethidium bromide accumulation, 
biofilm formation on plastic and PVM cell counts were analysed using an unpaired 
Student’s t-test to calculate significant differences between parental and mutant 
strains. A Student’s t-test allows comparison of the means of a normally distributed 
variable for two independent groups. Tests returning a P value of < 0.05 were 
considered significant. All analyses included at least nine biological replicates, each 
of which were replicated at least twice and data inputted into Microsoft Excel and 
entered into the appropriate table format in Prism. Virulence in G. mellonella was 
displayed as a Kaplan Meier survival curve. This method allows you to measure the 
fraction of subjects living for a certain amount of time after infection (Goel, Khanna et 
al. 2010). Statistical significance was calculated using a Log-rank (Mantel-Cox) test 
and a Gehan-Breslow-Wilcoxon test. Differences between parental and mutant 
strains were considered significant when both tests returned a P value of < 0.05. 
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2.11. RNA-Seq 
2.11.1. RNA extraction 
RNA was extracted from 4 bacterial cultures (= 4 biological replicates) using a 
RNAprotect™ Bacteria Reagent (Qiagen, UK, cat. no. 76506) and RNeasy Mini kit 
(Qiagen, UK, cat. no. 74104) for stabilisation and isolation of total RNA from bacterial 
cultures, using the enzymatic lysis protocol. Bacterial strains were grown with 
aeration overnight at 37°C and 1 ml of culture was added to 2 ml of RNAprotect 
Bacteria Reagent. The suspension was mixed by vortexing for 5 s and incubated at 
room temperature for 5 min. The suspension was centrifuged at 5000 x g for 10 min 
in a Hereaus Megafuge 40R (ThermoFisher Scientific, UK) and the supernatant 
removed. 
To enzymatically lyse the cells, 200 µl TE buffer containing 1 mg/ml lysozyme was 
added and mixed by using a vortex for 10 s. The suspension was incubated at room 
temperature for 5 min with 10 s mixing every 2 min. After incubation, 700 µl of RLT 
buffer was added and the suspension was vortexed vigorously. Finally, 500 µl of 
ethanol was added to the lysate and mixed by pipetting. 
To extract the RNA from the sample, the lysate was applied to an RNeasy Mini 
Column placed in a 2 ml collection tube and centrifuged for 15 s at 8000 x g in an 
Eppendorf MiniSpin Centrifuge. 700 µl Buffer RW1 was added to the RNeasy column 
and centrifuged for 15 s at 8000 x g to wash the column. Flow through was discarded 
after each step. The RNeasy column was transferred to a new 2 ml collection tube 
and 500 µl of Buffer RPA added to the column. The tube was centrifuged for 15 s at 
8000 x g in an Eppendorf MiniSpin Centrifuge and the flow through discarded. To 
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elute, the RNeasy column was transferred to a 1.5 ml collection tube and 30 µl 
RNase-free water was applied directly to the silica-gel membrane. The tube was 
centrifuged at 8000 x g for 1 min and the RNeasy column removed from the 
collection tube. RNA was stored at -80°C. 
2.11.2. DNase treatment of RNA samples 
DNA was removed from the RNA samples using an Ambion TURBO DNA-free™ kit 
(ThermoFisher Scientific, UK, cat. no. AM1907). After RNA extraction, 0.1 volume 10 
X TURBO DNase Buffer and 2 µl TURBO DNase was added to each RNA sample 
and incubated at 37°C for 1 hr. After incubation, 0.2 volume DNase Inactivation 
Reagent was added and mixed by pipetting. The suspension was incubated at room 
temperature for 5 min with occasional mixing and then centrifuged at 10,000 x g for 
1.5 min before transferring the supernatant to a fresh tube. RNA samples were 
confirmed as DNA by quantification of DNA and RNA concentrations using a Qubit® 
Fluorometer (Sigma-Aldrich Ltd., UK). Samples were prepared using the Qubit® 
dsDNA HS Assay Kit (Sigma-Aldrich Ltd., UK, cat. no. Q32851) and Qubit® RNA HS 
Assay Kit (Sigma-Aldrich Ltd., UK, cat. no. Q32852) as per the manufacturer’s 
instructions. Samples with a DNA concentration < 5% of the total nucleic acid 
concentration were considered DNA negative. 
2.11.3. Quantification of RNA 
The quality of the RNA samples was assessed using an Agilent 2100 Bioanalyzer 
(Agilent Technologies, USA) and Nanodrop 2100 (ThermoFisher Scientific, UK). 
Samples with total RNA > 1 µg, RNA concentration > 40 ng/µl, RNA integrity number 
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(RIN) > 7.0, 23S/16S > 1.0, OD260/280 > 1.8 and OD260/230 > 1.8 were considered 
acceptable for sequencing.  
2.11.4. Preparation of RNA-Seq libraries 
RNA-Seq experiments were carried out at different stages of the study and therefore 
different companies and protocols were used for library preparation and sequencing 
as protocols were improved over time. AYE and AYEΔadeRS libraries were prepared 
and sequenced by ARK genomics (Edinburgh, UK) in August 2012, AYE and 
AYEΔadeB libraries were prepared and sequenced by Grace Richmond at the 
University of Birmingham in March 2015 and S1 and S1ΔadeAB libraries were 
prepared and sequenced by BGI genomics (Hong Kong) in September 2015. For 
preparation of RNA-Seq libraries at the University of Birmingham, a Zymo RNA Clean 
and Concentrator™-5 (Zymo Research, USA, cat. no. R1015) was used to recover 5 
µg high quality, concentrated RNA from DNase treated samples. Diluted samples 
were added to a Zymo-Spin™ IC column and centrifuged for 30 seconds at 8000 x g. 
Columns were washed and the RNA was eluted in 26 µl RNase-free water by 
centrifugation for 1 min at 8000 x g. Ribosomal RNA was removed using a Ribo-
Zero™Magnetic Kit (Illumina, USA, cat. no. MRZB12424). Treatment of the total RNA 
samples with Ribo-Zero rRNA removal solution was carried out according to the kit 
protocol and rRNA was removed using a magnetic bead reaction. rRNA-depleted 
samples were then purified using a Zymo RNA Clean and Concentrator™-5 as 
described above. Samples were eluted in 20 µl RNase-free water. Samples were 
prepared for sequencing using a Tru-Seq® Stranded mRNA Sample Preparation Kit 
(Illumina, USA, cat. No. 122-2101). PolyA containing mRNA molecules were purified 
using polyT oligo attached magnetic beads and the RNA was fragmented and primed 
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for cDNA synthesis. Following this, first strand and second strand cDNA was 
synthesised and a single ‘A’ nucleotide was added to the 3’ ends of the blunt 
fragments to prevent them from ligating to one another. Multiple indexing adapters 
were then ligated to the ends of the double stranded cDNA, preparing them for 
hybridisation onto a flow cell. DNA fragments with an adaptor molecule on both ends 
were selectively enriched by PCR and the libraries were validated using the Agilent 
D1000 ScreenTape System (Agilent Technologies, UK) and a KAPA library 
Quantification Kit for Illumina Sequencing Platforms (KAPA Biosystems, UK, cat. no. 
KK4824). Finally, libraries were normalised and pooled in preparation for sequencing 
using a MiSeq sequencing platform. 
2.11.5. Sequencing of RNA-Seq libraries 
AYE and AYEΔadeB libraries were sequenced at Birmingham using an Illumina 
MiSeq. AYE and AYEΔadeRS libraries were sequenced by ARK genomics using an 
Illumina HiSeq. S1 and S1ΔadeAB libraries were sequenced by BGI genomics using 
an Illumina MiSeq. 
2.11.6. Analysis of RNA-Seq data 
All RNA-Seq datasets were analysed together by Al Ivens (University of Edinburgh). 
Raw sequences were quality assessed using FASTQC, which performs quality 
control checks on raw sequence data, and processed. Alignments to an AYE 
reference genome (Kersey, Allen et al. 2014) were performed using bowtie2. A bed 
file of the gene loci was generated from the gff annotation and bedtools used to count 
tags overlapping the regions of interest. Raw tag counts per sample were scale 
normalised to the sample with the lowest number of tags within each data set. 
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Counts were converted to log2 and quantile normalised within each series for 
comparisons within each data set. Pairwise comparisons were performed on the 
normalised tag counts using linear modelling (Bioconductor limma package). A raw P 
cut-off value of 0.05 was used to produce a list of changed genes that could be 
examined by phenotypic testing. No fold-change cut off was used. RNA-Seq data 
were submitted to ArrayExpress (accession E-MTAB-4047, E-MTAB-4049, E-MTAB-
4071). 
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3. The Role of the Two Component System AdeRS in Antibiotic 
Resistance, Biofilm Formation and Virulence 
3.1. Summary of background to this research 
AdeRS is a two component system that regulates expression of the multi-drug efflux 
pump AdeABC. Mutations in adeRS can cause overexpression of AdeABC and lead 
to MDR (Marchand, Damier-Piolle et al. 2004, Peleg, Adams et al. 2007). Deletion of 
either adeR or adeS in clinical isolates overexpressing AdeABC results in 
susceptibility to substrates of this pump (Marchand, Damier-Piolle et al. 2004). Strain 
AYE contains an Ala94Val mutation in AdeS that has been previously associated 
with upregulation of the AdeABC efflux system and increased resistance to 
antibiotics (Hornsey, Loman et al. 2011). Furthermore, two component systems have 
been shown previously to be involved in the regulation of other bacterial functions, 
such as growth, competence, metabolism, adaptation to starvation, osmoregulation 
and expression of toxins (West and Stock 2001, Mitrophanov and Groisman 2008). 
3.2. Hypothesis 
Deletion of adeRS will affect expression of genes and their products encoding 
antibiotic resistance, biofilm formation and virulence. 
3.3. Aims 
The aim of this study was to identify the consequences of deletion of adeRS in A. 
baumannii AYE. The objectives were to optimise the porcine vaginal mucosal model 
to measure A. baumannii biofilm formation on a mucosal surface, to use this and 
other methods to characterise the antibiotic resistance, biofilm formation and 
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virulence phenotype of deletion mutant AYEΔadeRS and to use RNA-Seq to identify 
transcriptomic changes in this strain. 
3.4. Choice of strains and verification of strains 
A. baumannii AYE was selected for this work as it is a well-characterised clinical 
isolate that is MDR (Fournier, Vallenet et al. 2006, Hornsey, Loman et al. 2011). AYE 
is sequence type (ST) 1 of International clone I and represents a clinically successful 
clone (Figure 3.4.1). Type strain ATCC 19606 (ST52) was included as a control in 
the ex vivo biofilm experiments as a strain that has a well-characterised biofilm 
phenotype (de Breij, Gaddy et al. 2009, de Breij, Haisma et al. 2012). Deletion of 
adeRS in AYE was carried out by Laura Evans (University of Birmingham) using a 
markerless deletion method (Amin, Richmond et al. 2013). Deletion was verified by 
amplification of the deleted region by PCR (Figure 3.4.2A). Amplification of the region 
in AYE produced a 3377 bp amplimer, whereas amplification in AYEΔadeRS 
produced a 2011 bp amplimer, confirming deletion of a 1366 bp fragment spanning 
the whole of the adeS gene and 126 bp of the adeR gene. This was subsequently 
confirmed by Sanger sequencing (Figure 3.4.2B). To predict how much of the AdeR 
protein was removed by deletion of 126 bp of the adeR gene and to illustrate which 
part of the protein remained and may still be functional, I-TASSER protein modelling 
software was used to generate a predicted protein model based on sequence 
homology to known protein structures (Yang, Yan et al. 2015). The protein structure 
was viewed in PyMOL (http://www.pymol.org) and the 42 amino acids for which the 
coding bases were deleted were highlighted in red (Figure 3.4.3). Deletion of 126 bp 
of adeR removed 27 amino acids of the signal receiver domain predicted by the 
NCBI domain predictor (http://www.ncbi.nlm.nih.gov/Structure/cdd/wrpsb.cgi). 
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Figure 3.4.1 Relationships between 615 A. baumannii isolates based on MLST data (Pasteur scheme) as calculated by the 
BURST algorithm 
 
 
Circles indicate major international groups and AYE is marked in red 
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Figure 3.4.2 Verification of adeRS gene deletion in AYE by PCR and DNA 
sequencing 
A. PCR to assess the size of the adeRS region 
 
Lane Template Predicted fragment 
size (bp) 
Actual fragment 
size (bp) 
1 Hyperladder 1kb - - 
2 AYE 3377 3377 
3 AYEΔadeRS 2011 2011 
4 Negative control 0 0 
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B. Alignment of AYE adeRS sequence with upstream sequencing data for 
AYEΔadeRS 
AYE           TCATAGCGTTTATATACACTCTGAGAATAAGAAGATCTTGCTTAATCTGACGCTGACTGA 
AYEΔadeRS     TCATAGCSTTTATATACACTCTGAGAATAAGAAGATCTTGCTTAATCTGACGCTGACTGA 
              ******* **************************************************** 
 
AYE           ATATAAAATTATTTCATTCATGATTGATCAGCCTCATAAAGTTTTTACGCGCGGAGAGCT 
AYEΔadeRS     ATATAAAATTATTTCATTCATGATTGATCAGCCTCATAAAGTTTTTACGCGCGGAGAGCT 
              ************************************************************ 
 
AYE           TATGAATCACTGCATGAATGATAGCGATGCACTAGAGCGAACCGTAGATAGCCATGTGAG 
AYEΔadeRS     TATGAATCA--------------------------------------------------- 
              *********                                                    
 
AYE           TAAGCTGAGAAAAAAACTAGAAGAACAAGGCATATTTCAAATGTTAATTAATGTGCGTGG 
AYEΔadeRS     ------------------------------------------------------------ 
                                                                           
 
AYE           CGTGGGATATAGACTAGATAATCCCCTAGCTGTAAAAGATGATGCCTAAataatattaaa 
AYEΔadeRS     ------------------------------------------------------------ 
                                                                           
 
AYE           aaatagctagggaatattttATGAAAAGTAAGTTAGGAATTAGTAAGCAACTTTTTATTG 
AYEΔadeRS     ------------------------------------------------------------ 
                                                                           
 
AYE           CCTTAACTATTGTGAATTTAAGCGTTACGCTATTTTCTATAGTATTGGGTTATATCATTT 
AYEΔadeRS     ------------------------------------------------------------ 
                                                                           
 
AYE           ATAACTATGCGATTGAAAAAGGCTGGATTAGCTTAAGCTCATTTCAACAAGAAGATTGGA 
AYEΔadeRS     ------------------------------------------------------------ 
                                                                           
 
AYE           CCAGTTTTCATTTTGTAGACTGGATCTGGTTAGCCACTGTTATCTTCTGTGGCTGTATTA 
AYEΔadeRS     ------------------------------------------------------------ 
                                                                           
 
AYE           TTTCATTAGTGATTGGCATGCGCCTCGCAAAGCGTTTTATTGTGCCAATTAACTTCTTAG 
AYEΔadeRS     ------------------------------------------------------------ 
                                                                           
 
AYE           TCGAAGCAGCAAAAAAAATTAGTCACGGCGACCTCTCTGCTAGAGCTTACGATAATAGAA 
AYEΔadeRS     ------------------------------------------------------------ 
                                                                           
 
AYE           TTCACTCCGCCGAAATGTCGGAGCTTTTATATAATTTTAATGATATGGCTCAAAAGCTAG 
AYEΔadeRS     ------------------------------------------------------------ 
                                                                           
 
AYE           AGGTTTCCGTCAAAAATGCGCAGGTTTGGAATGCAGCTATCGCACATGAGTTAAGAACGC 
AYEΔadeRS     ------------------------------------------------------------ 
                                                                           
 
AYE           CTATAACGATATTACAAGGTCGTTTACAGGGAATTATTGATGGCGTTTTTAAACCTGATG 
AYEΔadeRS     ------------------------------------------------------------ 
                                                                           
 
AYE           AAGTCCTATTTAAAAGCCTTTTAAATCAAGTTGAAGGTTTATCTCACTTAGTCGAAGACT 
AYEΔadeRS     ------------------------------------------------------------ 
                                                                           
 
AYE           TACGGACTTTAAGCTTAGTAGAGAACCAGCAACTCCGGTTAAATTATGAATTGTTTGACT 
AYEΔadeRS     ------------------------------------------------------------ 
                                                                           
 
AYE           TGAAGGCGGTAGTTGAAAAAGTTCTTAAAGCATTTGAAGATCGTTTGGATCAAGCTAAGC 
AYEΔadeRS     ------------------------------------------------------------ 
                                                                           
 
AYE           TAGTACCAGAACTTGACCTAACGTCCACTCCTGTATATTGCGACCGCCGTCGTATTGAGC 
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AYEΔadeRS     ------------------------------------------------------------ 
                                                                           
 
AYE           AAGTTTTAATTGCTTTAATTGATAATGCGATTCGCTATTCAAATGCAGGCAAACTTAAAA 
AYEΔadeRS     ------------------------------------------------------------ 
                                                                           
 
AYE           TCTCTTCAGAAGTGGTTGCAGACAACTGGATATTAAAAATTGAGGATGAAGGCCCCGGCA 
AYEΔadeRS     ------------------------------------------------------------ 
                                                                           
 
AYE           TTGCAACCGAGTTTCGGGACGATTTATTTAAGCCTTTCTTTAGATTAGAAGAATCAAGGA 
AYEΔadeRS     ------------------------------------------------------------ 
                                                                           
 
AYE           ATAAAGAATTTGGCGGCACAGGTTTAGGTCTTGCTGTTGTACATGCAATTATTGTGGCAC 
AYEΔadeRS     ------------------------------------------------------------ 
                                                                           
 
AYE           TGAAAGGCACTATTCAATATAGCAATCAAGGCTCGAAAAGTGTTTTCACCATAAAAATTT 
AYEΔadeRS     ------------------------------------------------------------ 
                                                                           
 
AYE           CTATGGGTCATGAAGAGATGGGGTAAttcgctaaattaaaaaatcttagagttaaagtgc 
AYEΔadeRS     ------------------------------------------------------------ 
                                                                           
 
AYE           cccctcactctcttttattcttctacgaatttcttctcgccattttgtggcattttcctg 
AYEΔadeRS     -------------------------------------------------CTGCATGAATG 
                                                                    *   ** 
 
AYE           ttgtttgtttaataggacacctaacatataagctgtaaccgcagcgccaattaaggctat 
AYEΔadeRS     ATAGCGATGCACTAGAGCGAACCGGATCCAAGCTGTAACCGCAGCSCCAATTAAGGCTAT 
               *     *  * ***  *       **  **************** ************** 
 
AYE           accggtttcataaataatatctataacaaattcgagcactccctccgacaaaaaatctaa 
AYEΔadeRS     ACCGGTTTCATAAATAATATCTATAACAAATTCGAGCACTCCCTCCGACAAAAAATCTAA 
              ************************************************************ 
Sequences were aligned using Clustal Omega. * indicates a position with a single, 
fully conserved residue. The adeR gene is highlighted in yellow and the adeS gene is 
highlighted in blue.  
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Figure 3.4.3 Predicted protein structure of AdeR and AdeS in AYEΔadeRS 
 
 
Amino acids for which the coding sequence was deleted are highlighted in red.  
AdeR 
AdeS 
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All strains used in this study were confirmed as A. baumannii using a gyrB PCR 
(Higgins, Wisplinghoff et al. 2007, Higgins, Lehmann et al. 2010). This protocol uses 
seven primers in a multiplex PCR to produce different sized amplimers, allowing 
differentiation between A. baumannii, A. calcoaceticus, A. pittii and A. nosocomialis. 
Each strain produced a 294 bp amplimer and a 490 bp amplimer, characteristic of 
this species. 
3.5. Determining the phenotype of an A. baumannii AYE mutant 
lacking the TCS AdeRS 
3.5.1. Bacterial growth kinetics of AYEΔadeRS 
To determine whether there was a growth defect in the AdeRS deletion mutant that 
may affect the results of subsequent experiments, the growth kinetics of AYE and 
AYEΔadeRS were determined by measuring optical density of cell cultures grown in 
LB broth at 37°C over time. There was no significant difference between the lag 
phase, generation time or the final optical density at stationary phase of AYE and 
deletion mutant AYEΔadeRS (Figure 3.5.1). To verify that there was no change in 
cell morphology, which can affect optical density measurements, cells were Gram-
stained and visualised by microscopy during lag phase, exponential phase and 
stationary phase. All cells appeared as Gram-negative rods, characteristic of this 
species, and no filamentation was observed at any growth stage. 
3.5.2. Antimicrobial susceptibility of AYEΔadeRS 
To determine whether there was a change in the drug resistance profile of AYE with 
deletion of AdeRS, the minimum inhibitory concentration (MICs) of commonly used 
antibiotics and dyes and those previously shown to be substrates of the AdeABC  
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Figure 3.5.1 Growth kinetics of AYE and AYEΔadeRS in LB broth at 37°C 
  
Data are shown as the mean of 3 biological replicates and are representative of a 
single independent experiment carried out at least 3 times. 
Generation times and optical density at stationary phase (± standard deviation) 
Strain Mean 
generation 
time (min) 
P value OD600 at 
stationary 
phase 
P value 
AYE 121 ± 3.295 - 1.323 ± 0.030 - 
AYEΔadeRS 115 ± 2.695 0.084 1.357 ± 0.007 0.129 
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RND efflux pump (Yoon, Nait Chabane et al. 2015) were determined (Table 3.5.1). 
Parental strain AYE was resistant to gentamicin and ciprofloxacin according to 
EUCAST breakpoint concentrations (http://www.eucast.org/clinical_breakpoints/). 
There were no EUCAST breakpoint concentrations available for Acinetobacter spp. 
and seven drugs: ampicillin, ceftazidime, kanamycin, norfloxacin, tetracycline, 
tigecycline or chloramphenicol. There was a decrease in the MIC of kanamycin, 
gentamicin, ciprofloxacin, tetracycline, tigecycline, chloramphenicol and the dye 
ethidium bromide with deletion of adeRS in AYE. Although some of these changes 
were only 2-fold, which is considered to be the margin of error for this method, these 
changes were consistent in multiple experiments (n = 3). 
3.5.3. Hoechst 33342 (bis-benzimide) accumulation by 
AYEΔadeRS 
Hoechst (H) 33342 is a dye that can be used to measure relative levels of efflux in 
bacterial cells (Coldham, Webber et al. 2010, Richmond, Chua et al. 2013). It 
fluoresces when bound to DNA and therefore its accumulation can be measured 
(Coldham, Webber et al. 2010). It has been previously shown that accumulation of 
H33342 is a good indication of efflux activity in A. baumannii (Richmond, Chua et al. 
2013). Accumulation of H33342 in AYE was compared with AYEΔadeRS to 
investigate whether there was a relative difference in the intracellular levels of this 
substrate. When compared with strain AYE, accumulation of H33342 in strain 
AYEΔadeRS was 40% higher (P < 0.0001), indicating reduced levels of efflux of this 
dye in the mutant (Figure 3.5.2). 
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Table 3.5.1 MICs of antibiotics and dyes against AYE and AYEΔadeRS 
                             MIC (µg/ml) 
 
 AYE AYEΔadeRS 
Ampicillin experiment 1 >1024 >1024 
 experiment 2 >1024 >1024 
 experiment 3 >1024 >1024 
Ceftazidime experiment 1 1024 1024 
 experiment 2 1024 1024 
 experiment 3 1024 1024 
Imipenem experiment 1 1.5 0.75 
 experiment 2 1.5 0.75 
 experiment 3 1.5 0.75 
Meropenem experiment 1 0.25 0.25 
 experiment 2 0.25 0.25 
 experiment 3 0.25 0.25 
Kanamycin experiment 1 1024 512 
 experiment 2 512 256 
 experiment 3 1024 512 
Gentamicin experiment 1 128 8 
 experiment 2 64 8 
 experiment 3 128 8 
Norfloxacin experiment 1 128 128 
 experiment 2 128 128 
 experiment 3 128 128 
Ciprofloxacin experiment 1 128 32 
 experiment 2 128 32 
 experiment 3 64 32 
Colistin experiment 1 1 1 
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 experiment 2 1 1 
 experiment 3 1 1 
Tetracycline experiment 1 256 128 
 experiment 2 256 128 
 experiment 3 256 64 
Tigecycline experiment 1 1 0.25 
 experiment 2 1 0.25 
 experiment 3 1 0.25 
Chloramphenicol experiment 1 512 256 
 experiment 2 512 256 
 experiment 3 512 256 
Carbonyl cyanide 3-
chlorophenylhydrazone 
experiment 1 32 32 
experiment 2 32 32 
experiment 3 32 32 
Phenylalanine-arginine 
beta-naphthylamide 
experiment 1 1024 1024 
experiment 2 1024 1024 
 experiment 3 1024 1024 
Ethidium bromide experiment 1 512 256 
 experiment 2 512 512 
 experiment 3 512 256 
Data are shown as the results of three individual experiments carried out on different 
days. Blue text indicates a decrease in MIC value compared with AYE. 
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Figure 3.5.2 Accumulation of H33342 by AYE and AYEΔadeRS 
A. Accumulation of H33342 in AYE and AYEΔadeRS over time 
 
Data are shown as fluorescence values over time and represent the mean of three 
biological replicates. Data are a representative example of a single independent 
experiment carried out at least three times. 
B. Fold change in accumulation of Hoechst H33342 in AYE and AYEΔadeRS 
  
Data are plotted as independent biological replicates to show variation within each 
strain. Data are presented as fold change compared to AYE at the point at which 
steady state accumulation was reached +/- standard deviation. Student’s t-tests were 
performed and those returning P values of less than 0.05 are indicated by *.  
* 
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3.5.4. Ethidium bromide efflux by AYEΔadeRS 
Ethidium bromide is a DNA intercalating dye and exhibits weak fluorescence when 
external to the cell and becomes strongly fluorescent when bound to DNA or in the 
periplasm due to binding to cellular components (Jernaes and Steen 1994). Ethidium 
bromide was allowed to accumulate in bacterial cells and fluorescence was used to 
monitor subsequent efflux of the dye. Fluorescence relative to the starting 
fluorescence in each strain was calculated to account for differing dye accumulation 
levels in the parent and mutant. AYE was compared with AYEΔadeRS to investigate 
whether there was a difference in efflux levels of this substrate. The rate of efflux of 
ethidium bromide was lower and the final level of accumulation was 92% higher (P < 
0.0001) in the AdeRS mutant than in parental strain AYE (Figure 3.5.3). These data 
suggest less efflux activity in AYEΔadeRS when compared with AYE. 
3.5.5. Biofilm formation by AYEΔadeRS in an ex vivo model 
To study biofilm formation in a clinically relevant model, an ex vivo porcine vaginal 
mucosal (PVM) model was used. This ex vivo model mimics a biofilm infection of the 
epithelium (Anderson, Parks et al. 2013). 
3.5.5.1. Validation of a porcine vaginal mucosal (PVM) biofilm 
model 
A. baumannii ATCC 19606 has been shown to form a robust biofilm on both plastic 
and human skin equivalents (de Breij, Gaddy et al. 2009, Gaddy, Tomaras et al. 
2009, de Breij, Haisma et al. 2012). Therefore, attachment of AYE and ATCC19606 
cells to PVM was imaged over six days using LIVE/DEAD© staining and confocal 
laser scanning microscopy (Figure 3.5.4). The LIVE/DEAD© stain consists of SYTO9 
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Figure 3.5.3 Efflux of ethidium bromide by AYE and AYEΔadeRS 
A. Efflux of ethidium bromide by AYE and AYEΔadeRS over time 
  
Data are shown as fluorescence relative to the starting fluorescence levels for each 
strain and represent the mean of three biological replicates. Data are a 
representative example of a single independent experiment carried out at least three 
times. 
B. Fold change in intracellular levels of ethidium bromide in AYE and 
AYEΔadeRS 
 
Data are plotted as independent biological replicates to show variation within each 
strain. Data are presented as fold change in final fluorescence value compared to 
AYE +/- standard deviation. Student’s t-tests were performed and those returning P 
values of less than 0.05 are indicated by *. 
* 
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Figure 3.5.4 Confocal laser scanning microscopy of AYE and ATCC19606 biofilms using LIVE/DEAD© staining and 
visualised at 1-6 days 
 
Uninfected epithelia are live (green) and intact. Red, rounded epithelial cells indicate cell death. Small, punctate, green staining 
indicates bacterial cells and large, green staining masses indicate bacterial biofilm. Black areas depict exposed extracellular matrix. 
Arrows indicate examples of live and dead epithelial cells, bacterial cells, epithelial cell sloughing and biofilm masses. 
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which stains live cells green, and propidium iodide (PI), which stains dead cells red. 
PI only penetrates cells with damaged membranes and once in close proximity to the 
SYTO9 it quenches the green signal, so only the red is visible 
(https://tools.thermofisher.com/content/sfs/manuals/mp10316.pdf). This allows live 
versus dead cells to be detected. These dyes are non-specific nucleic acid dyes, 
which do not discern between prokaryotic and eukaryotic cells (Haimovich and 
Tanaka 1995, Anderson, Parks et al. 2013, Tsai, Lin et al. 2013, Li, Gorle et al. 
2015). Epithelial and bacterial cells were distinguished from each other based on the 
size of the punctate staining, which could be clearly viewed by confocal microscopy, 
and the fact that the uninfected tissue, which had no bacteria present, stained green. 
Viability of the tissue at six days was confirmed by imaging of uninfected tissue over 
the same time course. Uninfected tissue stained green, indicating live, intact cells 
with tight cell junctions (Figure 3.5.4A-F). Over the six day time course, AYE and 
ATCC19606 showed a similar biofilm phenotype. At one day post infection, loss of 
mucosal integrity was evidenced by rounding of epithelial cells and adherent bacteria 
(small, bright green punctate staining) were visible on the tissue (Figure 3.5.4G&M). 
By three days post infection, epithelial cell death (red) was observed and the number 
of bacteria visualised was greater (Figure 3.5.4I&O). Black areas indicated sloughing 
of cells as the extra cellular matrix does not stain and some biofilm formation was 
visible with ATCC19606. By six days post infection, a large biofilm mass was visible 
for AYE and most of the tissue was covered by the biofilm (Figure 3.5.4R). 
3.5.5.2. Biofilm formation by AYEΔadeRS on mucosal tissue 
To investigate whether AdeRS is important for biofilm formation on biotic surfaces, 
growth of AYE and AYE∆adeRS on PVM was measured. Initial experiments were 
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carried out during a research visit to the University of Minnesota. Later experiments 
to confirm the phenotype were carried out by Michele Anderson (University of 
Minnesota). Counts of adherent and planktonic cells were taken at 24 hr time points 
up to 144 hours. There was a rapid increase in the number of adherent cells on PVM 
up to the one day time point, followed by a slow but steady increase between one 
and six days (Figure 3.5.5). There was no significant difference between numbers of 
adherent cells for AYE and AYEΔadeRS at any time point (Figure 3.5.5). However, 
LIVE/DEAD© staining and confocal laser scanning microscopy showed a difference 
between the infection phenotype of AYE and AYE∆adeRS (Figure 3.5.6). At three 
days post-infection, AYE infected tissue displayed epithelial cell death (Figure 
3.5.6C) and by six days post-infection large biofilm masses and epithelial cell 
sloughing was visible, as described above (Figure 3.5.6F). However, for 
AYEΔadeRS, although epithelial cell death was evident and the tissue exhibited 
some epithelial cell sloughing, in contrast to AYE infection, many dead epithelial cells 
remained visible. AYE∆adeRS cells appeared as single attached cells with no biofilm 
observed (Figure 3.5.6L). These data suggest a critical role for AdeRS in mucosal 
biofilm infections and host cell cytotoxicity. 
3.5.6. Biofilm formation in vitro by AYEΔadeRS 
To determine whether lack of AdeRS conferred a change in biofilm formation on an 
abiotic surface, the parental strain AYE and adeRS deletion mutant were grown in 
four different in vitro models to measure biofilm; a microfluidic cell, polypropylene 
pegs, polystyrene test tubes and glass cover slips. 
  
98 
 
Figure 3.5.5 Adherent and planktonic bacterial cells counts of AYE and 
AYEΔadeRS grown at 37°C on PVM 
 
Data are shown as mean CFU/ml of three biological replicates and are representative 
of a single independent experiment carried out at least three times. 
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Figure 3.5.6 Confocal laser scanning microscopy of AYE and AYEΔadeRS biofilms using LIVE/DEAD© staining and 
visualised at 1-6 days 
 
Uninfected epithelia are live (green) and intact. Red, rounded epithelial cells indicate cell death. Small, punctate, green staining 
indicates bacterial cells and large, green staining masses indicate bacterial biofilm. Black areas depict exposed extracellular matrix. 
Arrows indicate examples of live and dead epithelial cells, bacterial cells, epithelial cell sloughing and biofilm masses. 
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3.5.6.1. Biofilm formation by AYEΔadeRS in a microfluidic cell 
Biofilm formation by AYE and AYEΔadeRS was studied under flow conditions in 
order to more closely mimic biofilm formation on a medical device implanted in the 
body. Infection with A. baumannii is often associated with indwelling medical devices, 
which can provide a surface for biofilm development (Rodríguez-Baño, Martí et al. 
2008, Jung, Park et al. 2010). At 0 hrs, attachment of individual bacterial cells to the 
walls of the flow cell could be seen by phase microscopy (Figure 3.5.7). There was 
no difference in initial attachment of AYE and AYEΔadeRS. Both AYE and the 
deletion mutant formed a robust biofilm after 16 hrs and rapid growth could be seen 
in this time period. Thick biofilm coverage of the surface of the microfluidic cell was 
observed at 16, 24 and 48 hrs. When compared visually, there was no difference in 
the biofilm formed by either strain at any time point. 
3.5.6.2. Biofilm formation by AYEΔadeRS on polypropylene pegs 
To quantify the amount of biofilm formed by AYE and AYEΔadeRS after 8 hrs 
incubation, cells were grown in microtitre trays with polypropylene pegs submerged 
in the wells. This allows a biofilm to form on the peg at the air/liquid interface and 
previous experiments showed that at this time point AYE formed a similar biofilm to 
the previously characterised biofilm forming strain ATCC 19606. Plates were 
incubated at 30°C and 37°C to replicate wound and body temperature, respectively. 
Burns wards and operating theatres, where many patients become infected with A. 
baumannii, are also maintained at 37°C. Biofilms were quantified by crystal violet 
staining in order to compare biofilm mass between AYE and AYEΔadeRS. In this in 
vitro model, when compared with the parental strain there was no change in biofilm 
mass produced by the adeRS deletion mutant at either 30°C or 37°C (Figure 3.5.8). 
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Figure 3.5.7 Phase contrast microscopy images of AYE and AYEΔadeRS biofilms formed under flow conditions of 0.3 
dynes up to 48 hrs 
 
Images show attachment of bacterial cells to the inner surface of a microfluidic channel. Grey dots show adherence of individual 
cells to the surfaces whereas solid grey areas indicate bacterial growth and biofilm production. Black bar depicts a 10 µm scale.  
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Figure 3.5.8 Biofilm formation by AYE and AYEΔadeRS on polypropylene pegs 
as determined by crystal violet staining 
A. 30°C 
  
Data are plotted as independent biological replicates to show variation within each 
strain. Data are presented as fold change compared to AYE +/- standard deviation. 
Student’s t-tests were performed and those returning P values of less than 0.05 are 
indicated by *. 
B. 37°C 
 
Data are plotted as independent biological replicates to show variation within each 
strain. Data are presented as fold change compared to the parental strain +/- 
standard deviation. Student’s t-tests were performed and those returning P values of 
less than 0.05 are indicated by *.  
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3.5.6.3. Pellicle formation by AYEΔadeRS 
To assess the ability of AYE and AYEΔadeRS to form a pellicle at the air/liquid 
interface, cultures were incubated statically in polystyrene test tubes for 48 hours at 
37°C. A thick biofilm mat could be seen at the surface with both strains. However, 
there was no difference in the amount of pellicle formed by AYE or AYEΔadeRS 
(Figure 3.5.9). 
3.5.6.4. Biofilm formation by AYEΔadeRS on glass cover slips 
In order to visualise biofilms formed by AYE and AYEΔadeRS and to determine 
whether the two-component system (TCS) mutant was unable to adhere to abiotic 
surfaces or was adherent but unable to form a biofilm (as seen in the mucosal model) 
bacterial cultures were incubated on glass slides for 24 hrs before being fixed for 
scanning electron microscopy (SEM). Images obtained from the SEM showed an 
early biofilm formed by AYE with areas of complex three dimensional biofilm visible 
(Figure 3.5.10). Furthermore, an extracellular matrix (ECM) could clearly been seen 
in-between cells. AYEΔadeRS showed an altered biofilm phenotype compared with 
the parental strain AYE. Individual cells appeared attached to the glass cover slip but 
there was no clear biofilm formation (Figure 3.5.10). The coverage of the surface of 
the cover slip was more sparse after incubation with the mutant strain and no 
extracellular matrix was produced. This is in agreement with the phenotype observed 
in the mucosal biofilm model, in which the adeRS deletion mutant did not appear to 
form a mature biofilm. However, this difference was not seen in the other in vitro 
biofilm models used. 
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Figure 3.5.9 Pellicle formation by AYE and AYEadeRS incubated statically at 
37°C  
A. Visualised under white light 
 
B. Visualised under natural light 
 
105 
 
Figure 3.5.10 Scanning electron microscopy of AYE and AYEΔadeRS biofilms grown for 24 hrs on glass cover slips 
 
Images show attachment of bacterial cells, production of ECM and formation of a biofilm on the surface of a glass cover slip.
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3.5.7. Motility of AYEΔadeRS 
A. baumannii is generally considered to be non-motile due to its lack of flagella, but 
swarming and twitching motility have both been shown (Henrichsen 1975, 
Eijkelkamp, Stroeher et al. 2011, Skiebe, de Berardinis et al. 2012). AYE has been 
shown previously to display twitching motility but not swarming motility, typical of 
International Clone I (Eijkelkamp, Stroeher et al. 2011). To determine whether the 
AdeRS TCS is involved in the regulation of genes required for motility in AYE, 
twitching motility and swarming experiments were carried out with 1% Mueller Hinton 
agar and 0.3% Luria-Bertani agar, respectively (Figure 3.5.11). Strain AYE displayed 
twitching motility, but did not display swarming motility, as with the majority of A. 
baumannii strains. AYEΔadeRS did not display an altered twitching motility or 
swarming phenotype. 
3.5.8. Virulence of AYEΔadeRS in the G. mellonella model of 
infection 
It was hypothesised that AdeRS regulates the expression of genes responsible for 
virulence in A. baumannii AYE. For example, it has been shown that MDR efflux 
pumps are required for infection by several other Gram negative bacterial species 
(Buckley, Webber et al. 2006, Nishino, Latifi et al. 2006, Kvist, Hancock et al. 2008, 
Padilla, Llobet et al. 2010, Matsumura, Furukawa et al. 2011, Baugh, Ekanayaka et 
al. 2012, Perez, Poza et al. 2012, Liao, Schurr et al. 2013, Baugh, Phillips et al. 
2014). Previous studies have shown a positive correlation between virulence in the 
G. mellonella infection model and mammalian models (Jander, Rahme et al. 2000, 
Miyata, Casey et al. 2003). Furthermore, G. mellonella has been established as a  
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Figure 3.5.11 Twitching and swarming motility of AYE and AYEΔadeRS grown 
on 1% and 0.3% agar for 24 hrs at 37°C 
A. Twitching motility 
 
B. Swarming motility 
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good model system to study A. baumannii pathogenesis as larvae can be maintained 
at 37°C and have both a cellular and humoral immune response (Peleg, Jara et al. 
2009). In the G. mellonella model, when compared with the parental strain, 
AYE∆adeRS showed a small but not statistically significant decrease in virulence at 
an infectious dose of 106 CFU (Figure 3.6.1). 
3.6. Determining the transcriptome of AYEΔadeRS 
To identify changes in gene expression that may account for the difference in biofilm 
phenotype between AYE and AYEΔadeRS and to understand the role of the TCS 
AdeRS in regulation of genes involved in antimicrobial resistance and virulence in A. 
baumannii strain AYE, RNA-Seq was carried out. This technology allows 
transcriptome profiling using DNA sequencing. A population of total RNA is converted 
to a library of cDNA fragments tagged with adaptors. Each molecule is then 
sequenced using high-throughput technology to obtain short sequences (reads) from 
one end (single-end sequencing) or both ends (pair-end sequencing).The reads are 
typically 30–400 bp, depending on the DNA-sequencing technology used and can be 
mapped to a reference genome. Gene expression levels can be deduced from the 
total number of reads that map to the gene (depth) (Wang, Gerstein et al. 2009). 
RNA was prepared in Birmingham and sent to ARK Genomics, Edinburgh for library 
preparation and sequencing. Three biological replicates per strain were sequenced 
on an Illumina HiSeq platform using single ended reads. Data were checked for 
quality and analysed by bioinformatics collaborator, Dr Alasdair Ivens (University of 
Edinburgh) and submitted to ArrayExpress (E-MTAB-4047). RNA samples were 
prepared and sequenced in two separate batches as a two samples sent in the first 
shipment produced poor quality sequencing data. Heat map plotting of gene  
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Figure 3.6.1 Kaplan Meir survival curve to show virulence of AYE and 
AYEΔadeRS in G. mellonella 
 
 
Data show mean percentage survival (n=30) of G. mellonella after inoculation with 
106 CFU bacteria. Error bars represent SEM.  
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expression changes in individual samples showed that samples prepared and 
sequenced at the same time clustered together (Figure 3.6.2). Deletion of the entire 
1366 bp adeS gene and 126 bp of adeR was confirmed by the absence of reads 
mapping to this region of the genome in each AYEΔadeRS sample. AYE samples 
showed fairly low read depth (< 50) across adeRS with increased numbers of reads 
(read depth 100 – 2000) mapping across adeABC (Figure 3.6.3). This suggested a 
low level of expression of adeRS in the parental strain and high expression of the 
adeABC operon. AYEΔadeRS showed an absence of reads mapped to adeS and the 
126 bp deleted region of adeR and very low read depth across adeABC (Figure 
3.6.3). The absence of reads mapped to the deleted portion of adeRS demonstrated 
an absence of RNA transcribed from this region. Low read depth across adeABC 
suggested reduced expression of this operon compared with the parental strain. 
There was significantly less expression of adeS in AYEΔadeRS compared with AYE 
(Table 3.6.1, Table 3.6.2). There was no significant change in expression of adeR. 
All gene expression changes in AYEΔadeRS compared with AYE were plotted by 
locus tag to easily identify highly differentially expressed genes or operons (Figure 
3.6.4). The RND efflux pump operon adeABC showed a 128, 91 and 28-fold 
reduction in expression of each gene, respectively. Differential expression of operons 
encoding type IV pilus assembly, biogenesis and regulatory proteins such as pilGHIJ, 
pilTU and pilBCD was observed, with increased expression of up to 8-fold. These 
genes have previously been shown to be involved in twitching motility and natural 
transformation in A. baumannii (Antunes, Imperi et al. 2011, Harding, Tracy et al. 
2013, Wilharm, Piesker et al. 2013). Type IV pili have also been associated with the 
ability of A. baumannii to form a biofilm on plastic (Tucker, Nowicki et al. 2014). 
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Figure 3.6.2 Heat map plot of gene expression changes in 6 biological replicates (3 x AYE and 3 x AYEΔadeRS) prepared 
and sequenced on different days 
 
Samples AYE 1 and AYE 2 were prepared and sequenced as one set and samples AYEΔadeRS 1-3 and AYE 3 were prepared and 
sequenced as another. Lines represent individual genes and the X axis represents the whole AYE chromosome. 
Clustering of replicates 
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Figure 3.6.3 Number of reads aligned to each base across the adeRS adeABC 
region in each AYE and AYEΔadeRS sample 
A. AYE 
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B. AYEΔadeRS 
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Table 3.6.1 The top 10 genes with the most significantly changed expression in AYEΔadeRS compared with AYE 
Gene ID Start End Description 
Common 
Name Strand Type 
log2 
fold 
change 
Fold 
change P.Value 
ABAYE1819 1883328 1884413 
two-component 
sensor adeS - gene -6.90 0.008 2.00E-07 
ABAYE1822 1886521 1889631 RND protein adeB + gene -6.50 0.011 1.30E-05 
ABAYE1821 1885325 1886524 
membrane fusion 
protein adeA + gene -7.00 0.008 4.20E-05 
ABAYE1823 1889696 1891105 
outer membrane 
protein adeC + gene -4.80 0.036 5.60E-05 
ABAYE3702 3735843 3736049 
fragment of 
conserved 
hypothetical 
protein (partial)  - pseudogene -1.60 0.330 3.60E-04 
ABAYE1474 1541855 1542541 
putative 
glutathione S-
transferase  + gene -1.30 0.406 3.60E-04 
ABAYE1539 1603553 1604008 
3-dehydroquinate 
dehydratase type II aroQ - gene 1.80 3.482 4.40E-04 
ABAYE1561 1626579 1626947 
putative 
intracellular sulfur 
oxidation protein 
(DsrE-like) 
 
- gene -1.80 0.287 4.70E-04 
ABAYE2274 2318942 2319259 
hypothetical 
protein  + gene -3.10 0.117 7.10E-04 
ABAYE3074 3110289 3110585 
hypothetical 
protein putative 
membrane protein  - gene 2.20 4.595 8.50E-04 
115 
 
Table 3.6.2 The top 10 genes with the largest fold change in expression in AYEΔadeRS compared with AYE 
Gene ID Start End Description 
Common 
Name Strand Type 
log2 
Fold 
change 
Fold 
change P.Value 
ABAYE2369 2412094 2412888 
enoyl-CoA hydratase 
phenylacetic acid 
degradation paaG - gene 3.80 13.929 5.40E-02 
ABAYE2374 2416037 2416351 
subunit of 
Phenylacetate-CoA 
oxygenase phenylacetic 
acid degradation paaB - gene 3.50 11.314 5.00E-02 
ABAYE2372 2414752 2415252 
subunit of 
Phenylacetate-CoA 
oxygenase phenylacetic 
acid degradation paaD - gene 3.50 11.314 5.80E-02 
ABAYE2373 2415269 2416024 
subunit of 
Phenylacetate-CoA 
oxygenase phenylacetic 
acid degradation paaC - gene 3.40 10.556 5.20E-02 
ABAYE2370 2412885 2413658 
enoyl-CoA hydratase 
phenylacetic acid 
degradation paaF - gene 3.40 10.556 5.60E-02 
ABAYE1821 1885325 1886524 
membrane fusion 
protein adeA + gene -7.00 0.008 4.20E-05 
ABAYE1819 1883328 1884413 two-component sensor adeS - gene -6.90 0.008 2.00E-07 
ABAYE1822 1886521 1889631 RND protein adeB + gene -6.50 0.011 1.30E-05 
ABAYE_16s_5 487461 488915 ABAYE_16s_5 
 
+ rRNA -4.90 0.033 3.00E-02 
ABAYE1823 1889696 1891105 outer membrane protein adeC + gene -4.80 0.036 5.60E-05 
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Figure 3.6.4 Log2 fold change in expression of all genes of the AYE genome in AYEΔadeRS compared with AYE 
 
Genes with increased and decreased expression are coloured red and blue, respectively. Gene names or annotations are provided 
for genes within differentially expressed operons or highly differentially expressed genes with known function. 
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Increased expression of the paaZABCDEFGHJK operon was also seen. This operon 
encodes the PAA catabolic pathway which is important in the catabolism of several 
aromatic compounds. It has been shown previously that expression of this operon is 
regulated by the sensor kinase GacS, part of the GacSA two component system 
(Cerqueira, Kostoulias et al. 2014). Interestingly, deletion of gacS resulted in down-
regulation of the paa operon, whereas deletion of adeRS in the present study gave 
increased expression of up to 14-fold. Deletion of paaE by Cerqueira et al. showed a 
role for this operon in virulence in A. baumannii (Cerqueira, Kostoulias et al. 2014). 
A raw P value cut-off of 0.05 was used to produce a list of significantly changed 
genes (Table 3.6.1, Table 3.6.2). The raw P value was chosen as opposed to the 
more stringent adjusted P value as this gave a more comprehensive list of changed 
genes that may affect the phenotype and ensured that no genuinely changed genes 
would be excluded from the list. There were 308 genes with increased expression 
and 271 with decreased expression in AYEΔadeRS compared with AYE indicating a 
wide ranging impact that results from loss of this system. Differentially expressed 
genes were categorised into cluster of orthologous groups (COGs) (Tatusov, 
Galperin et al. 2000) and correlations with the phenotypic changes seen in 
AYE∆adeRS sought (Figure 3.6.5). Firstly, differential expression of genes known to 
confer antimicrobial resistance was identified. In addition to increased expression of 
the RND efflux pump genes adeABC, genes encoding four ethidium bromide 
resistance proteins (ebr) and chloramphenicol resistance protein A (cmlA) showed 
increased expression of 1.6- fold and a tetracycline resistance protein (tetA) had 1.3-
fold increased expression. One putative MDR RND efflux pump (ABAYE3036) had 
1.9 fold increased expression, whilst expression of another (ABAYE1796) was 
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Figure 3.6.5 Clusters of orthologous groups (COG) and the percentage of genes with increased expression (red) and 
decreased expression (blue) in AYEΔadeRS compared with AYE within each group as determined by RNA-Seq 
 
The total number of genes per COG is shown in parentheses. Groups related to antibiotic resistance, biofilm formation and 
virulence are marked by a green box. 
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decreased by 1.5 fold. Genes encoding products with known and potential virulence 
functions, such as pili (Bahar, Goffer et al. 2009) and acinetobactin transport systems 
(Gaddy, Arivett et al. 2012), had significant (P < 0.05) changes in expression levels in 
AYE∆adeRS. For instance, there was increased expression of genes that encode 
motility, such as competence genes comB, comC, comF, comL, comM, comN comO 
and comQ (2.5 – 9.8-fold). These genes putatively encode DNA uptake channels and 
deletion of comEC in A. baumannii has been shown to reduce DNA uptake, motility 
and virulence in G. mellonella (Wilharm, Piesker et al. 2013). There was also 
increased expression of pilB, pilC, pilD, pilG, pilH, pilI, pilJ, pilT, pilU and pilZ (1.7 – 
8-fold). As previously mentioned, these type IV pili genes play a role in natural 
transformation, twitching motility, biofilm formation and virulence. The pil and com 
genes were categorised into the ‘cell motility’ group by COG annotation. This was the 
largest group of changed genes in AYEΔadeRS by RNA-Seq with 47% of all motility 
genes showing decreased expression. Changed biofilm genes include decreased 
expression of a PgaC-like gene (2-fold) that putatively encodes a protein involved in 
synthesis of cell-associated poly-beta-(1-6)-N-acetylglucosamine (PNAG), which is 
required for biofilm formation on abiotic surfaces (Choi, Slamti et al. 2009) and 
decreased expression of five putative biofilm associated genes; ABAYE0792, 1395, 
1397, 1470, 1473 (1.7-2.5-fold). In addition, multiple putative transport protein, outer 
membrane protein and transcriptional regulator genes that lacked a comprehensive 
annotation showed differential expression.  
3.7. Discussion 
This work was carried out using an adeRS deletion mutant of strain AYE and the 
phenotype presented has been interpreted as the result of lack of both proteins of the 
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two component system AdeRS. However, as such a small part of adeR was deleted it 
is possible that part of the gene is still transcribed and a truncated protein may be 
produced. Mapping of RNA-Seq reads to the adeRS operon showed that in 
AYEΔadeRS there were no reads mapped to the deleted sequences; however there 
was a large peak in expression at the beginning of adeR. It is hypothesised that this 
is a result of the cell sensing low levels of AdeRS and attempting to increase 
production; this could result in truncated AdeR with no or reduced function being 
produced. This may be induced by the increased levels of AdeABC or changed levels 
of other proteins whose expression is regulated by AdeRS in the mutant. It is 
possible that AdeR, the response regulator, can receive a signal from a sensor 
kinase other than AdeS (West and Stock 2001). If a truncated, but functional, AdeR 
protein is produced in AYEΔadeRS it may be that some AdeR activity is retained. 
However, this is unlikely as protein domain prediction indicated that 27 amino acid of 
the signal receiver domain was deleted. Western blotting would allow detection of the 
AdeR protein by separating proteins from AYEΔadeRS using gel electrophoresis and 
staining for AdeR using specific antibodies. However, currently no such antibodies 
are available. Using an alternative method, Sun et al. were able to demonstrate 
constitutive production of a truncated AdeS protein in an A. baumannii clinical isolate 
and by introducing a series of recombinant adeRS constructs into an adeRS 
knockout strain, showed that the truncated product interacted with AdeR and 
stimulated expression of AdeABC (Sun, Perng et al. 2012). Ideally, a mutant in which 
the entire two component system operon adeRS is deleted should be used. 
However, due to the technical difficulties in genetically manipulating A. baumannii, 
particularly MDR strains such as AYE, this study was continued with the mutant 
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obtained. A previous study by Marchand et al. showed that deletion of adeR 
produced a very similar change in drug resistance profile as seen with deletion of 
adeS in A. baumannii (Marchand, Damier-Piolle et al. 2004). However, as these 
genes are transcribed as an operon, it is possible that disruption of adeR may have a 
polar effect on adeS, which is located downstream. This phenomenon would explain 
the similar phenotype seen in adeR and adeS mutants. 
Since the RNA-Seq experiments described here were carried out (August 2012), 
RNA-Seq protocols have been revised and bacterial RNA-Seq now uses paired end 
reads as these generate high-quality, alignable sequence data (Rumbo-Feal, Gómez 
et al. 2013). The clustering of RNA samples prepared on the same day demonstrates 
the variability in data generated from samples prepared on different days and 
sequenced on different runs and highlights the need to standardise as much of the 
procedure as possible in experiments of this kind. RNA extraction and library 
preparation of samples from the same strain should be carried out on the same day 
and all samples should be sequenced in a single run so as to minimise variation. 
The hypothesis explored was that AdeRS regulates expression of genes, including 
the RND MDR efflux pump genes adeABC, that are required for drug resistance, 
biofilm formation and virulence. In A. baumannii BM4587, a clinical isolate from 
France that has been extensively characterised by the Courvalin group, AdeABC has 
a well-defined role in resistance to antimicrobials. Characterisation of isogenic 
mutants overproducing or deleted for Ade pumps showed that AdeABC had a broad 
substrate range, including β-lactams, fluoroquinolones, tetracyclines-tigecycline, 
macrolides-lincosamides, and chloramphenicol, and conferred clinical resistance to 
aminoglycosides (Magnet, Courvalin et al. 2001, Yoon, Courvalin et al. 2013, Yoon, 
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Nait Chabane et al. 2015). Deletion of adeRS in AYE resulted in decreased MICs of 
the same antibiotics, leading to the conclusion that the decrease in expression of 
adeABC in AYEΔadeRS is responsible for the change in drug resistance profile seen 
in this strain. This is in agreement with previous studies to inactivate adeR and adeS 
in clinical isolate BM4454, which also led to susceptibility to substrates of the 
AdeABC efflux pump (Marchand, Damier-Piolle et al. 2004). However, it should be 
noted that, due to the vast range of antibiotic resistance mechanisms present in A. 
baumannii, determination of MICs of pump deletion mutants of MDR isolates may not 
be the best way to identify the substrates of an efflux pump. Background resistance 
due to a complex set of resistance determinants such as β-lactamases and 
aminoglycoside-modifiying enzymes means that the effect of deletion of efflux pump 
genes may be masked. The observed decrease in efflux activity in AYEadeRS 
supports the hypothesis that the increase in susceptibility to the antimicrobials tested 
in AYE lacking AdeRS is due to down regulation of AdeABC and therefore reduced 
efflux. The decrease in efflux activity means that substrates of the pump are not 
extruded as efficiently and therefore accumulate inside the cell and are lethal at lower 
external concentrations. The H33342 efflux assay measures accumulation of dye in 
the cell and has been shown to provide greater sensitivity in measuring efflux than 
some other methods (Coldham, Webber et al. 2010). However, not only is 
intracellular accumulation affected by efflux, but it is also influenced by other factors 
such as changes in membrane permeability caused by altered production of outer 
membrane porins (Coldham, Webber et al. 2010). Therefore, efflux activity can only 
be inferred by this assay as it is not being directly measured. For this reason a 
second efflux assay, using ethidium bromide, was used. In this method, cells are 
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‘pre-loaded’ with ethidium bromide and efflux of the dye is observed by measuring 
the decrease in fluorescence over time. This method measures efflux in a more direct 
manner. Data obtained with H33342 and ethidium bromide indicate lower levels of 
efflux in the adeRS mutant. 
The adeRS mutant displayed reduced biofilm formation on mucosal tissue. Although 
there was no change in the number of adherent cells on the mucosal tissue with 
deletion of adeRS, there was a clear difference in the structure of the biofilm when 
imaged with LIVE/DEAD© staining and confocal laser scanning microscopy. This is a 
phenomenon that has been previously observed with Staphylococcus aureus 
(Anderson, Lin et al. 2012). This suggests that AdeRS does not affect initial 
attachment to the tissue but that cells lacking this TCS are unable to form a mature 
biofilm on mucosal tissue. This was supported by SEM imaging of biofilms formed on 
glass cover slips. AYE was able to form a complex biofilm with visible extracellular 
matrix present, whereas the adeRS deletion mutant was not. As described above, 
there were 16 genes associated with biofilm formation with differential expression in 
AYEΔadeRS compared with AYE. Although these genes have previously only been 
associated with biofilm formation on abiotic surfaces, it is possible that these 
changes, along with the down-regulation of the RND efflux pump genes adeABC, 
may be responsible for the decreased biofilm formation on PVM observed in this 
mutant. Similar observations have been made in Salmonella efflux pump mutants, 
which are able to adhere to surfaces but not able to produce a mature biofilm 
(Baugh, Ekanayaka et al. 2012). MDR efflux pumps of the RND family have also 
been shown to be required for virulence and biofilm formation in several other Gram 
negative bacterial species (Buckley, Webber et al. 2006, Nishino, Latifi et al. 2006, 
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Kvist, Hancock et al. 2008, Padilla, Llobet et al. 2010, Matsumura, Furukawa et al. 
2011, Baugh, Ekanayaka et al. 2012, Perez, Poza et al. 2012, Liao, Schurr et al. 
2013, Baugh, Phillips et al. 2014). In Salmonella, inactivation or deletion of MDR 
efflux genes led to down-regulation of known virulence factors and genes involved in 
biofilm formation (Webber, Bailey et al. 2009, Baugh, Ekanayaka et al. 2012). PVM is 
made up of stratified squamous epithelium, similar in structure to human mucosal 
surfaces (Anderson, Parks et al. 2013). However, as A. baumannii most commonly 
colonise respiratory surfaces and wounds, this may not provide the most relevant 
surface on which to study A. baumannii infection. The surface of the vaginal mucosa 
is moist due to secretions from glands of the cervix and this may affect the biofilm 
ability of the strains tested here. Despite this, the growth characteristics of A. 
baumannii on the PVM were similar to those observed using a 3D human skin 
equivalent model (de Breij, Haisma et al. 2012). Therefore, differences in the ability 
of the A. baumannii TCS mutant, AYEΔadeRS, to form a biofilm in the PVM model 
may have implications for respiratory and wound infections. Nevertheless, the 
mucosal biofilm model also has limitations. In order to count cells and visualise 
biofilms, explants must be washed and stained. Therefore, a different explant must 
be used each day. This means that the biofilm imaged on day two is not a direct 
development of the biofilm visualised on day one. Variation between explants due to 
size, location and tissue damage during preparation is possible. To minimise this 
variation, each experiment was conducted using a single animal and explants of 
uniform size were obtained from the porcine vagina using a standard 5 mm biopsy 
punch. In addition, the mucosal tissue is colonised with normal flora when excised 
and has to be washed with a combination of antibiotics and anti-fungals to remove 
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any contaminating elements. Although measures were taken to ensure that there 
was no effect on viability of the tissue with washing, it is possible that this may have 
had an adverse effect on epithelial cells. Further limitations of the PVM model are the 
lack of blood supply, which would allow for influx of immune cells to the site of 
infection, and the inability to study biofilm dispersal as the model is static in nature 
(Anderson, Lin et al. 2012, Anderson, Parks et al. 2013, Anderson, Scholz et al. 
2013). 
3.8. Further work 
To confirm that there is no production of the AdeS protein and determine whether the 
AdeR protein is produced (despite a 126 bp fragment of the gene being deleted) in 
AYEΔadeRS Western blotting should be carried out. In order to do this, antibodies 
against AdeR and AdeS need to be generated. This method would show the 
presence or absence of the AdeR and AdeS proteins and confirm that deletion of the 
gene abolishes production of the TCS. It is possible that deletion of a single one of 
the two components of this system produces a different phenotype to the other. 
Inactivation of AdeS should remove the ability of the cell to sense certain 
extracellular signals, but not its ability to initiate a response and inactivation of AdeR 
should remove the ability to initiate a response but not the ability to sense 
extracellular signals. If another sensor kinase or response regulator were able to take 
the place of AdeS or AdeR, respectively, then TCS function may be retained. To give 
a complete picture of the role of the individual components of the AdeRS regulatory 
system, deletion mutants of adeR and adeS only and a double adeRS mutant should 
be made in AYE and their phenotype characterised and compared to that of the 
mutant described in this study. It should also be noted that these genes are 
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transcribed as an operon and therefore deletion of adeR may have a downstream 
effect on expression of adeS. 
The limitations of the method used for RNA-Seq have been discussed. RNA-Seq of 
the new single and double mutants should be repeated using paired end reads. 
Steps should be taken to minimise variation between samples, for example all RNA 
extractions should be performed on the same day and samples should be sequenced 
on the same run. To improve the robustness of the data, more biological replicates 
should be used. A recent study by Schurch et al recommended that at least 6 
replicates per condition are used for RNA-Seq experiments (Schurch, Schofield et al. 
2015). 
AdeRS is a two component system regulator. These systems allow bacteria to 
regulate their internal environment in response to extracellular signals. However, the 
nature of the signal and the mechanism of AdeRS activation are unknown 
(Marchand, Damier-Piolle et al. 2004). TCSs have previously been shown to respond 
to stress conditions such as antibiotic exposure, acid stress and starvation in other 
organisms (Elabed, Merghni et al. 2016, Kellogg and Kristich 2016, Liu, Liu et al. 
2016). To identify the extracellular signals that AdeRS responds to, AYE and 
AYEΔadeRS should be grown in different conditions such as varying iron, osmolarity, 
temperature and antibiotic stress. Those conditions at which the AdeRS deletion 
mutant shows a growth defect compared with the parental strain may reflect the 
extracellular signals that are sensed by this two component system. In addition, 
RNA-Seq of the parental strain AYE under different iron, osmolarity, temperature and 
antibiotic stress conditions should be carried out to identify conditions under which 
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adeABC is differentially expressed. This may indicate conditions under which the 
AdeRS TCS is activated, altering expression of the AdeABC efflux pump genes. 
3.9. Key findings 
 Deletion of AdeRS in A. baumannii strain AYE resulted in decreased MICs of 
antibiotics and dyes due to a reduction in efflux activity. 
 An AdeRS deletion mutant of A. baumannii strain AYE displayed decreased 
biofilm formation and epithelial cell killing in a mucosal model. 
 Deletion of AdeRS in A. baumannii strain AYE produced changed expression 
of 579 genes including several genes involved in drug resistance, biofilm 
formation and virulence.  
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4. The Role of the RND Efflux Pump AdeB in Antibiotic Resistance, 
Biofilm Formation and Virulence 
4.1. Background 
Increased expression of MDR efflux pump genes such as the Acinetobacter RND 
efflux pump genes adeABC leads to MDR and is commonly seen in clinical isolates 
of A. baumannii (Marchand, Damier-Piolle et al. 2004, Yoon, Courvalin et al. 2013). 
Multi-drug efflux systems have previously been associated with biofilm formation and 
virulence in a number of organisms using various models (Kvist, Hancock et al. 2008, 
Matsumura, Furukawa et al. 2011, Baugh, Ekanayaka et al. 2012, Liao, Schurr et al. 
2013, Yoon, Nait Chabane et al. 2015). As described in Chapter 3 deletion of adeRS 
in AYE resulted in a decrease in MICs of several antibiotics that have been 
previously described as substrates of this pump and a decrease in biofilm formation 
(Magnet, Courvalin et al. 2001, Yoon, Nait Chabane et al. 2015). To investigate 
whether the decreased expression of adeABC observed in AYEΔadeRS was 
responsible for the phenotype seen in this strain, an AdeB efflux pump mutant was 
created in AYE and the phenotype characterised. To determine whether the 
observed phenotype was strain-specific, a second efflux pump mutant in 
Singaporean clinical isolate S1 was also characterised. 
4.2. Hypothesis 
Deletion of adeB will result in a decrease in antibiotic resistance, biofilm formation 
and virulence and will alter the transcriptome in A. baumannii. 
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4.3. Aims 
The aim of this study was to identify the consequences of deletion of adeB in A. 
baumannii strain AYE and clinical isolate S1, respectively. The objectives were to 
use a novel gene deletion method to delete adeB in strain AYE, to characterise the 
antibiotic resistance, biofilm formation and virulence phenotype of deletion mutants 
AYEΔadeB and S1ΔadeAB and to use RNA-Seq to identify transcriptomic changes in 
these strains. 
4.4. Choice of strains and verification of strains 
The reasons for using A. baumannii AYE are discussed in Chapter 3. A clinical 
isolate from Singapore, S1, that was more susceptible to antibiotics than strain AYE 
and had no mutation in adeS and therefore did not express a high level of adeABC, 
was also studied. Together these strains represent clones that are internationally 
successful (strain AYE is ST 1 of International clone I and S1 is ST40 and 
representative of strains causing infection in SE Asia) (Koh, Tan et al. 2012) (Figure 
4.4.1). Deletion of 222 bp of adeA and 1914 bp of adeB in S1 to create the 
S1ΔadeAB mutant was carried out and verified by Professor Kim Lee Chua (National 
University of Singapore) using a markerless deletion method (Amin, Richmond et al. 
2013). Deletion was confirmed in Birmingham by amplification of the deleted region 
by PCR (Figure 4.4.2). Amplification of the region in S1 produced a 4103 bp 
amplimer, whereas amplification in S1ΔadeAB produced a 1842 bp amplimer, 
confirming deletion of a 2261 bp fragment spanning the last 222 bp of adeA, the first 
1914 bp of adeB and a 125 bp intergenic region. To predict how much of the AdeA 
and AdeB proteins were removed by deletion and to illustrate which part of the 
protein remained and may still be functional, I-TASSER protein modelling software 
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Figure 4.4.1 Relationships between 615 A. baumannii isolates based on MLST data (Pasteur scheme) as calculated by the 
BURST algorithm 
 
Circles indicate major international groups. AYE is marked in red and S1 is marked in blue. 
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Figure 4.4.2 Verification of adeAB gene deletion in S1 by PCR 
 
Lane Template Predicted fragment 
size (bp) 
Actual fragment 
size (bp) 
1 Hyperladder 1kb - - 
2 S1 4103 4103 
3 S1ΔadeAB 1842 1842 
4 Negative control 0 0 
Although all PCR products were electrophoresed on the same gel; the figure has 
been constructed from a single image to show only those strains relevant to this 
study.   
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was used. Deletion of 222 bp of adeA removed the last 74 amino acids of the AdeA 
protein (Figure 4.5.1). Deletion of 1914 bp of adeB removed the first 638 amino acids 
of the AdeB protein including the predicted AdeC binding domain and 
transmembrane helices (Figure 4.5.1). Deletion of adeB in AYE was jointly carried 
out in this study at University of Birmingham and Public Health England, Porton 
Down. All strains used in this study were confirmed as A. baumannii using a gyrB 
PCR as described in Chapter 3. 
4.5. Optimisation of the gene deletion method and deletion of 
adeB in AYE 
To delete the adeB gene in A. baumannii strain AYE, a modified version of a 
markerless deletion method was used (Amin, Richmond et al. 2013). E. coli S17-1 
containing a modified version of the pMo130-TelR suicide vector was created by 
Matthew Wand (PHE) and sent to Birmingham (Figure 4.5.2). This vector contained 
an A. baumannii groES promoter driving a modified sacB gene with an A. baumannii 
ompA leader sequence replacing the Burkholderia-originated leader sequence in the 
original vector (Matthew Wand, unpublished data). The vector backbone also 
contained upstream and downstream fragments of the AYE relA gene, which were 
later removed sequentially to maintain the BamHI restriction site between the two 
fragments. 
Primers were designed to amplify 855 bp and 874 bp fragments upstream (UP) and 
downstream (DWN) of the region of adeB to be deleted (Table 2.2.1). UP primers 
were designed with NotI and BamHI restriction sites and DWN primers were tagged 
with BamHI and SphI restriction sites. A 1131 bp region from position 995 to position  
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Figure 4.5.1 Predicted protein structure of AdeA and AdeB in S1ΔadeAB  
 
 
Amino acids for which the coding sequence was deleted are highlighted in red.  
AdeA 
AdeB 
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Figure 4.5.2 pMo130-TelR suicide vector containing a groES promoter driving a 
modified sacB gene with AYE relA up and down fragments 
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2126 was deleted in order to inactivate the gene whilst avoiding disrupting the genes 
upstream and downstream. However, it was noted that as adeABC is transcribed as 
an operon it was possible that transcription of adeC could be affected by deletion of a 
fragment of adeB. The pMo130-TelR vector was digested with NotI and BamHI 
restriction enzymes to excise the relA UP fragment and the adeB UP fragment was 
ligated into the digested plasmid. pM0130-TelR-adeBUP was then transformed into 
α-Select Electrocompetent Cells and the presence of the adeB UP fragment was 
confirmed by amplification of the UP fragment by colony PCR. Following this, the 
vector was digested with BamHI and SphI restriction enzymes to excise the relA 
DWN fragment and the adeB DWN fragment was ligated into the digested plasmid. 
The vector was then transformed into E. coli S17-1, verified by PCR and conjugated 
into A. baumannii AYE. Ligation of the DWN fragment and conjugation of the plasmid 
into AYE was carried out by Laura Bonney at PHE. After conjugation, candidate 
colonies containing the pMo130-TelR-adeBUPDWN vector integrated into the 
chromosome were streaked onto LB agar and those displaying a yellow halo, 
indicating presence of the xylE gene integrated onto the plasmid, were selected and 
streaked onto LB agar containing 10% sucrose. XylE converts pyrocatechol to a 
yellow-colored 2-hydroxymuconic semialdehyde (Amin, Richmond et al. 2013). 
Presence of sucrose in the medium stimulated loss of the plasmid as a result of SacB 
activity. The sacB gene encodes levansucrase, which can catalyse sucrose 
hydrolysis followed by levan synthesis. When the sacB gene is expressed in Gram-
negative bacteria the production of levansucrase is lethal in the presence of sucrose 
(Gay, Le Coq et al. 1985). This resulted in colonies containing the UP and DWN 
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region of the adeB gene with the fragment in-between deleted by double 
recombination. 
4.5.1. Verification of adeB deletion in AYE 
Deletion of adeB was verified by amplification of the deleted region by PCR and 
sequencing of the PCR amplimer (Figure 4.5.3). Amplification of the region in AYE 
produced a 5027 bp amplimer, whereas amplification in AYEΔadeB produced a 3896 
bp amplimer, confirming deletion of a 1131 bp fragment in the centre of the adeB 
gene (Figure 4.4.2A). Sequencing using the UP forward primer confirmed deletion of 
a region of adeB beginning at the 3’ end of the UP fragment and sequencing using 
the DOWN reverse primer confirmed that this deletion ended at the 5’ end of the 
DOWN fragment, as expected (Figure 4.4.2B). To predict which region of the AdeB 
protein was removed by this deletion, I-TASSER protein modelling software was 
used. Deletion of 1131 bp in the centre of the gene removed 377 amino acids which 
spanned the length of the predicted protein structure and included areas of the 
predicted AdeC binding domain and transmembrane helices (Figure 4.5.4). 
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Figure 4.5.3 Verification of adeB gene deletion in AYE by PCR and DNA 
sequencing 
 
Lane Template Predicted fragment 
size (bp) 
Actual fragment 
size (bp) 
1 Hyperladder 1kb - - 
2 AYEΔadeB 3896 3896 
3 AYE 5027 5027 
4 Negative control 0 0 
Although all PCR products were electrophoresed on the same gel; the figure has 
been constructed from a single image to show only those strains relevant to this 
study. 
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B. Alignment of the AYE adeB sequence with upstream sequencing data for 
AYEΔadeB 
AYE          AAAATGGTAAGCCTGCTACCGCGGCTGCAATTCAATTAAGCCCGGGAGCTAACGCCGTGA 
AYEadeB      AAAATGGTAAGCCTGCTACCGCGGCTGCAATTCAATTAAGCCCGGGAGCTAACGCCGTGA 
             ************************************************************ 
 
AYE          AAACTGCCGAAGGTGTTCGAGCAAAAATTGAAGAATTGAAGCTAAATTTACCGGAAGGCA 
AYEadeB      AAACTGCCGAAGGTGTTCGAGCAAAAATTGAAGAATTGAAGCTAAATTTACCGGAAGGCA 
             ************************************************************ 
 
AYE          TGGAATTTAGTATTCCTTACGACACCGCGCCGTTTGTCAAAATTTCAATTGAAAAGGTAA 
AYEadeB      TGGAATTTAGTATTCCTTACGACACCACGCCGTTGGATCCTGAAGGGTTGCCACAAGGTG 
             ************************** ******* *            *   * * *    
 
AYE          TTCATACATTACTTGAAGCCATGGTTCTGGTTTTCATTGTGATGTA--TCTATTTTTACA 
AYEadeB      ACAATATTTCTT--TAAAAATTGACCGTGAAAAGCTTAGTGCACTTGGTGTTAAGTTTTC 
                ***  *      **    **    **     * * ***   *   * *    **    
 
AYE          CAATGTCCGCTATACGCTTATTCCAGCAATTGTGGCGCCTATTGCCTTACTCGGTACTTT 
AYEadeB      TGATGTTTCAGACATCATCTCTACATCAATGGGTTCAATGTA--TATCAATGACTTCCCT 
               ****     * *   *   * ** **** *   *          * * *   * *  * 
 
AYE          TACCGTGATGTTGCTTGCCGGCTTTTCAATTAACGTACTCACCATGTTCGGT----ATGG 
AYEadeB      AA---TCAAG---------GACGTATGCAACAAGTCATTGTACAAGTTGAGGCTAAATCA 
              *   * * *         * * * *  *  **   * *   ** ***  *     **   
Sequences were aligned using Clustal Omega. * indicates a position with a single, 
fully conserved residue. The adeB gene is highlighted in yellow and the deleted 
region is highlighted in blue. 
B. Alignment of the AYE adeB sequence with downstream sequencing data for 
AYEΔadeB 
AYE          ATCTTTCAATTGCATACGTGATTTAGCCTCAACTTGTACAATGACTTGTTGCATACGTCC 
AYEadeB      ATCTTTCAATTGCATACGTGATTTAGCCTCAACTTGTACAATGACTTGTTGCATACGTCC 
             ************************************************************ 
 
AYE          TTGATTAGGGAAGTCATTGATATACATTGAACCCATTGATGTAGAGATGATGTCTGAAAC 
AYEadeB      TTGATTAGGGAAGTCATTGATATACATTGAACCCATTGATGTAGAGATGATGTCTGAAAC 
             ************************************************************ 
 
AYE          ATCAGAAAACTTAACACCAAGTGCACTAAGCTTTTCACGGTCAATTTTTAAAGAAATATT 
AYEadeB      ATCAGAAAACTTAACACCAAGTGCACTAAGCTTTTCACGGTCAATTTTTAAAGAAATATT 
             ************************************************************ 
 
AYE          GTCACCTTGTGGCAACCCTTCATTCCAAACCATATAGAACTTTTTATTCTTGGC---TGC 
AYEadeB      GTCACCTTGTGGCAACCCTTCAGGATCCAACGGCGTGGTGTCGTAAGGAATACTAAATTC 
             **********************      * *     *   *  * *    *      * * 
 
AYE          CAT----TGCCATAAGTTCATCTTGAGCAGC--CAATAAAGCAGG----CATACCTAAGT 
AYEadeB      CATGCCTTCCGGTAAATTTAGCTTCAATTCTTCAATTTTTGCTCGAACACCTTCGGCAGT 
             ***    * *  *** ** * *** *        * *   **  *    * * *   *** 
 
AYE          TAGCACGGTCTTGTAAACGTAGGCTGAAACCTGAAAAAGTACCTAACTCATCAATAGCGG 
AYEadeB      TTTCACGGCGTTAGCTCCCGG-GCTTAATTGAATTGCAGCCGCGGTAGCAGGCTTACCAT 
             *  *****  **     *    *** **         **   *     **    ** *   
 
AYE          GTGGTAAAACGGCCATGGTCTCGCCTTCCGTACTGTTCGCCATAGAAGAATTAACGTCGC 
AYEadeB      TTTCCAAAATGGCAAAGTTATATGCTTGTGAACCTATTTCTACATTGGCAACATCAGATA 
              *   **** *** * * * *   ***  * **   *  * * *   * *  * *      
Sequences were aligned using Clustal Omega. * indicates a position with a single, 
fully conserved residue. The adeB gene is highlighted in yellow and the deleted 
region is highlighted in blue.  
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Figure 4.5.4 Predicted protein structure of AdeB in AYEΔadeB  
Amino acids for which the coding sequence was deleted are highlighted in red.   
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4.6. Determining the phenotype of an A. baumannii AYE mutant 
lacking AdeB and an S1 mutant lacking AdeAB 
4.6.1. Bacterial growth kinetics of AYEΔadeB and S1ΔadeAB 
To ensure that there was no growth defect in either AYEΔadeB or S1ΔadeAB, the 
growth kinetics of the parental and mutant strains were determined. AYEΔadeB 
showed a significant reduction in generation time compared with AYE. However, 
there was no difference in the final optical density at 600 nm reached by the two 
strains (Figure 4.6.1). There was no difference in the generation times of S1ΔadeAB 
and S1. However, the final optical density at 600 nm reached by this mutant was 
significantly lower than that for AYE (Figure 4.6.1). 
4.6.2. Antimicrobial susceptibility of AYEΔadeB and S1ΔadeAB 
To determine whether there was a change in the drug resistance profile of AYE or S1 
with deletion of adeB, the MICs of commonly used antibiotics and dyes and those 
previously shown to be substrates of AdeABC (Yoon, Nait Chabane et al. 2015) were 
determined (Table 4.6.1). With deletion of adeB in AYE there was a decrease in the 
MIC of meropenem, imipenem, kanamycin, gentamicin, ciprofloxacin, tetracycline, 
tigecycline, chloramphenicol, the dye ethidium bromide and the efflux inhibitors 
CCCP (a proton gradient uncoupler) and PAβN (an inhibitor of AcrB and MexB, 
homologues of AdeB) with deletion of adeB in AYE. Other than meropenem, CCCP 
and PAβN, AYEΔadeB had altered susceptibility to the same compounds as 
AYEΔadeRS but the MIC of most antibiotics was lower after deletion of adeB. 
Deletion of adeAB in S1 resulted in a decrease in the MIC of PAβN only, although the  
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Figure 4.6.1 Growth kinetics of AYE, AYEΔadeB, S1 and S1ΔadeAB in LB broth 
at 37°C 
 
Data are shown as the mean of 3 biological replicates and are representative of a 
single independent experiment carried out at least 3 times. 
Generation times and optical density at stationary phase (± standard deviation) 
Strain Mean 
generation 
time (min) 
P value OD600 at 
stationary 
phase 
P value 
AYE 121 ± 3.295 - 1.323 ± 0.030 - 
AYEΔadeB 107 ± 7.087 0.036 1.318 ± 0.004 0.815 
S1 104 ± 6.024 - 1.365 ± 0.022 - 
S1ΔadeAB 112 ± 4.234 0.372 1.290 ± 0.012 0.006 
  
 142 
 
Table 4.6.1 MICs of antibiotics and dyes against AYE, AYEΔadeB, S1 and 
S1ΔadeAB 
 MIC (µg/ml) 
 
 
AYE 
AYE 
ΔadeB 
S1 S1 
ΔadeAB 
Ampicillin expt 1 >1024 >1024 16 16 
 expt 2 >1024 >1024 16 16 
 expt 3 >1024 >1024 16 16 
Ceftazidime expt 1 1024 1024 1024 1024 
 expt 2 1024 1024 1024 1024 
 expt 3 1024 1024 1024 1024 
Imipenem expt 1 1.5 0.75 0.125 0.125 
 expt 2 1.5 0.75 0.125 0.19 
 expt 3 1.5 0.75 0.125 0.125 
Meropenem expt 1 0.25 0.125 0.94 0.94 
 expt 2 0.25 0.125 0.94 0.94 
 expt 3 0.25 0.125 0.94 0.94 
Kanamycin expt 1 1024 256 1 1 
 expt 2 512 128 1 1 
 expt 3 1024 256 1 1 
Gentamicin expt 1 128 4 0.25 0.25 
 expt 2 64 4 0.25 0.25 
 expt 3 128 4 0.25 0.25 
Norfloxacin expt 1 128 128 2 2 
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 expt 2 128 128 2 2 
 expt 3 128 128 2 2 
Ciprofloxacin expt 1 128 32 0.25 0.25 
 expt 2 128 64 0.25 0.25 
 expt 3 128 32 0.25 0.25 
Colistin expt 1 1 1 0.5 0.5 
 expt 2 1 1 0.5 0.5 
 expt 3 1 1 0.5 0.5 
Tetracycline expt 1 256 128 4 4 
 expt 2 256 64 4 4 
 expt 3 256 128 4 4 
Tigecycline expt 1 1 0.25 0.12 0.12 
 expt 2 1 0.25 0.12 0.12 
 expt 3 1 0.25 0.12 0.12 
Chloramphenicol expt 1 512 256 128 128 
 expt 2 512 256 128 128 
 expt 3 512 256 128 128 
Carbonyl cyanide 
3-chlorophenyl 
hydrazone 
expt 1 32 16 16 16 
expt 2 32 16 16 16 
expt 3 32 16 16 16 
Phenylalanine-
arginine beta-
naphthylamide 
expt 1 1024 512 512 128 
expt 2 1024 256 512 128 
expt 3 1024 512 256 128 
Ethidium bromide expt 1 512 128 256 256 
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 expt 2 512 64 256 256 
 expt 3 512 128 256 256 
Data are shown as the results of three individual experiments carried out on different 
days. Blue text indicates a decrease in MIC value compared with the parental strain 
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MIC of most drugs against S1 was much lower than for AYE with only ceftazidime 
and chloramphenicol displaying MICs of > 128 µg/ml (Table 4.6.1). 
4.6.3. Hoechst 33342 (bis-benzimide) accumulation by AYEΔadeB 
and S1ΔadeAB 
As described in Chapter 3, accumulation of H33342 is a good indication of efflux 
activity in A. baumannii (Richmond, Chua et al. 2013). Accumulation of H33342 in 
AYE and S1 was compared with AYEΔadeB and S1ΔadeAB, respectively, to 
investigate whether there was a relative difference in the intracellular levels of this 
substrate. When compared with AYE, the steady state accumulation level of the dye 
H33342 in AYEΔadeB was 34% higher (P < 0.0001), indicating reduced levels of 
efflux in this deletion mutant (Figure 4.6.2). When compared with AYEΔadeRS 
(Chapter 3), AYEΔadeB showed similar levels of H33342 accumulation, suggesting 
that the reduction in efflux activity displayed by the AdeRS deletion mutant is a result 
of down-regulation of the adeABC efflux pump genes. There was no difference in 
accumulation of H33342 in S1ΔadeAB when compared with its parental strain S1, 
consistent with the minimal changes in MICs (Figure 3.5.2). 
4.6.4. Ethidium bromide efflux by AYEΔadeB and S1ΔadeAB 
To investigate whether there was a relative difference in ethidium bromide efflux 
levels, efflux of this dye by AYE and S1 was compared with that by AYEΔadeB and 
S1ΔadeAB, respectively. The final intracellular level of ethidium bromide was 56% 
higher in the AYEΔadeB mutant (P > 0.0001) and 36% higher in the S1ΔadeAB 
mutant (P > 0.05) when each was compared with their respective parental strain 
(Figure 4.6.3B). This indicated reduced efflux of this dye in both mutants.   
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Figure 4.6.2 Accumulation of H33342 by AYE, AYEΔadeB, S1 and S1ΔadeAB 
A. Accumulation of H33342 in AYE, AYEΔadeB, S1 and S1ΔadeAB over time 
 
Data are shown as fluorescence values over time and represent the mean of three 
biological replicates. Data are a representative example of a single independent 
experiment carried out at least three times. 
B. Fold change in accumulation of Hoechst H33342 in AYE, AYEΔadeB, S1 and 
S1ΔadeAB 
 
Data are plotted as independent biological replicates to show variation within each 
strain. Data are presented as fold change compared to the parental strain +/- 
standard deviation. Student’s t-tests were performed and those returning P values of 
less than 0.05 are indicated by *. 
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Figure 4.6.3 Efflux of ethidium bromide by AYE, AYEΔadeB, S1 and S1ΔadeAB 
A. Efflux of ethidium bromide by AYE, AYEΔadeB, S1 and S1ΔadeAB over time 
 
Data are shown as fluorescence relative to the starting fluorescence levels for each 
strain and represent the mean of three biological replicates. Data are a 
representative example of a single independent experiment carried out at least three 
times. 
B. Fold change in intracellular levels of ethidium bromide in AYE, AYEΔadeB, 
S1 and S1ΔadeAB 
 
Data are plotted as independent biological replicates to show variation within each 
strain. Data are presented as fold change compared to the parental strain +/- 
standard deviation. Student’s t-tests were performed and those returning P values of 
less than 0.05 are indicated by * 
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Furthermore, the rate of efflux was greatly reduced in S1ΔadeAB when compared 
with S1 (as seen by the initial change in relative fluorescence of the two strains; 
Figure 4.6.3A). These results are in contrast with the Hoechst accumulation assay, 
which did not detect any change in efflux levels in S1ΔadeAB when compared with 
S1, suggesting that the ethidium bromide efflux assay may be a more sensitive assay 
and is able to detect subtle changes in efflux that cannot be seen when measuring 
accumulation of H33342 or MICs of antibiotics. Furthermore, the reduction in efflux in 
AYEΔadeB was greater than that seen in AYEΔadeRS, suggesting that efflux levels 
are lower in the AdeB mutant than in the AdeRS mutant in this strain. This result is in 
line with the lower MICs of some antibiotics observed for AYEΔadeB when compared 
with AYEΔadeRS. 
4.6.5. Biofilm formation by AYEΔadeB and S1ΔadeAB in an ex 
vivo model 
To investigate whether AdeB is important for biofilm formation on biotic surfaces, 
growth of AYE, AYEΔadeB, S1 and S1∆adeAB on PVM was measured. Experiments 
with AYEΔadeB were carried out by Michele Anderson (University of Minnesota) 
Counts of adherent and planktonic cells were taken at 24 hr time points up to 144 
hours. As seen previously with AYE and ATCC 19606, there was a rapid increase in 
the number of adherent cells on PVM up to the one day time point, followed by a 
slow but steady increase between one and six days Figure 4.6.4. S1 showed similar 
growth to strain AYE in both adherent cell counts and biofilm imaging. There was no 
significant difference between numbers of adherent cells of parental or mutant strain 
for at any time point (Figure 4.6.4). However, LIVE/DEAD© staining and confocal 
laser scanning microscopy showed a similar difference between the infection  
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Figure 4.6.4 Adherent and planktonic bacterial cells counts of AYE, AYEΔadeB, 
S1 and S1ΔadeAB grown at 37°C on PVM  
 
Data are shown as mean CFU/ml of 3 biological replicates and are representative of 
a single independent experiment carried out at least 3 times. 
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phenotype of AYE and AYEΔadeB and S1 and S1∆adeAB, respectively (Figure 
4.6.5). As with previous experiments, at three days post-infection AYE infected tissue 
displayed epithelial cell death (red) and by six days post-infection large biofilm 
masses and epithelial cell sloughing was visible, as described in Chapter 3. S1 was 
able to form a robust biofilm more rapidly than AYE and a thick biofilm mat could be 
seen by day five, at which point the experiment was stopped (Figure 4.6.5 panels M-
Q). However, when compared with their respective parental strains, both adeB 
mutants showed a defect in biofilm formation when imaged by confocal microscopy. 
At days five and six, S1 and AYE, respectively, formed large biofilm masses with 
extensive epithelial cell sloughing (Figure 4.6.5 panels F&Q) whereas, although the 
mutants were able to cause epithelial cell death, only individual bacterial cells were 
observed to be attached to the mucosal tissue and less sloughing was evident 
(Figure 4.6.5 panels L&V). These data suggest that the AdeABC efflux pump plays a 
key role in biofilm formation on mucosal tissue and host cell cytotoxicity and that 
decreased production of this MDR efflux pump may be responsible for the similar 
phenotype seen in AYEΔadeRS. 
4.6.6. Biofilm formation by AYEΔadeB and S1ΔadeAB in vitro 
To determine whether lack of AdeB in AYE and S1 also conferred a change in biofilm 
formation on an abiotic surface, each parental strain and deletion mutant were grown 
in three different in vitro models to measure biofilm; a microfluidic cell, polypropylene 
pegs and polystyrene test tubes. 
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Figure 4.6.5 Confocal laser scanning microscopy of AYE, AYEΔadeB, S1 and S1ΔadeAB biofilms using LIVE/DEAD© 
staining and visualised at 1-6 days 
 
Uninfected epithelia are live (green) and intact. Red, rounded epithelial cells indicate cell death. Small, punctate, green staining 
indicates bacterial cells and large, green staining masses indicate bacterial biofilm. Black areas depict exposed extracellular matrix. 
Arrows indicate examples of live and dead epithelial cells, bacterial cells, epithelial cell sloughing and biofilm masses. 
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4.6.6.1. Biofilm formation by AYEΔadeB and S1ΔadeAB in a 
microfluidic cell 
Biofilm formation by AYE, AYE∆adeB, S1 and S1∆adeAB was studied under flow 
conditions in order to replicate formation on a medical device implanted in the body. 
At 0 hrs, attachment of individual bacterial cells to the walls of the flow cell could be 
seen by phase microscopy (Figure 4.6.6). There was no difference between initial 
attachment of AYE and AYEΔadeB or S1 and S1ΔadeAB. All strains formed a robust 
biofilm after 16 hrs and rapid growth could be seen in this time period. Thick biofilm 
coverage of the surface of the microfluidic cell was observed at 16, 24 and 48 hrs 
(Figure 4.6.6). When compared visually, there was no difference in the biofilm formed 
by either strain at any time point (Figure 4.6.6). 
4.6.6.2. Biofilm formation by AYEΔadeB and S1ΔadeAB on 
polypropylene pegs 
To quantify the amount of biofilm formed by AYE, AYE∆adeB, S1 and S1∆adeAB 
after 8 hrs incubation, biofilms were grown on polypropylene pegs and quantified by 
crystal violet staining. In this in vitro model, there was a 30% decrease in biofilm 
mass (P < 0.001) at 30°C and a 19% decrease in biofilm mass (P < 0.01) at 37°C 
produced by AYEΔadeB when compared with AYE (Figure 4.6.7). However, there 
was no change in biofilm formation by S1ΔadeAB at either temperature (Figure 4.6.7) 
suggesting that the role of AdeABC in biofilm formation is dependent on both the 
strain of A. baumannii and the biofilm model used. 
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Figure 4.6.6 Phase contrast microscopy images of AYE, AYE∆adeB, S1 and S1∆adeAB biofilms formed under flow 
conditions of 0.3 dynes up to 48 hrs 
 
Images show attachment of bacterial cells to the inner surface of a microfluidic channel. Grey dots show adherence of individual 
cells to the surfaces whereas solid grey areas indicate bacterial growth and biofilm production. Black bar depicts a 10 µm scale. 
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Figure 4.6.7 Biofilm formation by AYE, AYE∆adeB, S1 and S1∆adeAB on 
polypropylene pegs as determined by crystal violet staining 
A.30˚C 
 
Data are plotted as independent biological replicates to show variation within each 
strain. Data are presented as fold change compared to the parental strain +/- 
standard deviation. Student’s t-tests were performed and those returning P values of 
less than 0.05 are indicated by *. 
B. 37˚C 
 
Data are plotted as independent biological replicates to show variation within each 
strain. Data are presented as fold change compared to the parental strain +/- 
standard deviation. Student’s t-tests were performed and those returning P values of 
less than 0.05 are indicated by *. 
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4.6.6.3. Pellicle formation by AYEΔadeB and S1ΔadeAB 
To assess the ability of AYE, AYE∆adeB, S1 and S1∆adeAB to form a pellicle at the 
air/liquid interface, cultures were incubated statically in polystyrene test tubes for 48 
hours at 30°C and 37°C. A thick biofilm mat could be seen at the surface with all 
strains but there was no difference between strains in the amount of pellicle formed 
when examined visually (Figure 4.6.8). 
4.6.6.4. Biofilm formation by AYEΔadeB and S1ΔadeAB on glass 
cover slips 
In order to visualise biofilms formed by adeB deletion mutants in AYE and S1 and to 
determine whether mutants were unable to adhere to abiotic surfaces or were 
adherent but unable to form a biofilm, as seen in AYEΔadeRS and in the mucosal 
model, bacterial cultures were incubated on glass slides for 24 hrs before being fixed 
for scanning electron microscopy (SEM). As described in Chapter 3, AYE formed a 
three dimensional biofilm with ECM visibly produced. AYEΔadeB showed an altered 
biofilm phenotype compared with AYE, with no clumping of cells and no ECM. 
Individual cells also appeared slightly more rounded and the surface of the cells was 
uneven (Figure 4.6.9). Furthermore, the coverage of the surface of the cover slip was 
far sparser after incubation with AYEΔadeB, as was observed with AYEΔadeRS. 
This is in agreement with results seen in the mucosal model and the in vitro 
polypropylene peg model. In contrast with AYE, strain S1, did not form a mature 
biofilm at the 24 hour time point. There was good biofilm coverage of the cover slip 
after incubation with S1, however, very little three dimensional clumping of cells could 
be seen and there was minimal evidence of ECM (Figure 4.6.9). Like AYEΔadeB,  
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Figure 4.6.8 Pellicle formation by AYE, AYE∆adeB, S1 and S1∆adeAB incubated 
statically at 37˚C 
A. Visualised under white light 
 
B. Visualised under natural light  
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Figure 4.6.9 Scanning electron microscopy of AYE, AYEΔadeB, S1 and 
S1ΔadeAB biofilms on glass cover slips 
 
Images show attachment of bacterial cells, production of ECM and formation of 
a biofilm on the surface of a glass cover slip. 
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S1ΔadeAB was not able to form a biofilm and showed sparse coverage of the cover 
slip, although there was still some attachment to the surface (Figure 4.6.9). As 
discussed in Chapter 3, although this difference was not observed in the other in vitro 
models, it is possible that they are not sensitive enough to detect the change seen in 
this mutant by SEM. 
4.6.7. Motility of AYEΔadeB and S1ΔadeAB 
As described in Chapter 3, strain AYE displayed some twitching motility but did not 
show swarming motility, as with the majority of A. baumannii strains. S1 showed a 
similar phenotype with slightly more twitching motility evident and no swarming 
motility. AYE∆adeB did not show any defect in twitching or swarming motility when 
compared with parental strain AYE (Figure 4.6.10). S1∆adeAB showed no difference 
in swarming motility but there was a small decrease in twitching motility when 
compared with S1 (Figure 4.6.10). This was not visible with an adeB mutant in AYE, 
but this may be due to the lower levels of motility displayed by this strain. 
4.6.8. Virulence of AYEΔadeB and S1ΔadeAB in the Galleria 
mellonella model of infection 
S1ΔadeAB displayed attenuated virulence in the G. mellonella model, when 
compared with S1. After infection with S1, all larvae were dead by day two, whereas 
60% were still alive at day five after infection with the mutant (Figure 4.6.11). AYE 
was less virulent in G. mellonella compared with S1 and there was no significant 
difference in the killing of larvae by AYE and AYEΔadeB (Figure 4.6.11). This 
suggests a strain-specific role for AdeABC in virulence in A. baumannii. It is possible   
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Figure 4.6.10 Twitching and swarming motility of AYE, AYE∆adeB, S1 and 
S1∆adeAB grown on 1% and 0.3% agar for 24 hrs at 37°C 
A. Twitching motility 
 
B. Swarming motility  
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Figure 4.6.11 Kaplan Meir survival curves to show virulence of AYE, 
AYE∆adeB, S1 and S1∆adeAB in G. mellonella 
 
Data show percentage survival (n=30) of G. mellonella after inoculation with 106 CFU 
bacteria. Error bars represent SEM. 
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that the AdeABC efflux pump is not expressed by AYE in vivo, possibly explaining 
the reduced virulence displayed by this strain and the absence of altered virulence 
levels in the AYEΔadeB mutant. 
4.7. Determining the transcriptome of AYEΔadeB and 
S1ΔadeAB 
To identify changes in gene expression that may account for the change in 
phenotype with deletion of adeB in AYE and S1 and to give insight into the difference 
in phenotype between the two deletion mutants, RNA-Seq was carried out. 
Transcriptomic changes in AYEΔadeB were also compared to those in AYEΔadeRS 
to help to understand to what extent the down-regulation of adeABC is responsible 
for the phenotype of AYEΔadeRS. AYE and AYEΔadeB RNA was prepared and four 
biological replicates were sequenced in Birmingham in March 2015, whilst S1 and 
S1ΔadeAB RNA was prepared in Birmingham in September 2015 and sent to BGI 
genomics, Hong Kong for library preparation and sequencing of three biological 
replicates. Data were checked for quality and analysed by Dr Alasdair Ivens 
(University of Edinburgh) and submitted to ArrayExpress (accession E-MTAB-4049, 
E-MTAB-4071). Deletion of a 1131 bp fragment in the centre of adeB in AYEΔadeB 
and a 2261 bp fragment spanning the last 222 bp of adeA, the first 1914 bp of adeB 
and a 125 bp intergenic region in S1ΔadeAB was confirmed by the absence of reads 
mapping to these regions of the genes in each sample (Figure 4.7.1). As seen in 
Chapter 3, parental strain AYE showed fairly low read depth (< 50) across adeRS 
with higher read depth (> 100) across adeABC (Figure 4.7.1). This suggested a low 
level of expression of adeRS in AYE and high expression of the adeABC operon.  
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Figure 4.7.1 Number of reads aligned to each base across the adeRS adeABC 
region in each sample 
A. AYE 
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B. AYEΔadeB 
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C. S1 
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D. S1ΔadeAB 
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AYEΔadeB samples showed an absence of reads mapping to the deleted fragment 
in the middle of the adeB gene. In excess of 4000 reads were mapped to the 
undeleted region of the adeABC operon resulting in a 28, 14 and 24-fold increase in 
expression of adeA, adeB and adeC, respectively, in AYEΔadeB compared with AYE 
(Figure 4.7.2). Less than 100 reads mapped to the adeRS and adeABC operons in 
S1. Aside from the large deleted fragment spanning adeA and adeB, S1ΔadeAB 
showed similar read depth to the parental strain, S1, across both adeRS and 
adeABC. There was a 2.3-fold decrease in expression of adeB in S1ΔadeAB 
compared with S1. As only 222 bp of the 3’ end of adeA was deleted, reads were still 
mapped to the first 978 bp of this gene; there was also no significant change in gene 
expression. 
All gene expression changes in AYEΔadeB compared with AYE and S1ΔadeAB 
compared with S1 were plotted by locus tag to identify highly differentially expressed 
genes or operons (Figure 4.7.2, Figure 4.7.3). There was decreased expression of 
multiple com and pil operons in both adeB deletion mutants. AYEΔadeB also had 
highly increased expression of genes encoding several putative products such as 
signal peptides (ABAYE0235, ABAYE1501), sulfate permeases (ABAYE0262), porin 
proteins (ABAYE0924) and exported proteins (ABAYE2861, ABAYE3861) and ecnB, 
a bacteriolytic lipoprotein. Decreased expression of comBCEF, comMNOLQ, pilGIJ, 
pilTU and pilBCD operons was also observed in this strain along with decreased 
expression of genes encoding putative fimbrial proteins (ABAYE0304), exported 
proteins (ABAYE2434, ASBAYE2435, ABAYE2444, ABAYE2463, ABAYE2464), 
transcriptional regulators (ABAYE2443, ABAYE0671), β-lactamases (ABAYE2456), 
efflux pumps (ABAYE2419) and lipid A biosynthesis proteins (ABAYE2468). 
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Figure 4.7.2 Log2 fold change in expression of all genes of the AYE genome in AYEΔadeB compared with AYE 
  
Genes with increased and decreased expression are coloured red and blue, respectively. Gene names or annotations are 
provided for genes within differentially expressed operons or highly differentially expressed genes with known function. 
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Figure 4.7.3 Log2 fold change in expression of all genes of the AYE genome in S1ΔadeAB compared with S1 
  
Genes with increased and decreased expression are coloured red and blue, respectively. Gene names or annotations are 
provided for genes within differentially expressed operons or highly differentially expressed genes with known function. 
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S1ΔadeAB had highly increased expression of genes encoding putative products 
such as transcriptional regulators (ABAYE0181, ABAYE2199, ABAYE 3085), 
membrane proteins (ABAYE1139) and MFS transporters (ABAYE3553), and the pnt 
operon which encodes pyridine nucleotide transhydrogenase. Decreased expression 
of comMNOLQ, pilGHIJ, pilTU, pilBCD and pqqABCDE operons was also observed 
in S1ΔadeAB. Furthermore, in this train there was decreased expression of genes 
encoding putative transcriptional regulators (ABAYE1900, ABAYE1908, 
ABAYE1912), MFS permeases (ABAYE1907), transposases (ABAYE3706, 
ABAYE3707) and phospholipase D fragments (ABAYE3304, ABAYE3305, 
ABAYE3893, ABAYE3894, ABAYE1870, ABAYE1871). Genes with large changes in 
expression encoding hypothetical or putative products were often found directly 
upstream or downstream of the com or pil genes with changed expression. This 
suggests that they may be encoded as an operon. 
A raw P value cut-off of 0.05 was used to produce a list of significantly changed 
genes (Table 4.7.1, Table 4.7.2, Table 4.7.3, Table 4.7.4). The raw P value was 
chosen as opposed to the more stringent adjusted P value as this gave a more 
comprehensive list of changed genes that may affect the phenotype and ensured that 
no genuinely changed genes would be excluded from the list. Compared with AYE, 
there were 693 genes with increased expression in AYEΔadeB and 477 genes with 
decreased expression. Compared with S1, there were 164 genes with increased 
expression and 119 genes with decreased expression in S1ΔadeAB. Differentially 
expressed genes were categorised into cluster of orthologous groups (COGs) 
(Tatusov, Galperin et al. 2000) and correlations with the phenotypic changes seen in 
each efflux pump mutant sought (Figure 4.7.4, Figure 4.7.5). Genes encoding 
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Table 4.7.1 The top 10 genes with the most significantly changed expression in AYEΔadeB compared with AYE 
Gene ID Start End Description Common 
Name 
Strand Type log2 fold 
change 
Fold 
change 
P.Value 
ABAYE2456 2507740 2509014 putative beta-
lactamase 
 + gene -5.50 0.022 1.50E-12 
ABAYE2463 2512856 2514487 putative exported 
protein 
 + gene -7.10 0.007 2.00E-12 
ABAYE2436 2483124 2484032 hypothetical 
protein 
 - gene -6.10 0.015 3.00E-12 
ABAYE2418 2465596 2465997 hypothetical 
protein 
 + gene -5.60 0.021 3.10E-12 
ABAYE2460 2510646 2511596 putative 
hydroxyacyl-CoA 
dehydrogenase 
 - gene -5.00 0.031 3.40E-12 
ABAYE2415 2463296 2463799 hypothetical 
protein 
 - gene -6.40 0.012 3.80E-12 
ABAYE2444 2493411 2493728 putative exported 
protein 
 - gene -5.00 0.031 5.80E-12 
ABAYE2416 2463816 2464349 hypothetical 
protein 
 - gene -6.00 0.016 9.00E-12 
ABAYE2465 2515510 2516814 putative Permease 
(major facilitator 
superfamily) 
 - gene -5.00 0.031 1.80E-11 
ABAYE2419 2466093 2467037 putative transport 
protein (ABC 
superfamily) 
 + gene -4.30 0.051 2.00E-11 
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Table 4.7.2 The top 10 genes with the largest fold change in expression in AYEΔadeB compared with AYE 
Gene ID Start End Description Common 
Name 
Strand Type log2 fold 
change 
Fold 
change 
P.Value 
ABAYE1821 1885325 1886524 membrane fusion 
protein 
adeA + gene 4.80 27.858 1.80E-10 
ABAYE0262 275986 278187 putative sulfate 
permease 
 + gene 4.70 25.992 8.00E-08 
ABAYE1823 1889696 1891105 outer membrane 
protein 
adeC + gene 4.60 24.251 6.80E-10 
ABAYE1822 1886521 1889631 RND protein adeB + gene 3.80 13.929 3.70E-09 
ABAYE1824 1891198 1892112 conserved 
hypothetical 
protein 
 - gene 3.80 13.929 2.00E-09 
ABAYE2454 2503999 2507145 hypothetical 
protein 
 - gene -8.40 0.003 7.70E-11 
ABAYE2413 2461269 2461772 conserved 
hypothetical 
protein 
 - gene -8.20 0.003 1.30E-10 
ABAYE2453 2501269 2503986 fragment of 
putative Rhs family 
protein 
 - pseudo 
gene 
-7.90 0.004 1.10E-09 
ABAYE2414 2461822 2463318 conserved 
hypothetical 
protein 
 - gene -7.50 0.006 2.40E-08 
ABAYE2463 2512856 2514487 putative exported 
protein 
 + gene -7.10 0.007 2.00E-12 
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Table 4.7.3 The top 10 genes with the most significantly changed expression in S1ΔadeAB compared with S1 
Gene ID Start End Description Common 
Name 
Strand Type log2 fold 
change 
Fold 
change 
P.Value 
ABAYE1878 1936951 1938105 coenzyme PQQ 
synthesis protein E 
pqqE - gene -9.10 0.002 3.40E-09 
ABAYE1877 1935882 1936958 Zn-dependent 
dipeptidase 
acdP - gene -8.30 0.003 5.30E-09 
ABAYE1880 1938383 1939141 coenzyme PQQ 
synthesis protein C 
pqqC - gene -9.60 0.001 1.30E-08 
ABAYE1910 1963576 1964997 putative D-beta-
hydroxybutyrate 
permease 
 - gene -7.80 0.004 2.80E-08 
ABAYE1881 1939150 1940061 coenzyme PQQ 
synthesis protein B 
pqqB - gene -9.80 0.001 3.60E-08 
ABAYE3706 3350123 3351448 putative 
phospholipase D 
protein fragment 
 + pseudo 
gene 
-7.80 0.004 3.80E-08 
ABAYE1866 1929033 1929386 hypothetical 
protein 
 - gene -8.70 0.002 6.70E-08 
ABAYE1879 1938102 1938386 coenzyme PQQ 
synthesis protein D 
pqqD - gene -7.50 0.006 1.20E-07 
ABAYE1893 1948063 1948755 molybdate 
transport protein 
(ABC superfamily) 
modB - gene -7.50 0.006 1.50E-07 
ABAYE1885 1940590 1942509 fragment of 
polyphosphate 
kinase 
polyphosphoric 
acid kinase 
ppk - pseudo 
gene 
-10.00 0.001 3.20E-07 
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Table 4.7.4 The top 10 genes with the largest fold change in expression in S1ΔadeAB compared with S1 
Gene ID Start End Description Common 
Name 
Strand Type log2 fold 
change 
Fold 
change 
P.Value 
ABAYE1338 1398953 1399354 putative 
transthyretin 
domain 
 - gene 2.80 6.964 4.00E-05 
ABAYE1833 1900750 1900971 hypothetical 
protein 
 - gene 2.80 6.964 1.90E-04 
ABAYE2140 2189632 2189811 putative exported 
protein 
 + gene 2.80 6.964 1.10E-03 
ABAYE3658 3685510 3685983 Protein arsC 
(Arsenate 
reductase) 
arsC + gene 2.80 6.964 1.20E-04 
ABAYE2199 2247394 2247723 putative 
transcriptional 
regulator (ArsR 
family) 
 - gene 2.70 6.498 2.40E-04 
ABAYE1885 1940590 1942509 fragment of 
polyphosphate 
kinase 
ppk - pseudo 
gene 
-10.00 0.001 3.20E-07 
ABAYE1881 1939150 1940061 coenzyme PQQ 
synthesis protein B 
pqqB - gene -9.80 0.001 3.60E-08 
ABAYE1880 1938383 1939141 coenzyme PQQ 
synthesis protein C 
pqqC - gene -9.60 0.001 1.30E-08 
ABAYE1878 1936951 1938105 coenzyme PQQ 
synthesis protein E 
pqqE - gene -9.10 0.002 3.40E-09 
ABAYE1866 1929033 1929386 hypothetical 
protein 
 - gene -8.70 0.002 6.70E-08 
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Figure 4.7.4 Clusters of orthologous groups (COG) and the percentage of genes with increased expression (red) and 
decreased expression (blue) in AYEΔadeB compared with AYE within each group as determined by RNA-Seq 
The total number of genes per COG is shown in parentheses. Groups related to antibiotic resistance, biofilm formation and 
virulence are marked by a green box. 
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Figure 4.7.5 Clusters of orthologous groups (COG) and the percentage of genes with increased expression (red) and 
decreased expression (blue) in S1ΔadeAB compared with S1 within each group as determined by RNA-Seq 
The total number of genes per COG is shown in parentheses. Groups related to antibiotic resistance, biofilm formation and 
virulence are marked by a green box. 
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products known to confer antibiotic resistance were identified in each mutant. In 
AYEΔadeB there was increased expression of a tetracycline efflux pump gene, tetA 
(1.4-fold); membrane fusion protein gene AdeT (1.4-fold), which is associated with 
MDR by active efflux in A. baumannii (Srinivasan, Rajamohan et al. 2011), a gene 
annotated as a putative porin associated with imipenem resistance (ABAYE0924) 
(4.3-fold) and two genes annotated as putative MDR efflux systems (ABAYE1777, 
ABAYE3036) (1.4-fold, 3-fold). There was decreased expression of genes encoding 
a putative tetracycline resistance protein (ABAYE2235) (1.7-fold) and the lipid 
phosphoethanolamine transferase EptA (2.5-fold), which has been associated with 
colistin resistance, (Adams, Nickel et al. 2009, Arroyo, Herrera et al. 2011, Beceiro, 
Llobet et al. 2011). There was altered expression of six genes putatively encoding β-
lactamases (ABAYE0825, 1940, 2122, 2456, 3619, 3623; 2.2-50-fold) in AYEΔadeB. 
The only gene that was possibly related to drug-resistance and for which differential 
expression was detected, albeit a small increase, in S1ΔadeAB was a putative MDR 
efflux system (ABAYE3036) (1.1-fold). Interestingly, increased expression of this 
gene was seen in all three deletion mutants. In the adeB deletion mutants and similar 
to strain AYEΔadeRS, genes encoding products with known and potential virulence 
functions such as pili (Bahar, Goffer et al. 2009) and acinetobactin transport systems 
(Gaddy, Arivett et al. 2012), also had significant changes in expression levels. The 
ferric acinetobactin transport system operon bauDCEBA, which encodes proteins 
required for persistence and virulence (Mihara, Tanabe et al. 2004, Gaddy, Arivett et 
al. 2012), had decreased expression in AYEΔadeB (1.9 – 3.7-fold). In contrast to the 
significant increase in expression of these genes in AYEΔadeRS and the most 
striking change observed in both efflux pump mutants was in expression of cell 
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motility genes. The competence (com) genes which, as previously discussed, are 
associated with DNA uptake, motility and virulence, were all expressed significantly 
less in AYEΔadeB and S1ΔadeAB (1.7–10-fold). Likewise, there was a significant 
decrease in expression of the type IV pili genes, which are involved in natural 
transformation, twitching motility and biofilm formation. One other putative biofilm-
associated gene (ABAYE0792) showed increased expression (3-fold) in AYEΔadeB. 
No other genes with an annotated biofilm function had altered expression in 
S1ΔadeAB. However, multiple putative transcriptional regulators (araC, lysR and tetR 
family) that lacked a comprehensive annotation had differential expression in both 
mutants. 
4.8. Discussion 
This study was carried out using two different efflux pump mutants. AYEΔadeB was 
created specifically for this study using an optimised method for creating targeted 
gene deletions in A. baumannii (Amin, Richmond et al. 2013). Primers were designed 
to delete a 1131 bp region in the middle of the adeB gene, rendering it inactive. 
Mapping of RNA-Seq reads showed that in this mutant there were no reads mapped 
to the deleted sequences. It was assumed that lack of expression of this region 
would result in lack of AdeB protein. However, it was not possible to confirm this by 
Western blotting as no antibodies were available and time did not permit raising 
them. Interestingly, RNA-Seq showed increased expression of adeA and adeC in the 
mutant. It is hypothesised that lack of AdeB triggers the cell to increase adeABC 
expression in order to produce more of the AdeABC efflux pump proteins and it is 
this that causes the apparent increase in the number of adeA, adeB and adeC reads 
mapped to the genome. It is also possible that the increased expression of these 
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genes may result in increased protein production and this could have caused some 
or all of the phenotypes observed in this mutant. Previous studies in E. coli and S. 
Typhimurium have shown that some MFPs homologous to AdeA, such as AcrA, can 
form a complex with multiple different RND components, such as AcrB and AcrF, and 
this may affect antibiotic resistance (Elkins and Nikaido 2003, Smith and Blair 2014). 
Altered expression of OMPs such as OmpA38, OmpA32, CarO and OmpW and has 
also been implicated in A. baumannii resistance to tetracycline, chloramphenicol, 
aztreonam and nalidixic acid (Yun, Choi et al. 2008, Smani, Fabrega et al. 2014). 
S1ΔadeAB was created in the laboratory of Professor Kim Lee Chua (National 
University of Singapore) (Amin, Richmond et al. 2013). The deletion spanned 222 bp 
of adeA and 1914 bp of adeB. RNA sequencing showed that the first 978 bp of adeA 
was still transcribed. Therefore is it possible that a truncated protein of 326 amino 
acid may be produced. However, as almost one fifth of the protein is missing it is 
unlikely that this protein would retain function and therefore, the phenotype presented 
has been interpreted as the result of lack of both proteins. This presents some 
difficulties with comparing this mutant with the AYE adeB deletion mutant; as the 
latter still produces a functional AdeA. However, due to the technical difficulties in 
genetically manipulating A. baumannii, this study was continued with the mutant 
obtained. 
Individual RNA-Seq experiments described here and in Chapter 3 were carried out 
on separate occasions. A summary of the protocols used for each experiment can be 
seen in Table 4.8.1. Although the experiments were carried out according to best 
practice, as discussed in Chapter 3, it is now known that there can be variability in   
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Table 4.8.1 Protocols used for RNA-Seq experiments 
Dataset Date Service 
provider 
Machine Sequencing 
type 
No. of 
biological 
replicates 
AYE vs 
AYEΔadeRS 
Aug-12 ARK genomics Hi-seq Single-end 3 
AYE vs 
AYEΔadeB 
Mar-15 University of 
Birmingham 
Mi-seq Paired-end 4 
S1 vs 
S1ΔadeAB 
Sep-15 BGI Hong Kong Hi-seq Paired-end 3 
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data generated from samples prepared on different days and sequenced on different 
runs and it is important to standardise as much of the RNA-Seq procedure as 
possible. In order to minimise variability as much as possible when comparing 
between data sets, all RNA-seq data from across the three individual experiments 
were analysed as a single set by Dr Alasdair Ivens (University of Edinburgh), a 
renowned expert in bioinformatics. This allowed gene expression changes in one 
mutant to be compared with another. However, future work would ensure that all 
RNA-seq experiments are carried out at the same time, using the same protocol and 
technology. 
The hypothesis investigated was that the AdeABC efflux pump is required for drug 
resistance, biofilm formation and virulence. Deletion of adeB in AYE resulted in 
decreased MICs of similar antibiotics previously shown by the Courvalin group to be 
substrates of the AdeABC efflux pump in A. baumannii BM4587 (Magnet, Courvalin 
et al. 2001, Yoon, Courvalin et al. 2013, Yoon, Nait Chabane et al. 2015). The 
observed decrease in efflux activity in AYEΔadeB suggests that increased drug 
susceptibility is a result of reduced levels of efflux in this strain. Changes in MICs 
were more pronounced with deletion of adeB than adeRS. This suggests that 
although deletion of adeRS results in up to 128-fold decrease in expression of 
adeABC, the efflux pump is still transcribed albeit at low level in the adeRS mutant. It 
may be that this is also responsible for the difference in the amount of biofilm formed 
by these strains on plastic. Whilst deletion of adeB in strain AYE resulted in a 
significant decrease in biofilm formation at both 30°C and 37°C, deletion of adeRS 
had no significant effect. It is hypothesised that low levels of expression of adeABC in 
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strain AYEΔadeRS are sufficient to maintain biofilm function, whereas inactivation of 
the pump in AYEΔadeB significantly reduces the ability to form a biofilm. 
Deletion of adeAB in a different background, clinical isolate S1, resulted in no change 
in drug susceptibility however increased susceptibility to the efflux inhibitor, PAβN 
was detected. It is hypothesised that the limited impact upon susceptibility to 
antimicrobials after inactivation of AdeAB in S1 is a result of little change in 
expression of adeABC between S1 and its mutant. S1 does not possess the 
Ala94Val mutation in AdeS that is associated with overexpression of adeABC 
(Hornsey, Loman et al. 2011) and so does not express high levels of adeABC. This 
may explain the modest impact of deletion of adeAB in S1 upon susceptibility to 
antibiotics and is why S1 is more susceptible to antibiotics than strain AYE. The 
observed decrease in efflux in S1ΔadeAB was also less than that seen in 
AYEΔadeB, supporting this hypothesis. Deletion of adeAB in S1 also had no 
significant effect on biofilm formation on plastic, which also may be due to the small 
impact of deleting a gene expressed at low level. 
Both the adeB mutant in AYE and the adeAB mutant in S1 displayed reduced biofilm 
formation on mucosal tissue when visualised by confocal laser scanning microscopy. 
Furthermore, as seen with the adeRS mutant in AYE, there was no change in the 
number of adherent cells on the mucosal tissue. S1 was able to form a biofilm more 
rapidly than AYE, suggesting that there may be other factors present in this strain 
that contribute to biofilm formation on mucosal tissue. The biofilm phenotype of the 
efflux pump deletion mutants was similar to that observed in the AdeRS deletion 
mutant (Chapter 3), suggesting that the biofilm defect in these strains is due to down 
regulation or deletion of the adeB gene. Deletion of adeB in AYE and adeAB in S1 
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also resulted in decreased expression of pil genes. These encode type IV pili, which 
have previously been associated with the ability of A. baumannii to form a biofilm on 
plastic (Tucker, Nowicki et al. 2014) and this may play a role in the biofilm defect 
observed in these mutants. 
Despite a change in expression of known (and putative) genes that confer virulence 
in A. baumannii, such as the acinetobactin iron acquisition system, and pilin genes, 
deletion of adeB in strain AYE had no effect on virulence in G. mellonella. A similar 
observation was made for the AYEΔadeRS mutant (Chapter 3). It is possible that 
AYE does not express the adeABC efflux genes in vivo. In contrast, deletion of 
adeAB in S1 greatly reduced virulence in the G. mellonella model. The membrane 
fusion protein (MFP) gene, adeA, is also partially deleted in strain S1, which may 
account for this observation. As discussed above, previous studies have shown that 
some MFPs can interact with multiple different RND components (Elkins and Nikaido 
2003, Smith and Blair 2014). The presence of AdeA in strain AYE may allow it to 
interact with other proteins and so compensate for the lack of AdeB and ameliorate 
any impact upon virulence in this model. However, no other A. baumannii efflux 
pumps have so far been shown to play a role in virulence. This could indicate a 
strain-specific role for the AdeABC efflux pump in virulence. As a correlation between 
virulence in G. mellonella and in humans has previously been observed with A. 
baumannii (Peleg, Jara et al. 2009) this could indicate that for some A. baumannii 
strains, such as S1, AdeABC is required for infection in humans. 
 183 
 
4.9. Further work 
To confirm that AdeB is not produced in either mutant and to determine whether 
AdeA is produced in S1ΔadeAB (despite a 222 bp fragment of the gene being 
deleted), Western blotting should be carried out. In order to do this, antibodies 
against AdeA and AdeB need to be generated as there are currently none available. 
This method would show the presence or absence of the AdeA and AdeB proteins 
and confirm whether deletion of a fragment of the gene abolishes production of the 
efflux pump proteins. It is possible that the different sized fragments deleted in 
AYEΔadeB and S1ΔadeAB affected the phenotype of these mutants. In order to 
standardise the experiment, the same deletion should be created in each strain to 
confirm that AdeB has a strain-specific role in antibiotic resistance, biofilm formation 
and virulence. To elucidate the role of each component of the efflux pump in each 
strain, adeA and adeB should be deleted alone and in combination in both AYE and 
S1. Nonetheless, it should be noted that the adeABC efflux pump genes are 
transcribed as an operon and therefore deletion of adeA is likely to have a 
downstream effect on expression of adeB. Furthermore, adeB should be deleted in 
other A. baumannii strains representative of those causing infection in different 
countries. 
As mentioned previously, this study used RNA-Seq data from multiple experiments 
carried out at different times using different protocols. In order to minimise variation, 
all RNA-Seq experiments should be repeated together, ensuring that the same 
service provider, machine and sequencing method is used. As discussed in Chapter 
3, steps should be taken to minimise variation in sample preparation and sequencing 
and more biological replicates should be used to give more robust data. 
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4.10. Key findings 
 Deletion of AdeB in A. baumannii strain AYE resulted in decreased MICs of 
antibiotics and dyes and was associated with a reduction in efflux activity. 
 An AdeB deletion mutant of A. baumannii strain AYE and an AdeAB deletion 
mutant of S1 displayed decreased biofilm formation and epithelial cell killing in 
a mucosal model. 
 Deletion of AdeB had a strain-specific effect on biofilm formation on plastic 
and virulence in G. mellonella. 
 Deletion of AdeB in A. baumannii strain AYE and AdeAB in S1 produced 
changed expression of genes related to drug resistance, biofilm formation and 
virulence.
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5. The Role of AdeRS and AdeAB in Antibiotic Resistance, Biofilm 
Formation and Motility in Military Isolate AB5075 
5.1. Background 
As described in Chapters 3 and 4, deletion of AdeRS or AdeB in MDR strain AYE 
resulted in decreased susceptibility to antibiotics by reduced efflux activity and 
decreased biofilm formation on biotic and abiotic surfaces. Deletion of AdeAB in 
another strain, clinical isolate S1, resulted in a different phenotype to that observed in 
AYE; decreased biofilm formation on a biotic surface only and decreased virulence in 
Galleria mellonella. To determine whether the strain-specific effect of deletion or 
down-regulation of the AdeABC efflux pump in AYE and S1 was also seen in a strain 
representative of contemporary isolates from infections in military casualties, the 
phenotype of military isolate AB5075 was characterised and compared to isogenic 
mutants with transposon insertions in adeR, adeS, adeA and adeB (Jacobs, 
Thompson et al. 2014, Gallagher, Ramage et al. 2015). 
5.2. Hypothesis 
Inactivation of adeR, adeS, adeA or adeB by transposon insertion will affect antibiotic 
resistance, biofilm formation and motility in a MDR contemporary military isolate 
AB5075. 
5.3. Aims 
The aim of this study was to identify the consequences of transposon mutagenesis of 
adeR, adeS, adeA and adeB in A. baumannii strain AB5075. The objectives were to 
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characterise the antibiotic resistance, biofilm formation and motility phenotype of 
transposon mutants of AB5075 obtained from the University of Washington. 
5.4. Choice of strains and verification of strains 
Strain AB5075 is a clinical isolate from a patient in the US military health care system 
and was selected by Jacobs et. al. as a model strain that is representative of current 
clinical isolates. It is highly virulent in established model infections, and can be 
genetically manipulated without a potential sacrifice to virulence and antibiotic 
resistance (Jacobs, Thompson et al. 2014). AB5075 was isolated from a patient with 
osteomyelitis in 2008. Like strain AYE, AB5075 is ST1 of International clone 1. 
Comparison of the genomes of AYE and AB5075 using the Basic Local Alignment 
Search Tool (BLAST) Ring Image Generator (BRIG) (Alikhan, Petty et al. 2011) 
showed high sequence similarity between the two strains (Figure 5.4.1) and 
alignment of the adeRS and adeABC sequences of AYE and AB5075 using the 
Artemis Comparison Tool (ACT) (Carver, Rutherford et al. 2005) showed 100% 
sequence identity between the two strains, with AB5075 possessing the same 
Ala94Val mutation in AdeS as AYE (Figure 5.4.2). This mutation has been previously 
associated with upregulation of the AdeABC efflux system and increased resistance 
to antibiotics (Hornsey, Loman et al. 2011). A comprehensive ordered transposon 
(Tn26 and Tn101) mutant library was constructed in this strain by Gallagher et al., 
providing an arrayed library of mutants with defined transposon insertions in most 
non-essential genes (Gallagher, Ramage et al. 2015). In order to minimise missed 
genotype-phenotype associations arising from non-inactivating mutations, several 
different mutations were constructed for each gene. Due to the long and labourious  
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Figure 5.4.1 BRIG output image of BLAST comparison of the AB5075 genome 
(purple) against an AYE reference genome 
 
The black inner ring represents the AYE genome and the purple ring represents the 
AB5975 genome. Gaps in the purple ring indicate areas of the AYE genome that are 
not present in AB5075.  
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Figure 5.4.2 Snapshot of a BLASTN comparison of the adeRS and adeABC 
regions of AYE and AB5075 using ACT 
 
The adeRS and adeABC operons are marked by the blue box. Red indicates 100% 
sequence identity.  
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process required to create genetic modifications in A. baumannii, Tn26 or Tn101 
mutants with insertional inactivation of adeR, adeS, adeA and adeB were obtained 
from this transposon mutant library (Gallagher, Ramage et al. 2015). Two mutants, 
with insertions in different locations in each gene were obtained for each of adeR, 
adeS, adeA and adeB (Table 5.4.1). Transposon insertion into each gene was 
confirmed by PCR using primers internal to the transposon in combination with 
primers with homology to the gene, and with primers that spanned the insertion 
region, producing a larger or no amplimer for the transposon insertion mutant (Figure 
5.4.1, Figure 5.4.2). Amplification of a 1284 bp product was seen using a reverse 
primer binding to adeS and a forward primer specific to the Tn26 transposon in Tn26-
adeR1. For Tn101-adeR2 verification, a 694 bp product was produced from parental 
strain AB5075 using primers spanning the Tn101 insertion site, whereas no product 
was observed for the mutant. Amplification of a 589 bp product was seen using a 
reverse primer binding to adeS and a forward primer binding to the Tn26 transposon 
in Tn26-adeS1. For Tn26-adeS2 verification, a 979 bp product was produced from 
parental strain AB5075 using primers spanning the Tn101 insertion site, whereas no 
product was observed for the mutant. Amplification of a 724 bp and 948 bp product 
was seen using a forward primer binding to adeA and a reverse primer specific to the 
Tn26 transposon in Tn26-adeA1 and Tn26-adeA2, respectively. Amplification of a 
2385 bp and 2373 bp product was seen using a forward primer binding to adeA and 
a reverse primer specific to the Tn26 transposon in Tn26-adeB1 and Tn26-adeB2, 
respectively. 
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Table 5.4.1 Transposon mutants obtained from the University of Washington Transposon Mutant Library  
Strain 
name Transposon 
Genome 
Position 
Tn 
Direction Ab Locus Strand 
Gene 
Name 
Position within gene 
(total bp of gene) Frame 
Tn26-
adeR1 Tn26 1974926 F ABUW_1973 - adeR 671(744) -3 
Tn101-
adeR2 Tn101 1975476 F ABUW_1973 - adeR 121(744) -2 
Tn26-
adeS1 Tn26 1974227 F ABUW_1972 - adeS 595(1086) -2 
Tn26-
adeS2 Tn26 1974689 R ABUW_1972 - adeS 133(1086) +2 
Tn26-
adeA1 Tn26 1976299 F ABUW_1974 + adeA 558(1191) +1 
Tn26-
adeA2 Tn26 1976523 F ABUW_1974 + adeA 782(1191) +3 
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Tn26-
adeB1 
 
Tn26 
 
1977961 
 
F 
 
ABUW_1975 + 
 
adeB 
 
1030(3108) 
 
+2 
Tn26-
adeB2 Tn26 1979116 F ABUW_1975 + adeB 2185(3108) +2 
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Figure 5.4.1 Schematic showing the location of transposon insertion in each AB5075 transposon mutant 
A. Transposon insertion in adeR 
 
B. Transposon insertion in adeS 
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C. Transposon insertion in adeA 
 
D. Transposon insertion in adeB 
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Figure 5.4.2 Verification of transposon insertion in AB5075 transposon mutants 
by PCR 
A. Tn26-adeR1 and Tn101-adeR2 verification 
Panels: A, PCR amplimers produced using primer internal to the transposon and 
primer with homology to the gene; B, PCR amplimers produced using primers 
spanning the insertion region. 
Lane Template Predicted fragment 
size (bp) 
Actual fragment 
size (bp) 
1 Hyperladder 1kb - - 
2 AB5075 0 0 
3 Tn26-adeR1 1284 1284 
4 Negative control 0 0 
5 Hyperladder 1kb - - 
6 AB5075 694 694 
7 Tn101-adeR2 2451 0 
8 Negative control 0 0 
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B. Tn26-adeS1 and Tn26-adeS2 verification 
Panels: A, PCR amplimers produced using primer internal to the transposon and 
primer with homology to the gene; B, PCR amplimers produced using primers 
spanning the insertion region.  
Lane Template Predicted fragment 
size (bp) 
Actual fragment 
size (bp) 
1 Hyperladder 1kb - - 
2 Tn26-adeS1 589 589 
3 AB5075 0 0 
4 Negative control 0 0 
5 Hyperladder 1kb - - 
6 AB5075 979 979 
7 Tn26-adeS2 2765 0 
8 Negative control 0 0 
Although all PCR products were electrophoresed on the same gel; the figure has 
been constructed from a single image to show only those strains relevant to this 
study. 
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C. Tn26-adeA1 and Tn26-adeA2 verification 
 
Lane Template Predicted fragment 
size (bp) 
Actual fragment 
size (bp) 
1 Hyperladder 1kb - - 
2 AB5075 0 0 
3 Tn26-adeA1 724 724 
4 Tn26-adeA2 948 948 
5 Negative control 0 0 
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D. Tn26-adeB1 and Tn26-adeB2 verification 
 
Lane Template Predicted fragment 
size (bp) 
Actual fragment 
size (bp) 
1 Hyperladder 1kb - - 
2 AB5075 0 0 
3 Tn26-adeB1 2385 2385 
4 Tn26-adeB2 2373 2373 
5 Negative control 0 0 
Although all PCR products were electrophoresed on the same gel; the figure has 
been constructed from a single image to show only those strains relevant to this 
study. 
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5.5. Determining the phenotype of adeR, adeS, adeA and adeB 
transposon mutants in AB5075 
5.5.1. Bacterial growth kinetics of AB5075 transposon mutants 
To determine whether Tn26 or Tn101 inactivation of adeR, adeS adeA or adeB had 
an effect on the growth rate of AB5075, the growth kinetics of the parental strain and 
Tn mutants were determined by measuring the optical density of cell cultures grown 
in LB broth at 37°C over time. The generation time of both adeB transposon mutants 
was significantly lower than that of the parental strain AB5075 (P < 0.05), suggesting 
that deletion of adeB in this strain confers a small growth defect (Figure 5.5.1, Table 
5.5.1). However, there was no difference in the final optical density at 600 nm 
reached by the adeB transposon mutants. A similar phenotype was observed in an 
adeB deletion mutant in AYE, with a significant decrease in generation time but no 
change in final optical density at 600 nm. The final optical density at 600 nm reached 
by Tn26-adeR1 and Tn26-adeS1 was significantly lower than that reached by the 
parental strain (P < 0.05), but there was no difference in the generation times of 
these mutants when compared with AB5075 (Figure 5.5.1, Table 5.5.1). 
5.5.2. Antimicrobial susceptibility of AB5075 transposon mutants 
To determine whether transposon insertion into adeR, adeS, adeA or adeB resulted 
in a change in susceptibility to antimicrobials, the MICs of commonly used antibiotics 
and dyes and those previously shown to be substrates of the AdeABC RND efflux 
pump in BM4587 (Yoon, Nait Chabane et al. 2015) were determined.. According to 
EUCAST recommended breakpoints (http://www.eucast.org/clinical_breakpoints/) the 
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Figure 5.5.1 Growth kinetics of AB5075 transposon mutants in LB broth at 37°C 
Panels: A, Tn-adeR mutants; B, Tn-adeS mutants; C, Tn-adeA mutants; D, Tn-adeB mutants. Data are shown as the mean of 3 
biological replicates and are representative of a single independent experiment carried out at least 3 times. 
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Table 5.5.1 Generation times and optical density at stationary phase of AB5075 
transposon mutants in LB broth at 37°C 
Strain Mean 
generation 
time (min) 
P value OD600 at 
stationary 
phase 
P value 
AB5075 103 ± 9.090 - 1.324 ± 0.009 - 
Tn26-adeR1 101 ± 12.103 0.927 1.265 ± 0.004 0.001- 
Tn101-adeR2 89 ± 13.622 0.379 1.317 ± 0.024 0.655 
Tn26-adeS1 114 ± 12.982 0.425 1.199 ± 0.051 0.014 
Tn26-adeS2 79 ± 3.976 0.104 1.313 ± 0.020 0.426 
Tn26-adeA1 105 ± 13.383 0.847 1.292 ± 0.137 0.708 
Tn26-adeA2 78 ± 1.703 0.092 1.244 ± 0.140 0.382 
Tn26-adeB1 70 ± 1.846 0.042 1.344 ± 0.009 0.063 
Tn26-adeB2 72 ± 1.398 0.049 1.155 ± 0.077 0.054 
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parental strain AB5075 was resistant to gentamicin, imipenem, meropenem and 
ciprofloxacin (Table 5.5.2). There were no EUCAST recommended breakpoint 
concentrations available for Acinetobacter spp. and seven drugs: ampicillin, 
ceftazidime, kanamycin, norfloxacin, tetracycline, tigecycline or chloramphenicol. 
There was a decrease in the MICs of kanamycin, gentamicin, tigecycline and the 
efflux inhibitor PAβN for all eight transposon mutants tested (Table 5.5.2). Although 
some of these changes were only 2-fold, which is considered to be the margin of 
error for this method, these changes were consistent in three independent 
experiments. A decrease in the MIC of these antibiotics was also observed with 
deletion of adeRS or adeB in strain AYE (Table 3.5.1, Table 4.6.1). The change in 
the MIC of kanamycin and gentamicin was greater in transposon mutants Tn26-
adeA1 and Tn26-adeA2 and greater still in Tn26-adeB1 and Tn26-adeB2. 
Furthermore, a decrease in the MICs of ciprofloxacin and ethidium bromide was also 
observed for Tn26-adeB1 and Tn26-adeB2. The Tn26 transposon contains a 
tetracycline resistance gene; in accordance with this there was an increase in the 
MIC of tetracycline in Tn26-adeR1, Tn26-adeS1, Tn26-adeS2 and Tn26-adeA1, 
Tn26-adeA2, Tn26-adeB1 and Tn26-adeB2. There was a small decrease in the MIC 
of colistin in Tn26-adeS1, Tn26-adeS2 and Tn26-adeA2 and an increase in Tn26-
adeA2, Tn26-adeB1 and Tn26-adeB2. 
5.5.3. Hoechst 33342 (bis-benzimide) accumulation by AB5075 
transposon mutants 
As described in Chapter 3, accumulation of H33342 is a good indication of efflux 
activity in A. baumannii (Richmond, Chua et al. 2013). To determine whether there  
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Table 5.5.2 MICs of antibiotics and dyes against AB5075 transposon mutants 
MIC (µg/ml) 
 
AB5075 
Tn26-
adeR1 
Tn101-
adeR2 
Tn26-
adeS1 
Tn26-
adeS2 
Tn26-
adeA1 
Tn26-
adeA2 
Tn26-
adeB1 
Tn26-
adeB2 
Ampicillin 1024 1024 1024 1024 1024 1024 1024 1024 1024 
Ceftazidime >1024 >1024 >1024 >1024 >1024 >1024 >1024 >1024 >1024 
Imipenem 19 19 19 19 19 19 19 19 19 
Meropenem 24 24 24 24 24 24 24 24 24 
Kanamycin 1024 512 512 512 512 256 256 128 128 
Gentamicin 64 8 8 4 4 4 4 2 2 
Norfloxacin 128 128 128 128 128 128 128 128 128 
Ciprofloxacin 128 128 128 128 128 128 128 64 64 
 203 
 
Colistin 2 2 2 0.5 1 8 2 8 4 
Tetracycline 1 16 1 16 16 16 16 16 16 
Tigecycline 2 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 
Chloramphenicol 512 512 512 512 512 512 512 512 512 
PAβN 1024 512 512 512 512 512 512 512 512 
Ethidium bromide 512 512 512 512 512 512 512 256 256 
Blue text indicates a decrease in MIC compared to that for AB5075; red text indicates an increase in MIC compared to that for 
AB5075. 
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was a relative difference in the intracellular accumulation levels of this substrate 
accumulation of H33342 in each transposon mutant was compared with that in 
AB5075 (Figure 5.5.2). When compared with AB5075, there was no significant 
difference in the steady state accumulation level of H33342 in any of the Tn26 or 
Tn101 mutants. These data suggest that there is no change in efflux levels of this 
substrate with inactivation of adeR, adeS, adeA or adeB. 
5.5.4. Ethidium bromide efflux by AB5075 transposon mutants 
Efflux of ethidium bromide by AB5975 and its transposon mutants was measured to 
investigate whether there was a difference in the relative efflux levels of this 
substrate. Except for Tn26-adeS2, the relative steady state accumulation level of 
ethidium bromide was significantly higher in all mutants (Figure 5.5.3). The biggest 
change in accumulation was observed in Tn26-adeA2, in which the final 
accumulation level of ethidium bromide was 62% higher than in the parental strain 
AB5075. 
5.5.5. Biofilm formation by AB5075 transposon mutants in vitro 
AB5075 is a clinical isolate taken from the US military health care system and is 
representative of current clinical isolates causing infection in hospitals (Jacobs, 
Thompson et al. 2014). In order to determine whether the ability to form a biofilm in 
abiotic surfaces is important in the clinical success of these isolates and whether 
AdeRS and AdeAB play a role in this process, biofilm formation in three different in 
vitro models was measured. 
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Figure 5.5.2 Accumulation of H33342 by AB5075 transposon mutants 
A. Accumulation of H33342 in AB5075 transposon mutants over time 
 
Panels: A, Tn-adeR mutants; B, Tn-adeS mutants; C, Tn-adeA mutants; D, Tn-adeB mutants. Data are shown as fluorescence 
values over time and represent the mean of three biological replicates. Data are a representative example of a single independent 
experiment carried out at least three times. 
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B. Fold change in accumulation of Hoechst H33342 in AB5075 transposon mutants 
 
Panels: A, Tn-adeR mutants; B, Tn-adeS mutants; C, Tn-adeA mutants; D, Tn-adeB mutants. Data are plotted as independent 
biological replicates to show variation within each strain. Data are presented as fold change compared to AB5075 at the point at 
which steady state accumulation was reached +/- standard deviation. Student’s t-tests were performed and those returning P values 
of less than 0.05 are indicated by *. 
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Figure 5.5.3 Efflux of ethidium bromide by AB5075 transposon mutants 
A. Efflux of ethidium bromide by AB5075 transposon mutants over time 
  
Panels: A, Tn-adeR mutants; B, Tn-adeS mutants; C, Tn-adeA mutants; D, Tn-adeB mutants . Data are shown as fluorescence 
relative to the starting fluorescence levels for each strain and represent the mean of three biological replicates. Data are a 
representative example of a single independent experiment carried out at least three times. 
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B. Fold change in intracellular levels of ethidium bromide in AB5075 transposon mutants 
 
Panels: A, Tn-adeR mutants; B, Tn-adeS mutants; C, Tn-adeA mutants; D, Tn-adeB mutants . Data are plotted as independent 
biological replicates to show variation within each strain. Data are presented as fold change in final fluorescence value compared to 
AYE +/- standard deviation. Student’s t-tests were performed and those returning P values of less than 0.05 are indicated by *. 
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5.5.5.1. Biofilm formation by AB5075 transposon mutants in a 
microfluidic cell 
Biofilm formation by AB5075 and its transposon mutants was studied under flow 
conditions in order to mimic biofilm formation on a medical device implanted in the 
body. AYE, which is also ST1, was included as a comparator and an example of a 
strain that rapidly produces a robust biofilm. As seen previously, AYE formed a 
robust biofilm after 16 hrs and thick biofilm coverage of the surface of the microfluidic 
cell was observed at 48 hrs (Figure 5.5.4). In contrast, AB5075 and the Tn26 and 
Tn101 mutants showed very little evidence of biofilm formation, even after 48 hrs. 
5.5.5.2. Biofilm formation AB5075 transposon mutants on 
polypropylene pegs 
To quantify the amount of biofilm formed by AB5075 and its transposon mutants, 
biofilms were grown on polypropylene pegs at 30°C and 37°C as described in 
Chapter 3. In this in vitro model, Tn26-adeA2 showed a statistically significant 
decrease in biofilm formation. However this was only observed at 37°C (Figure 
5.5.5). When compared with AYE, neither the parental strain nor the transposon 
mutants displayed a strong biofilm phenotype. This agrees with the results seen in 
the microfluidic cell. The mass of the AYE biofilm was 2.8 and 2.3 times that of 
AB5075 at 30° and 37°, respectively (Figure 5.5.5). 
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Figure 5.5.4 Phase contrast microscopy images of AB5075 transposon mutant biofilms formed under flow conditions of 
0.3 dynes at 48 hrs 
 
Images show attachment of bacterial cells to the inner surface of a microfluidic channel. Grey dots show adherence of individual 
cells to the surfaces whereas solid grey areas indicate bacterial growth and biofilm production. Black bar depicts a 20 µm scale. 
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Figure 5.5.5 Biofilm formation by AB5075 transposon mutants on 
polypropylene pegs as determined by crystal violet staining 
A. 30°C 
 
Data are plotted as independent biological replicates to show variation within each 
strain. Data are presented as fold change in final fluorescence value compared to 
AB5075 +/- standard deviation. Student’s t-tests were performed and those returning 
P values of less than 0.05 are indicated by *. 
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B. 37C̊ 
  
Data are plotted as independent biological replicates to show variation within each 
strain. Data are presented as fold change in final fluorescence value compared to 
AB5075 +/- standard deviation. Student’s t-tests were performed and those returning 
P values of less than 0.05 are indicated by *. 
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5.5.5.3. Pellicle formation by AB5075 transposon mutants 
To examine the ability of AB5075 and its transposon mutants to form a pellicle at the 
air/liquid interface, cultures were incubated in test tubes for 48 hrs and pellicle 
formation was examined visually. A thick biofilm mat could be seen on the surface of 
the liquid of all cultures (Figure 5.5.6). However, there was no visual difference in the 
size of the pellicle formed by any of the Tn26 or Tn101 mutants. 
5.5.6. Motility of AB5075 transposon mutants 
To determine whether inactivation of adeR, adeS, adeA or adeB had any effect on 
motility of AB5075, twitching and swarming motility were measured in 1% Mueller 
Hinton agar and 0.3% Luria-Bertani agar, respectively. AB5075 displayed some 
twitching motility and no swarming motility, typical of International Clone I (Figure 
5.5.7); this motility phenotype was also observed with strain AYE. There was no 
change in twitching motility displayed by any of the Tn26 and Tn101 mutants. 
However, there was an increase in swarming motility in some of the mutants; AB5075 
displayed coverage of 1.87% of the agar plate at 24 hrs whereas Tn101-adeR2, 
Tn26-adeS2, Tn26-adeB1 and TnadeB2 covered 15.44%, 18.37%, 26.29% and 
95.83%, respectively. This increase in motility was not seen in any of the AYE or S1 
deletion mutants characterised in Chapters 3 and 4. However, a significant change in 
the expression of motility genes was observed in AYEΔadeRS, AYEΔadeAB and 
S1ΔadeAB and it may be a similar change in expression of genes such as the pil and 
com operons that produces the increase in motility seen in these Tn26 and Tn101 
mutants. 
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Figure 5.5.6 Pellicle formation by AB5075 transposon mutants incubated statically at 37˚C and visualised under white light 
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Figure 5.5.7 Swarming motility of AB5075 Tn mutants grown on 0.3% agar for 24 hrs at 37°C 
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5.6. Protein modelling of AB5075 transposon mutants 
To predict how much of the AdeR, AdeS, AdeA and AdeB proteins are removed by 
transposon insertion into the gene and to illustrate which part of the protein remains 
and may still be functional, I-TASSER protein modelling software was used to 
generate a predicted protein model based on sequence homology to known protein 
structures (Yang, Yan et al. 2015). Protein structures were viewed in PyMOL 
(http://www.pymol.org) and amino acids that were coded for downstream of the 
transposon insertion site were coloured in red. It was predicted that the STOP 
codons within the transposon sequence would prevent translation of the protein 
downstream of the insertion site and so these parts of the protein would not be 
produced. 
Insertion of the transposon in Tn26-adeR1 occurred at position 671 in the gene, 
resulting in the last 25 amino acids being deleted (Figure 5.6.1). As the coding region 
for the first 223 amino acids was still intact and this includes the effector domain and 
the majority of the signal receiver domain, this could result in an assembled protein, 
retaining some AdeR function. However, the MIC changes observed for Tn26-adeR1 
were the same as those observed for Tn101-adeR2, which only has the coding 
region for the first 40 amino acids intact (Figure 5.6.1). AdeR in Tn101adeR2 is very 
unlikely to retain any function as only the first 28 amino acids of the effector domain 
and none of the signal receiver domain is present. These data suggest that AdeR is 
inactivated in both of these mutants. In Tn26-adeS1 and Tn26-adeS2, translation of a 
substantial part of the protein, including the histidine kinase domain and the 
transmembrane domain, was removed by transposon insertion 
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Figure 5.6.1 Predicted protein structures of AdeR, AdeS, AdeA and AdeB generated by I-TASSER 
   
 
 
 
 
 
Tn26-adeR1 
Tn26-adeS1 Tn26-adeS2 
Tn101-adeR2 
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Amino acids upstream and downstream of the transposon insertion site are coloured in blue and red, respectively. 
Tn26-adeB1 
Tn26-adeA1 
Tn26-adeA2 
Tn26-adeB2 
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(163 and 317 amino acids, respectively), suggesting that AdeS is likely to be non-
functional in both of these mutants (Figure 5.6.1). In Tn26-adeA1 and Tn26-adeA2, 
translation of 211 and 136 amino acids, respectively, was removed by transposon 
insertion (Figure 5.6.1), which is likely to result in a non-functional protein. In Tn26-
adeB1 and Tn26-adeB2, translation of 693 and 308 amino acids, respectively, was 
removed by transposon insertion (Figure 5.6.1). In both Tn26-adeB mutants, the 
deletion spanned the length of the predicted protein structure and included areas of 
the predicted AdeC binding domain and transmembrane helices. Therefore, these 
mutants were considered to have inactive proteins and a non-functional AdeABC 
MDR efflux pump. 
5.7. Discussion 
The mutants used in this study were obtained from the University of Washington 
(Gallagher, Ramage et al. 2015). This allowed multiple deletion mutants in a 
contemporary military wound isolate to be studied. Both the Tn26 and Tn101 
transposons produced multiple STOP codons irrespective of the location of the frame 
insertion. However, it was not possible to confirm lack of protein production by 
Western blotting as no antibodies were available for AdeR, AdeS, AdeA or AdeB. 
Therefore protein modelling was used to determine whether a possible truncated 
protein could be produced containing the region(s) required for activity. It is possible 
that a truncated protein could be produced in each of the mutants. However, as 
demonstrated by protein modelling, it is unlikely that these proteins would be 
translated or retain functionality. 
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The hypothesis was that AdeRS and AdeAB play a similar role in strain AB5075 as in 
AYE and S1 and that inactivation of the genes encoding this TCS and efflux pump 
would affect antibiotic resistance, biofilm formation and motility in a similar manner as 
described in Chapters 3 and 4. AYE is representative of International clone I 
(Fournier, Vallenet et al. 2006) and was isolated in 2001 from a patient in France 
(Poirel, Menuteau et al. 2003). S1 is representative of strains causing infection in SE 
Asia; it was isolated in 2006 in Singapore (Koh, Tan et al. 2012). It is possible that 
AYE and S1 are not representative of the clinical isolates infecting patients in USA 
and UK hospitals. AB5075 is a clinical isolate from an osteomyelitis infection in a 
patient in the US military hospital system in 2008 and was selected as a model strain 
that is highly virulent and representative of current clinical isolates (Jacobs, 
Thompson et al. 2014). In this study, transposon mutants of AB5075 were used to 
demonstrate the role of AdeRS and AdeAB in antibiotic resistance, biofilm formation 
and motility in a contemporary clinical isolate. 
All of the Tn26 and Tn101 mutants displayed lower MICs of antibiotics previously 
shown to be substrates of the AdeABC efflux pump (Yoon, Nait Chabane et al. 
2015). As seen with adeRS and adeB deletion mutants in AYE, changes in MIC were 
more pronounced with inactivation of genes encoding components of the AdeABC 
efflux pump that those encoding the TCS AdeRS. This supports the hypothesis that 
although inactivation of adeR or adeS results in a decrease in expression of adeABC, 
the efflux pump is still transcribed at a low level in these mutants. The decrease in 
efflux of ethidium bromide in all Tn26 and Tn101 mutants supports the hypothesis 
that the increase in susceptibility to the antimicrobials tested was due to down-
regulation or inactivation of AdeABC and therefore reduced efflux. This was also 
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observed in adeRS and adeB deletion mutants of AYE. These results are in contrast 
with the Hoechst accumulation assay, which did not detect any change in efflux 
levels in the Tn26 or Tn101 mutants. This phenomenon was also observed with an 
efflux pump mutant in clinical isolate S1, suggesting that the ethidium bromide efflux 
assay is a more sensitive assay and ethidium bromide may be a more appropriate 
substrate for measuring efflux by AdeABC. A difference in the MIC of colistin was 
detected for some of the Tn26 mutants. There is no evidence to show that efflux 
pumps are involved in resistance to colistin in A. baumannii and so it is hypothesised 
that this is due to changed expression of other genes as a result of inactivation of 
adeS, adeA or adeB. For example, analysis of the transcriptome of an adeB deletion 
mutant in AYE showed decreased expression of the lipid phosphoethanolamine 
transferase gene eptA, which has been previously associated with colistin resistance, 
(Adams, Nickel et al. 2009, Arroyo, Herrera et al. 2011, Beceiro, Llobet et al. 2011). 
Unlike strain AYE, AB5075 did not produce a strong biofilm in vitro. It is hypothesised 
that this low starting level of biofilm formation in the parental strain of the mutants is 
responsible for the lack of change in biofilm formation in the transposon mutants. 
Unfortunately, it was not possible to measure biofilm formation of these strains on in 
the PVM model due to time and logistical constraints (it required secondment to the 
USA). It is possible that like strain S1, which did not appear to form a strong biofilm 
on glass cover slips but did form microcolonies in the PVM model, AB5075 may still 
be able to form a biofilm on a mucosal surface despite a low biofilm phenotype on 
abiotic surfaces. Similarly, it was not possible to measure virulence in these strains; 
however, previous work has shown that AB5075 is highly virulent in murine 
pulmonary and G. mellonella models of infection (Jacobs, Thompson et al. 2014). It 
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is hypothesised that as in strain S1, which was also highly virulent in G. mellonella, 
inactivation or down-regulation of the efflux pump AdeABC by transposon insertion in 
either adeR, adeS, adeA or adeB would produce a significant virulence defect in this 
strain. 
Interestingly, transposon inactivation of adeR, adeS and adeB produced a motility 
phenotype that was not seen in deletion mutants of these genes in AYE or S1. 
Increased swarming motility was observed in Tn101-adeR2 and Tn26-adeS2 but not 
in Tn26-adeR1 or Tn26-adeS1. These data suggest that the location of the 
transposon insertion is important in determining the motility phenotype. Transposon 
mutants Tn101-adeR2 and Tn26-adeS2 have a much larger part of the protein 
deleted, which may impact motility more significantly than in Tn26-adeR1 and Tn26-
adeS1. Tn26-adeR1 retains the entire effector domain, whereas Tn26-adeR2 does 
not. This domain is hypothesised to trigger a cellular response upon phosphorylation. 
Tn26-adeS1 retains a histidine kinase ATP-ase, which is deleted in Tn26-adeS2. 
This domain is predicted to be an ATP binding site. It is possible that the presence of 
these domains allows Tn26-adeR1 and Tn26-adeS1 to retain some AdeR and AdeS 
activity and therefore an altered motility phenotype is not observed in these strains. 
Previous work has shown no effect on motility with overexpression of efflux pumps in 
A. baumannii but has highlighted reduced expression of the diaminobutyrate-2-
oxoglutarate aminotransferase involved in biosynthesis of diaminopropane (a 
polyamine required for A. baumannii surface-associated motility) in an efflux pump 
overexpresser (Skiebe, de Berardinis et al. 2012, Yoon, Nait Chabane et al. 2015). It 
is possible that transposon mutants that do not produce AdeR, AdeS or AdeB may 
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have increased production of diaminobutyrate-2-oxoglutarate aminotransferase, 
resulting in increased motility on wet agar. 
5.8. Further work 
As discussed in Chapters 3 and 4, it is possible that individual components of the 
AdeRS and the AdeABC systems may interact with components of other systems, 
allowing some function of these systems to be retained. In order to gain a greater 
understanding of the role of each system in antimicrobial resistance, biofilm and 
virulence, both single and double mutants should be created in strain AB5075. 
Furthermore, it would be interesting to include AdeC in this study, creating both a 
single and a triple mutant in combination with adeA and adeB to elucidate the role of 
this OMP in the phenotype. 
To further understand the role of AdeRS and AdeAB in biofilm formation and 
virulence, the phenotype of the transposon mutants should be tested in other models. 
This study has shown that biofilm formation can vary significantly depending on the 
model used and therefore it is important to measure biofilm formation in multiple in 
vitro and ex vivo models as described in Chapter 3. AB5075 was selected by Jacobs 
et. al. as a strain that is representative of clinical isolates due to its high levels of 
virulence in a murine pulmonary and G. mellonella model (Jacobs, Thompson et al. 
2014). It is therefore an ideal strain in which to study the role of the AdeRS TCS and 
the AdeABC efflux pump in virulence. Further work should focus on measuring 
virulence of the AB5075 transposon mutants in multiple models such as the murine 
pulmonary and G. mellonella models. 
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5.9. Key findings 
 Inactivation of adeR, adeS, adeA and adeB by transposon insertion in AB5075 
resulted in a decrease in the MICs of some antibiotics. 
 adeR, adeS, adeA and adeB transposon mutants in AB5075 displayed 
decreased levels of efflux of ethidium bromide. 
 adeR, adeS and adeB transposon mutants displayed increased swarming 
motility.  
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6. Overall Discussion and Conclusions 
Acinetobacter baumannii is a nosocomial pathogen and is a significant problem in 
hospitals worldwide. This organism is often multi-drug resistant, can persist in the 
environment and forms a biofilm on environmental surfaces and wounds. 
Overproduction of efflux pumps that export toxic compounds can lead to multi-drug 
resistance. 
A summary of the results presented in this thesis can be seen in Table 5.9.1. The 
primary aim of this study was to characterise the phenotype of a mutant lacking the 
two component system AdeRS in the MDR strain AYE. A mutant lacking AdeRS 
displayed increased susceptibility to antibiotics and decreased levels of efflux of 
ethidium bromide. Furthermore, RNA-seq data showed a 128, 91 and 28-fold 
decrease in expression of adeA, adeB and adeC, respectively, in the AdeRS deletion 
mutant when compared with the parental strain AYE. A reduction in efflux explains 
the increased susceptibility to antibiotics as when these toxic compounds are 
extruded at a reduced rate they accumulate in the bacterial cell and so are lethal at 
lower external concentrations. These data add to those from previous studies that 
show that AdeRS is a regulator of the RND efflux pump AdeABC, which extrudes 
several classes of antibiotics including aminoglycosides, β-lactams, fluoroquinolones, 
tetracyclines, tigecycline and chloramphenicol (Marchand, Damier-Piolle et al. 2004, 
Yoon, Nait Chabane et al. 2015).  
A porcine vaginal mucosal (PVM) model was adapted in this study to measure A. 
baumannii biofilm formation on a mucosal surface that represents a natural infection 
of the epithelium (Anderson, Parks et al. 2013). In this model, inactivation of AdeRS 
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Table 5.9.1 Summary of mutant phenotypes compared with their respective parental strains 
 
 
Antibiotic 
resistance 
Motility 
Biofilm 
formation on 
plastic 
Biofilm 
formation on 
PVM 
Biofilm 
formation on 
glass 
Virulence 
AYEΔadeRS 
 
↓ = = ↓ ↓ = 
AYEΔadeB 
 
↓ = ↓ ↓ ↓ = 
S1ΔadeAB 
 
= = = ↓ ↓ ↓ 
AB5075 Tn26-
adeR1 
↓ = = ND ND ND 
AB5075 Tn101-
adeR2 
↓ ↑ = ND ND ND 
AB5075 Tn26-
adeS1 
↓ = = ND ND ND 
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AB5075 Tn26-
adeS2 
↓ ↑ = ND ND ND 
AB5075 Tn26-
adeA1 
↓ = = ND ND ND 
AB5075 Tn26-
adeA2 
↓ = = ND ND ND 
AB5075 Tn26-
adeB1 
↓ ↑ = ND ND ND 
AB5075 Tn26-
adeB2 
↓ ↑ = ND ND ND 
↑, increased compared with the parental strain; ↓, decreased compared with the parental strain; ND, experiment not done for 
this strain 
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in AYE also resulted in a decrease in biofilm formation. Multi-drug efflux systems 
have been previously associated with biofilm formation in several other species 
(Kvist, Hancock et al. 2008, Matsumura, Furukawa et al. 2011, Baugh, Ekanayaka et 
al. 2012, Liao, Schurr et al. 2013, Yoon, Nait Chabane et al. 2015). However, 
previous work with A. baumannii used an abiotic model of biofilm formation in which 
biofilms are grown on plastic surfaces and quantified using crystal violet staining 
(Yoon, Nait Chabane et al. 2015). In the present study, using a similar colorimetric 
quantification model to Yoon et al. no change in biofilm formation was observed with 
deletion of adeRS. However, a reduction in biofilm formation was observed when 
biofilms on glass cover slips and mucosal tissue were visualised by microscopy. 
Strain AYE formed a robust, complex biofilm with evidence of an extracellular matrix 
whereas only individual cells of AYEΔadeRS were attached to the surface. 
Quantification of the number of adherent cells of AYEΔadeRS on the mucosal tissue 
showed no difference to the number of wild type AYE, suggesting that cells are able 
to attach but lack the ability to form a mature biofilm. A similar observation was made 
for S. aureus and S. Typhimurium (Anderson, Lin et al. 2012, Baugh, Ekanayaka et 
al. 2012). This may explain why no difference was observed with alternative biofilm 
quantification methods as these do not differentiate between attached cells and those 
in a complex biofilm. This highlights the need to measure biofilm formation in different 
models. It has also been shown by others that the factors required for attachment 
and biofilm formation may differ depending on the surface (Anderson, Moreau-
Marquis et al. 2008, Otto 2008, de Breij, Gaddy et al. 2009, Anderson, Lin et al. 
2012). 
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The next aim of this research was to determine whether the phenotype of the 
AYEΔadeRS mutant was due to decreased expression of the efflux pump genes 
adeABC in strain AYE. Inactivation of adeB produced decreased susceptibility to the 
same antibiotics, a similar decrease in efflux activity and reduced biofilm formation on 
PVM as seen for the AYEΔadeRS mutant. These data support the hypothesis that 
the phenotype observed in AYEΔadeRS is a result of decreased expression of the 
AdeABC efflux pump genes in this mutant. The MICs of some antibiotics were lower 
against AYEΔadeB than those against AYEΔadeRS. It is hypothesised that the 
greater reduction in efflux in the AdeB mutant, resulted in increased accumulation of 
antibiotic in the cell. This suggests that AdeABC may be a better target for inhibitors 
and drug discovery research than AdeRS. 
Inactivation of AdeRS and AdeAB by transposon insertion in military clinical isolate 
AB5075 also resulted in increased susceptibility to substrates of AdeABC and 
decreased efflux activity. Like strain AYE, AB5075 is ST1 and MDR and so it was 
expected that inactivation of AdeRS and AdeAB in this clinical isolate would result in 
a similar phenotype to that in AYE. However, unlike in strain AYE, inactivation of 
AdeRS and AdeB also resulted in an increase in motility in AB5075. Analysis of the 
genome of AB5075 showed no difference in the genomic context of AdeRS, AdeABC 
or known motility genes so it is hypothesised that this phenotype is due to expression 
changes in motility genes that were not present in AYE due to strain variation. 
Altered motility in A. baumannii has previously been observed as a result of 
inactivation or changed expression of pil, com, dat and ddc genes but not efflux 
pump genes (Antunes, Imperi et al. 2011, Skiebe, de Berardinis et al. 2012, Harding, 
Tracy et al. 2013, Wilharm, Piesker et al. 2013, Yoon, Nait Chabane et al. 2015). 
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Inactivation of AdeAB in clinical isolate S1, which is ST40, did not produce any 
change in susceptibility to antibiotics. S1 has no mutation in adeRS and so does not 
overexpress the efflux pump AdeABC. It has been shown by the Courvalin group that 
AdeABC is tightly regulated and only confers MDR when overexpressed (Magnet, 
Courvalin et al. 2001, Yoon, Courvalin et al. 2013, Yoon, Nait Chabane et al. 2015). 
Therefore, it is hypothesised that deletion of the pump genes in S1 had no effect on 
the MICs of antibiotics because they are only expressed at low levels to begin with. 
However, S1ΔadeAB showed reduced biofilm formation in the PVM model and on 
glass cover slips, further supporting the hypothesis that AdeABC plays an important 
role in biofilm formation. PVM is made up of stratified squamous epithelium, similar in 
structure to human mucosal surfaces (Anderson, Parks et al. 2013) and the growth 
characteristics of A. baumannii on the PVM were similar to those observed using a 
3D human skin equivalent model (de Breij, Haisma et al. 2012). Therefore, 
differences in the ability of A. baumannii mutants to form a biofilm in the PVM model 
may have implications for the formation of biofilms in respiratory and wound 
infections. These data suggest that inhibition of MDR efflux pumps may be a useful 
strategy to help prevent or treat colonisation in patients by A. baumannii. 
Furthermore, deletion of AdeAB in S1 significantly reduced virulence in a Galleria 
mellonella model, suggesting that the AdeABC efflux pump is required for killing of G. 
mellonella in this strain. This effect was not seen with deletion of AdeB in strain AYE, 
indicating that AdeABC has a strain-specific role in A. baumannii and may perform 
different functions in different strains. A correlation between pathogenicity in G. 
mellonella and in humans has previously been observed with A. baumannii (Peleg, 
Jara et al. 2009). Therefore, these data suggest that for some A. baumannii strains, 
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such as S1, AdeABC may be required for infection in humans. The finding that the 
major MDR RND efflux pump in A. baumannii can also play a fundamental role in its 
ability to infect its host further underscores a role for MDR efflux pumps in the biology 
of pathogenic bacteria. However, data presented here suggest that broad 
conclusions about the role of specific genes and proteins in this species should not 
be drawn from the study of single strains and that multiple A. baumannii strains 
should be used in future studies. 
6.1. Future work arising from this study 
There are several hypotheses arising from the work described in this thesis: 
Hypothesis 1 
Disruption of AdeRS or AdeABC in different strains of A. baumannii will have a strain-
specific effect on antibiotic resistance, biofilm formation, virulence and motility. 
Suggested work 
Create deletion mutants of individual genes adeR, adeS, adeA, adeB and adeC in 
each of the strains studied here; AYE, S1 and AB5075. This will allow the effect of 
inactivation of each component of the AdeRS two component system and the 
AdeABC RND efflux pump to be established. This will also allow the phenotype of 
deletion mutants in different strains to be directly compared.  
Hypothesis 2 
Disruption of AdeRS or AdeABC in different A. baumannii strains will alter the 
expression of genes involved in antibiotic resistance, biofilm formation, virulence and 
motility. 
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Suggested work 
Western blotting should be used to confirm that deletion of each gene removes 
expression of the protein product for that gene and does not affect expression of 
other proteins encoded downstream. RNA-Seq experiments should be carried out 
with each deletion mutant to determine changes in the transcriptome compared with 
the parental strain. Changes in the transcriptome of deletion mutants created in 
different strain backgrounds should also be compared with a particular focus on 
genes known to encode proteins required for motility, virulence and biofilm formation 
as this study has identified differences in these phenotypic functions. Reverse 
transcription PCR would then be used to confirm expression changes in genes of 
interest. 
Hypothesis 3 
Deletion or decreased expression of AdeABC in A. baumannii will affect biofilm 
formation in animal models. 
Suggested work 
Biofilm formation by each deletion mutant should be measured in alternative models, 
such as the murine wound model described by Thompson et al. (Thompson, Black et 
al. 2014). A. baumannii wound infections are common in military casualties and 
biofilms are an important virulence factor in wound infection (Davis, Moran et al. 
2005, Hujer, Hujer et al. 2006, Sebeny, Riddle et al. 2008, O'Shea 2012, Percival, Hill 
et al. 2012). The murine wound model allows an inoculum of a clinically relevant 
MDR A. baumannii strain to proliferate and form a biofilm within a wound, which can 
then be assessed using multiple quantitative and qualitative techniques (Thompson, 
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Black et al. 2014). Furthermore RNA-seq technology should be used to determine 
transcriptomic changes in cells whilst in a biofilm compared with planktonic cells, 
providing insight into the genes that may play a role in biofilm formation on wound 
surfaces.  
Hypothesis 4 
Deletion or decreased expression of AdeABC in A. baumannii will affect virulence in 
animal models. 
Suggested work 
Mouse models of infection should be used to evaluate the virulence of the deletion 
mutants. A. baumannii most commonly causes ventilator-associated pneumonia, 
which can be modelled through instillation of a bacterial suspension into the trachea 
or intranasally (van Faassen, KuoLee et al. 2007, Wang, Ozer et al. 2014, Yoon, 
Balloy et al. 2016), whilst systemic infection can be modelled using intraperitoneal 
injection (Breslow, Meissler et al. 2011, Roux, Danilchanka et al. 2015, Yoon, Balloy 
et al. 2016). Using these models, Yoon et al. recently showed that overproduction of 
the AdeABC efflux pump in A. baumannii BM4587 resulted in decreased 
competitiveness in an intraperitoneal mouse model (Yoon, Balloy et al. 2016). 
However, the AdeABC-overexpressing mutant was more virulent in mice inoculated 
intranasally, demonstrating the importance of measuring virulence in different 
models. It has been suggested that the intranasal model of infection is the most 
clinically relevant model as it mimics the most frequent type of human A. baumannii 
infection (Yoon, Balloy et al. 2016). Use of these animal models may provide a more 
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accurate and clinically relevant measure of the role of AdeRS and AdeABC in A. 
baumannii infection. 
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